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2 Abbreviations and Acronyms 
(v/v)   Volume/volume percent 
[M+H]+  Protonated molecule of metabolite M 
17-DMAG  17-Dimethylaminoethylamino-17-demethoxygeldanamycin 
2-HG   2-Hydroxyglutarate 
3-P-glycerate 3-Phosphoglycerate 
5-HIAA  5-Hydroxyindoleacetate 
Ala   Alanine 
AML   Acute myeloid leukemia 
ANOVA  Analysis of variance 
AP   Atmospheric pressure 
APCI   Atmospheric pressure chemical ionization 
APCI I  First-generation APCI source 
APCI II  Second generation APCI source 
APCI(+)  Atmospheric pressure chemical ionization positive mode 
APCI/+H2O  APCI with water infusion 
APCI/-H2O  APCI without water infusion 
API   Atmospheric pressure ionization 
APLI   Atmospheric pressure laser ionization 
APPI   Atmospheric pressure photo ionization 
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Asn   Asparagine 
Asp   Aspartate 
AUC   Area under the curve 
CD   Cyclodextrin 
CI   Chemical ionization 
CID   Collision-induced dissociation 
Cys   Cysteine 
D/L-2-HG  D and L enantiomers of 2-hydroxyglutarate 
Da   Dalton 
DA-APLI  Dopant-assisted atmospheric pressure laser ionization 
DA-APPI  Dopant-assisted atmospheric pressure photo ionization 
DART   Direct Analysis in Real Time 
DB   Database 
DIP   Direct Inlet Probe 
E. coli   Escherichia coli 
EI   Electron ionization 
EIC   Extracted ion chromatogram 
ESI   Electrospray ionization 
FAME   Fatty acid methyl ester 
FC   Fold change 
FDA   Food and Drug Administration 
FDR   False discovery rate 
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FID   Flame ionization detector 
FMF   Find Molecular Features 
FN   False negative 
FP   False positive 
FPR   False positive rate 
FTICR  Fourier transform ion cyclotron resonance 
G6P   Glucose-6-phosphate 
GABA   Gamma amino butyrate 
GC   Gas chromatography 
GC×GC  Comprehensive two-dimensional gas chromatography 
GLC   Gas liquid chromatography 
Gln   Glutamine 
Glu   Glutamate 
Gly   Glycine 
Glycerol-1-P  Glycerol-1-phosphate 
GSC   Gas solid chromatography 
HDA   Heptadecanoate 
His   Histidine 
HMDB  Human Metabolome Database 
HPLC   High performance liquid chromatography 
HRTOF  High-resolution time-of-flight 
Hsp90  Heat-shock protein 90 
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IAS   Ion activation stage 
IDH   Isocitrate dehydrogenase 
Ile   Isoleucine 
IPT   Isopentenyl phosphotransferase encoding gene 
IS   Internal standard 
KEGG  Kyoto Encyclopedia of Genes and Genomes 
LC   Liquid chromatography 
Leu   Leucine 
LLOQ   Lower limit of quantification 
LOD   Limit of detection 
logPoctanol/water Logarithm of partition coefficient 
LOQ   Limit of quantification 
LR   Linear range 
Lys   Lysine 
m/z   mass-to-charge ratio 
MCF   Methyl chloroformate 
Me   Methyl 
MeOx   Methoximation 
Met   Methionine 
MRM   Multiple reaction monitoring 
MS   Mass spectrometry 
MS/MS  Tandem mass spectrometry 
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MSE Simultaneous acquisition mode of high and low collision energy 
spectra 
MSn   Tandem mass spectrometry 
MSTFA  N-methyl-N-(trimethylsilyl) trifluoroacetamide 
NA   Nonanoate 
NAA   N-acetylaspartate 
NADP+/NADPH Nicotinamide adenine dinucleotide phosphate (oxidized and re-
duced form) 
NDA   Nonadecanoate 
netCDF  Network Common Data Format 
NIST   National Institute of Standards and Technology 
NMR   Nuclear magnetic resonance 
NPAH   Nitrated polycyclic aromatic hydrocarbon 
Nval   Norvaline 
OH   Hydroxy 
Orn   Ornithine 
PAH   Polycyclic aromatic hydrocarbon 
PBM   Probability-based matching 
PBS   Phosphate-buffered saline 
PCA   Principal component analysis 
PCF   Propyl chloroformate 
PDA   Pentadecanoate 
PFPP   Pentafluorophenyl propyl 
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Phe   Phenylalanine 
PLS-DA  Partial least squares discriminant analysis 
ppm   parts per million 
ppmV   parts per million by volume 
Pro   Proline 
PTV   Programmed-temperature vaporization 
PU   E. coli double-mutant (PntAB-UdhA) strain 
qMS   Quadrupole mass spectrometry 
qTOF   Quadrupole- Time-of-flight hybrid mass spectrometry 
R²   Square of the linear regression coefficient R 
RI   Linear retention index 
ROC   Receiver operator characteristic 
RSD   Relative standard deviation 
Rt-DEXsa 2,3-di-acetoxy-6-O-tert-butyl-dimethylsilyl gamma CD doped into 
14% cyanopropylphenyl/86% dimethyl polysiloxane 
S/N   Signal-to-noise ratio 
SD   Standard deviation 
Ser   Serine 
SIL-IS   Stable isotope-labeled internal standard 
SIM   Selected ion monitoring 
SP   Stationary phase 
SVM   Support vector machines 
TCA   Tricarboxylic acid 
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TDA   Tridecanoate 
Thr   Threonine 
TIC   Total ion current 
TMS   Trimethylsilyl 
TN   True negative 
TOCSY  Total correlated spectroscopy 
TOF   Time-of-flight 
TP   True positive 
TPR   True positive rate 
Trp   Tryptophan 
TSP   Trimethylsilyl propanoic acid 
Tyr   Tyrosine 
U-13C   Uniform 13C-labeled 
U-2H   Uniform 2H-labeled 
UDA   Undecanoate 
ULOQ   Upper limit of quantification 
UTI   Urinary tract infection 
Val   Valine 
VOC   Volatile organic compound 
wh   Peak width measured at half the peak height 
wt   wild type 
m   mass error 
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3 Motivation 
Metabolomics aims at the measurement of the largest possible number of metabolites in 
a single analysis. The ultimate goal is the identification and quantification of those that 
differ significantly between groups. Knowing the identity and quantity of discriminating 
metabolites allows the interpretation of metabolic changes in the context of metabolic 
pathways, which is essential for understanding the underlying biology.  
Gas chromatography – electron ionization – mass spectrometry (GC-EI-MS) in combi-
nation with a derivatization is a valuable tool in metabolomics due to high analytical 
reproducibility, low detection limits, and the availability of large mass spectral libraries 
that also include trimethylsilyl derivatives that are commonly used. Nevertheless, many 
derivatives of metabolites are not found in standard commercial libraries rendering the 
annotation of corresponding signals in the GC-MS chromatogram cumbersome. Ele-
mental formulas can be calculated from the accurate mass of molecular ions as a first 
step towards the de-novo identification of unknown metabolites, but electron ionization 
causes strong fragmentation and does not always yield the molecular ion. Hence, soft 
ionization techniques, such as chemical ionization (CI), must be applied. In the 1970s, 
Horning et al. introduced atmospheric pressure chemical ionization (APCI) as a soft 
ionization technique for coupling GC to MS [1,2], but it was not widely used at that time 
because of the required expensive instrumentation and it did not reach maturity for 
commercialization. Another 30 years later, McEwen and McKay as well as Schiewek et 
al. continued the studies on APCI and developed independently ion sources suited for 
coupling mass spectrometry with both gas and liquid chromatography [3,4]. Their work 
led in 2008 to the introduction of commercially available APCI sources for GC-MS and 
their hyphenation with high-resolution mass analyzers to exploit such powerful features 
as accurate mass measurement and tandem mass spectrometry for the identification of 
unknowns. The great potential of high-resolution time-of-flight mass spectrometry 
(HRTOF-MS) in metabolomics is not only based on accurate mass measurement for 
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structural assignment of unknown species but also on the option to perform targeted 
quantification simultaneously. The latter benefitted from the introduction of the analog-
to-digital converter, which led to a distinct increase in the dynamic range of TOFMS 
instruments [5]. This was highly needed as metabolites vary tremendously in their con-
centration levels. Since GC-APCI-TOFMS has shown high detection sensitivity in initial 
studies [6], it appeared to be promising for quantitative metabolic profiling.  
Prior to my master thesis in 2010 and this doctoral research work, there had been few 
reports on the use of GC-APCI-HRTOFMS. Reported applications included the identifi-
cation of unknown compounds in pharmaceutical research [7], analysis of foodstuff [8], 
and metabolomics [9-11]. Its performance had not been compared to established GC-
MS approaches. The technique had only been applied to study metabolite composition 
in human cerebrospinal fluid [9], but comparative metabolic fingerprinting of several 
sample classes had not been performed to that date. Furthermore, the outstanding 
quantitative capabilities of GC-APCI-HRTOFMS had only been demonstrated using 
metabolite standards [9,10] and not been used for metabolic profiling, i.e., the quantita-
tive analysis of known metabolites, in biological specimens.  
My master thesis and the research done by Carrasco et al. in 2009 [9] were the first 
GC-APCI-HRTOFMS studies that investigated the ionization behavior of a broad range 
of metabolites. In my master thesis, 43 metabolites from different compound classes, 
such as amino acids, organic acids, sugars, and alcohols, were analyzed. APCI source 
parameters were optimized and the quantitative performance of GC-APCI-HRTOFMS 
was comprehensively compared to that of GC×GC-EI-TOFMS, GC-EI-TOFMS, GC-CI-
quadrupole mass spectrometry (qMS) and GC-EI-qMS, respectively. In addition, com-
parative metabolic fingerprinting was performed in wild type and mutant Escherichia coli 
(E. coli) strains and a workflow for the identification of unknown metabolites was estab-
lished based on the accurate mass and isotopic pattern of their protonated molecules 
([M+H]+). For validation, results were compared to a previous study that had employed 
GC×GC-EI-TOFMS [12]. Although the general applicability of GC-APCI-HRTOFMS in 
metabolomics could be shown, the quantitative performance of GC-APCI-HRTOFMS 
was less than satisfying, mainly because of inconsistent ionization. Factors influencing 
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ionization efficiency and reproducibility needed to be studied in more detail, such as the 
infusion of water into the ionization source and potential matrix effects due to co-eluting 
compounds. Hence, the initial results of my master thesis formed the basis for this doc-
toral thesis. 
 
Aim #1: Investigation and optimization of factors influencing APCI 
1.1 Water infusion  
Already in the course of my master thesis it became obvious that humidity in the labora-
tory critically affects reproducibility of APCI. Therefore, the first aim of this thesis was a 
systematic assessment of the effect of water infusion into the APCI source on efficiency 
and repeatability of APCI for the two most commonly used derivatization protocols, 
namely alkylation using methyl chloroformate (MCF) and methoximation-silylation, in 
GC-MS based metabolome analysis. To that end, 20 metabolite standards and five 
different water infusion rates between 0.1-0.5 mL/h were tested. As a proof of principle, 
MCF derivatization and GC-APCI-TOFMS w/o water infusion were applied to the detec-
tion of changes in metabolite abundance in pancreatic cancer cells upon treatment with 
the heat-shock protein 90 (Hsp90) inhibitor 17-dimethylaminoethylamino-17-
demethoxygeldanamycin (17-DMAG).  
 
1.2 Matrix effects  
In liquid chromatography (LC)-MS, APCI is known to be prone to matrix effects hamper-
ing accurate quantification. Hence, the aim of this project was to study whether biologi-
cal matrices affect GC-APCI-HRTOFMS. To investigate potential interferences from 
matrix compounds, an E. coli extract as well as human serum and urine specimens 
were spiked with 15 metabolite standards and recovery rates determined. In addition, 
for three pairs of co-eluting compounds, possible interferences between the analyte of 
interest and defined amounts of its co-eluent were studied. The purpose of this experi-
ment was to reveal whether APCI might be an actual source of ion suppression or en-
hancement in the case of co-eluting analytes in the absence of a biological matrix.  
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1.3 APCI source type 
During my thesis, Bruker Daltonics (Bremen, Germany) introduced a redesigned “GC-
APCI II” source that supposedly addressed shortcomings of the original GC-APCI I 
source such as gas turbulences, cold spots, and insufficient heating, which had exerted 
a negative impact on ionization and ion transfer into the MS. The new source was there-
fore subjected to comprehensive testing to evaluate detection sensitivity, repeatability 
and suitability for metabolic fingerprinting. Initially, a commercial 37-component FAME 
mixture was used to investigate the repeatability of retention time, peak width and ioni-
zation efficiency for structurally similar compounds over a wide boiling point range. To 
assess the quantitative potential of APCI II in comparison to its predecessor, figures of 
merit for metabolic profiling were determined from calibration curves of 20 MeOx-TMS 
derivatized metabolite standards and nine ISs. Both source types were also employed 
in the analysis of three biological replicates of cell culture supernatants with the objec-
tive of comparing their performance with regard to technical variability and identification 
of metabolites. 
 
Aim #2: Application of GC-APCI-HRTOFMS to the enantioselective quantitative 
profiling of D/L-2-HG 
The goal was the development of an enantioselective, sensitive, and reliable quantifica-
tion approach for 2-hydroxyglutarate (2-HG). Analysis of 2-HG has become increasingly 
important in cancer biology due to the observed accumulation of D-2-HG in several 
types of cancer mostly as a result of neomorphic mutations in the isocitrate dehydro-
genase (IDH) 1 and 2 genes. To separate D and L enantiomers of 2-HG, MCF derivati-
zation and a chiral cyclodextrin (CD)-based Rt-DEXsa capillary column were tested 
based on previous experiences in our laboratory with the enantioselective GC analysis 
of amino acids. To prove its reliability, the method was validated by means of spike-in 
experiment in serum and cross-validation of total 2-HG levels in human urine specimens 
was carried out using HPLC-ESI(-)-MS/MS. 
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4 Background 
Parts of this chapter were published in book chapters [15] and [16]. The focus is primari-
ly on GC-MS based metabolomics.  
 
4.1 Metabolomics 
Metabolomics aims at providing an in-depth view of chemical changes in cells, tissues, 
organs or organisms evoked by cellular processes in response to genetic and environ-
mental causes [18]. It is an integral part of systems biology and provides a direct link 
between an external stimulus and the non-structural phenotype or physiology of a bio-
logical system [19,20]. Since the metabolome represents the endpoint of the “omics” 
cascade (Figure 4.1), it yields a more predictive phenotype than the genome, transcrip-
tome and proteome, respectively. It also captures the dynamic changes that occur in 
response to genetic and environmental constraints much better, with the composition of 
the metabolome having been observed to change within seconds, whereas turnover in 
the proteome and transcriptome (minutes to hours) is considerably slower [21]. 
 
 7
 
 
 
 
Figure 4.1 The metabolome represents the endpoint of the "omics" cascade. Reprinted with permission 
from [22].  
4.1.1 Challenges 
Metabolome analysis comprises both the qualitative and the quantitative assessment of 
low-molecular mass compounds (<1,000 Da), which show tremendous diversity in their 
chemical and physical properties. Moreover, metabolite concentrations range over up to 
ten orders of magnitude. The physicochemical diversity and wide range of abundance of 
metabolites in biological specimens constitute major challenges in the comprehensive 
determination of the metabolic state of biological systems, requiring the combination of 
several analytical platforms such as nuclear magnetic resonance (NMR) spectroscopy 
and direct-infusion or hyphenated mass spectrometry (MS). Proton NMR presents the 
closest to a universal nondestructive detector that provides in combination with carbon-
13 NMR an indispensable tool for the structural elucidation of unknown metabolites. 
However, it lacks the detection sensitivity of MS required for the determination of me-
tabolites in the submicromolar concentration range. For that reason, MS in combination 
with chromatographic separation techniques such as LC and GC has become a widely 
used, albeit still to be perfected tool in targeted and non-targeted metabolomics. Exist-
ing shortcomings include instrumental drift, ion suppression and the lack of comprehen-
sive mass spectral libraries for LC-MS and in case of GC-MS the frequent need for 
derivatization, which carries pitfalls such as the degradation of metabolites and the lack 
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of metabolite mass spectral libraries for derivatives other than silylated compounds. 
Moreover, reference compounds are only available for a subset of metabolites. One 
way of overcoming the lack of comprehensive mass spectral libraries is the use of soft 
ionization techniques that generate gas-phase ions without extensive fragmentation. In 
combination with high-resolution MS, measurement of the accurate mass of non-
fragmented protonated molecules allows calculation of elemental formulas that can then 
be searched against metabolite databases for putative metabolite identification. In addi-
tion to cross-platform approaches to cope with analyte diversity, various metabolite 
databases can be searched (e.g. HMDB [23], LIPID MAPS [24], and Metlin [25]). Once 
identified, metabolites may be visualized within their metabolic pathways (e.g. provided 
by KEGG database) to facilitate biological interpretation. Finally, metabolomics data can 
be incorporated with results obtained by the other –omics methods to obtain a global 
picture of the biological entity under study.  
Apart from the high diversity of metabolites, undesired variation in metabolite levels 
might be introduced at each stage of the metabolomics workflow and pose an additional 
challenge to the analytical chemist. In order to minimize variability introduced during 
sample preparation, standardized protocols for quenching, extraction and derivatization 
steps are essential and should be followed as proposed by Sumner et al. in 2007 [26]. 
Still, it is almost impossible to avoid analyte losses during sample preparation. There-
fore, stable isotopically labeled internal standards (SIL-ISs) are commonly used to ac-
count for analyte losses, and apart from that for injection variability, instrumental drift 
and ion suppression. 
4.1.2 Strategies 
Two different strategies are mostly used in metabolomics [22,27]. These are metabolite 
profiling or targeted analysis of a small number of analytes on the one hand, and meta-
bolic fingerprinting on the other hand. For metabolite profiling, i.e., the quantitative anal-
ysis of pre-selected metabolites, analytical methods are tailored for the separation and 
sensitive detection of the target analytes. Reference substances in known concentra-
tions and an appropriate set of internal standards are used to construct calibration 
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curves to quantify the target analytes in biological specimens. Alternatively, isotope 
dilution analysis can be employed for quantification. Stable isotopically labeled analogs 
of the target analytes are spiked into the samples in known concentration and quantifi-
cation is performed by comparing the peak area of the target analyte to that of the la-
beled standard. For metabolic fingerprinting, the complete GC-MS or LC-MS chromato-
gram is exported and analyzed. One can either search for signals that change 
significantly between sample groups or use the chromatograms to classily samples. 
This does not require knowledge of the identity of the signals, often referred to as fea-
tures or markers. Metabolite identification is then restricted to those features that yield-
ed significant differences in signal intensity between sample groups. Aiming at the sim-
ultaneous detection of the highest possible number of metabolites, sample preparation 
is typically kept to a minimum in metabolite fingerprinting to prevent analyte losses. In 
targeted studies, on the other hand, sample preparation is tailored to the specific ana-
lytes and, thus, typically more extensive to reduce chemical complexity of the samples 
prior to analysis. 
Apart from targeted and untargeted analyses, the analysis of metabolic flux using stable 
isotopically labeled substrates has been a valuable tool in the study of dynamic pro-
cesses in a cell. Instead of measuring only metabolite abundances, flux experiments 
can reveal the flux of carbon (or nitrogen) atoms derived from substrates such as glu-
cose, glutamine or other amino acids, through different metabolic pathways and detect 
changes in rates of metabolic reaction due to certain perturbations. The number of 
publications reporting flux experiments has increased steadily in recent years [28,29]. 
 
4.2 Established GC-MS approaches in metabolomics 
Gas chromatography coupled to mass spectrometry (GC-MS) is an indispensable tool in 
metabolomics. It is perfectly suited for the analysis of small volatile metabolites. Capil-
lary GC is capable of resolving very complex mixtures and MS provides highly selective 
and sensitive detection of metabolites along with their identification. Capillary GC can 
be easily interfaced with an MS instrument as carrier gas flow rates of about 1 mL/min 
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are compatible with modern MS vacuum systems. Moreover, analytes have already 
been transferred into the gas phase before reaching the ion source of the MS.  
4.2.1 Derivatization strategies 
Major prerequisites for GC-MS analysis include a sufficient vapor pressure and thermal 
stability of metabolites. Most metabolites, such as amino acids, organic acids, sugars 
and alcohols, possess polar functional groups, which have to be derivatized prior to GC 
analysis. Apart from increasing volatility and thermal stability, derivatization of the ana-
lytes can improve chromatographic properties. It can provide additional structural infor-
mation and improve both, lower limits of quantification and selectivity for quantitative 
measurements. However, derivatization prolongs overall analysis time and adds vari-
ance to the analysis. It can also hamper identification of metabolites, derivatives of 
which are not contained in mass spectral libraries. Overall, derivatization should be 
simple, fast, automatable, efficient, reproducible, and spectral libraries of the derivatives 
are needed. Halket and Zaikin extensively reported on derivatives for mass spectrome-
try in a series of reviews, which in each case deals with a single derivatization reaction, 
e.g., silylation [30]. Among others, silylation, acylation, alkylation/esterification, the for-
mation of cyclic derivatives and generation of mixed derivatives of polyfunctional com-
pounds has been performed for GC-MS.  
4.2.1.1 MeOx-TMS derivatization  
In 2011, Koek et al. [31] reviewed a large number of metabolomics studies with respect 
to the pursued derivatization strategy. The majority of GC(-MS) methods employed 
silylation with or without prior oximation. Figure 4.2 provides the example of a typical 
two-step derivatization strategy including methoximation followed by silylation using N-
methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA).  
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Figure 4.2 Commonly used two-step derivatization procedure for GC-MS based metabolomics. 
Oximation reagents, such as hydroxylamines or alkoxyamines, react with aldehyde and 
keto groups. They react with open-chain reducing sugars thereby preventing ring for-
mation of reducing sugars. The derivatization results in the formation of two stereoiso-
mers (syn and anti form) that can be separated chromatographically. Further, decarbox-
ylation of -ketocarboxylic acids and keto-enol tautomerism is hindered. MSTFA or 
N,O-bis-(trimethylsilyl)-trifluoroacetamide (BSTFA) are typically used reagents for silyla-
tion. They replace active hydrogen atoms in functional groups, such as -COOH, -OH,     
-NH and -SH, with a trimethylsilyl (TMS) group. In case of silylation reagents that con-
tain chlorine atoms, small amounts of a catalyst, e.g. 1% of trimethylchlorosilane, are 
added. Silyl derivatives are prone to hydrolysis in the presence of traces of water. Con-
sequently, anhydrous conditions have to be employed. Bulkier silylation reagents, such 
as N-methyl-N-(tert-butyldimethylsilyl)-trifluoroacetamide (MTBSTFA), have been shown 
to be less susceptible to hydrolysis [32]. Moreover, tert-butyldimethylsilyl derivatives 
show characteristic [M-57]+ ions in EI-MS, which may facilitate the identification of un-
known compounds [33], but requires harsher reaction conditions.  
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Oximation followed by silylation is often employed in non-targeted metabolomics [12,17] 
because of the ready derivatization of many different functional groups and the availabil-
ity of large spectral libraries [31]. However, degradation or rearrangement reactions 
have been reported, e.g. arginine is decomposed to form ornithine [34], and glutamate 
rearranges to pyroglutamate. Partial silylation yielding multiple peaks for amino acids is 
a well-known problem, which can be addressed by either weighting correctly the multi-
ple peaks [35] or by summing up the responses of all derivatives [36].  
Modern GC instruments equipped with advanced sample robots (e.g., from CTC Analyt-
ics AG or Gerstel) enable the sequential automated derivatization of sample analytes 
immediately prior to their analysis instead of off-line en bloc derivatization, thereby min-
imizing hydrolysis and variability in the ratio of partially derivatized metabolites.  
Large numbers of derivatizable groups may lead to indefinite retention of an analyte on 
the GC column or the molecular mass of the derivative might exceed the mass range of 
the detector [30]. Native lactose, for example, has a molecular mass of 342 Da, which 
increases to 947 Da after methoximation and the introduction of 8 trimethylsilyl groups. 
Furthermore, silylation is neither simple nor fast, as it cannot be performed in aqueous 
solution or in the presence of protic solvents and usually requires heating for some time, 
especially in case of amines.  
4.2.1.2 Derivatization with alkyl chloroformates 
In 2011, Villas-Bôas et al. [37] compared silylation to derivatization with methyl chlo-
roformate. The authors concluded, that a combination of both derivatization approaches 
leads to a more comprehensive coverage of the metabolome. Alkyl chloroformates are 
used as reagents to esterify carboxylic groups to form the corresponding alkyl ester, 
while carbamates are derived from amino groups (Figure 4.3). This derivatization has 
emerged as an attractive alternative to silylation, especially for amino acids [38,39] and 
non-amino organic acids [40]. The reaction is fast and feasible in aqueous media at 
room temperature, which makes it easy to handle. Kaspar et al. [38] demonstrated its 
potential for full automation. Nevertheless, alkyl chloroformate derivatization is less 
versatile compared to silylation. Moreover, comprehensive mass spectral libraries are 
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still lacking and need to be developed, which renders methoximation/silylation overall 
the method of choice in GC-MS based metabolomics.  
Interestingly, in contrast to the study by Koek et al. in 2006 [41], Villas-Bôas et al. [37] 
described a poor analytical performance for TMS derivatives. This underscores the 
importance of strictly enforced standard operation procedures such as the regular re-
placement of GC-inlet liners and trimming of the inlet end of the capillary column, as 
well as the addition of several SIL-ISs to monitor performance of extraction and derivati-
zation [41]. More details on experimental strategies including quality control are provid-
ed in subchapter 4.4. 
OHO
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OO
HN
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Figure 4.3 Reaction scheme for the derivatization of amino acids with methyl chloroformate. 
4.2.2 GC stationary phases  
For GC separation, analytes have to be transferred into the gas phase, which is typically 
achieved by a hot split/splitless injector or by a programmed-temperature vaporizer 
(PTV). Nowadays, GC separation is commonly performed using capillary columns. 
These are open tubular columns with an inner diameter of less than 1 mm and a length 
of 1 – 100 m. The stationary phase is coated to the inner wall of the column. The sta-
tionary phase can either be a highly viscous liquid (WCOT – wall coated open tubular 
column), with analyte separation attained by partitioning of the analytes into the liquid 
(GLC – gas liquid chromatography), or a solid adsorbent (PLOT – porous layer open 
tubular column) for adsorption-based separation (GSC – gas solid chromatography). 
GSC is mainly used for highly volatile analytes such as permanent gases. In metabo-
lomics, GLC prevails. A variety of stationary phases (SPs) are available. Non-polar SPs 
provide separation of analytes as a function of mere differences in vapor pressure, while 
polar SPs allow the exploitation of additional polar interactions. Common SPs are pol-
ysiloxanes, which are modified with both non-polar methyl groups (PDMS – polydime-
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thylsiloxane) and polar phenyl- or cyanopropyl groups to tune the polarity of the phase. 
The recently introduced ionic liquid SPs are an attractive alternative to polysiloxane 
SPs. Furthermore, direct stereoselective analyses can be carried out using chiral SPs, 
such as the widely used Chirasil-L-Val SP or CD-based SPs, which separate enantio-
mers by formation of inclusion complexes. However, due to the huge chemical diversity 
of metabolites there is no single ideal column chemistry capable of covering entire 
metabolomes. Rather, multiple SP chemistries tailored to different classes of metabo-
lites or their derivatives have to be employed sequentially to achieve comprehensive 
coverage.  
4.2.3 GC-MS with EI and CI sources 
Capillary GC lends itself to interfacing with MS, as analytes have been already trans-
ferred into the gas phase and carrier gas flow rates are compatible with modern vacuum 
systems. Hyphenation of GC and MS is typically accomplished by means of electron 
ionization (EI), which is a hard ionization technique under high vacuum. Electrons are 
emitted from a heated wire filament usually at electron energies of 70eV. In an initial 
step, radical cations are generated from gas phase molecules. Subsequent fragmenta-
tion reactions, losses of neutral groups and rearrangement of secondary ions occur 
because electron energies are by far exceeding ionization energies of organic mole-
cules. This yields predictable ion patterns, which can be interpreted by the experienced 
scientist. Moreover, EI is highly reproducible and, therefore, huge commercial spectral 
libraries containing currently up to 242,000 unique compounds (NIST 14 Mass Spectral 
Library) have been built for routine identification of analytes. However, structural iso-
mers often show similar EI spectra, thus precluding unambiguous compound identifica-
tion in the absence of additional information such as differences in chromatographic 
retention. Further, both the still incomplete coverage of natural metabolites in spectral 
libraries and the frequent absence of molecular ions in EI mass spectra continue to 
constitute major bottlenecks in the identification of group discriminating features. There-
fore, soft ionization techniques that preserve intact protonated molecules have become 
prominent in recent years, such as chemical ionization (CI) and APCI (subchapter 4.3). 
Operation in CI mode takes place under low vacuum in the presence of a reagent gas, 
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e.g. methane, isobutane or ammonia. Electrons emitted from a heated wire filament 
initially ionize the reagent gas, which is present in great excess. Subsequently, analytes 
are ionized by ion-molecule reactions (Figure 4.4). 
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Figure 4.4 Primary reaction gas (methane) ion formation and secondary analyte (M) ion formation in 
positive chemical ionization mode. 
However, extensive soft ionization mass spectral libraries have not been built yet. In 
case of CI this is owed to the strong dependence of mass spectra on the nature and 
pressure of the reactant gas. Hence, a lot of manual effort by the user is still required 
during data analysis.  
The appropriate choice of mass analyzer depends on the aim of the study. Mainly quad-
rupole (qMS) and time-of-flight mass spectrometers (TOFMS) are applied to metabo-
lomics. Quadrupole mass analyzers enjoy widespread use. They are inexpensive, ro-
bust and easy to handle. But they are limited in mass range and scan speed and, in 
most cases, restricted to nominal mass resolution. Therefore, quadrupoles are com-
monly used in routine analysis either in full scan mode or selected ion monitoring (SIM) 
mode, with the latter achieving lower limits of quantification due to a longer dwell time 
on pre-selected masses. Even more powerful is the sequential combination of three 
quadrupoles, which offers highly specific and sensitive quantitative analysis. In addition, 
structural information on the analytes is provided as an asset by tandem mass spec-
trometry (MS/MS). TOFMS instruments provide not only low limits of quantification but 
also wide dynamic ranges over up to four orders of magnitude. Fast-acquisition TOFMS 
instruments, which acquire up to 500 spectra per second, are a prerequisite for the 
successful resolution and integration of the very narrow chromatographic peaks realized 
by fast GC or GC×GC. Typically, however, they provide only nominal mass resolution. 
On the other hand, TOFMS instruments that are operated at acquisition rates of 20 – 50 
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spectra/s provide enhanced mass spectral resolution and accuracy of ion masses, 
which facilitates the identification of unknown compounds. However, TOFMS instru-
ments are sensitive to voltage or temperature fluctuations requiring external as well as 
internal (re-)calibration of the mass scale on a regular basis. Even better suited for the 
identification of unknowns are hybrid qTOFMS instruments that combine one or more 
quadrupoles with a TOF mass analyzer. This MS type enables the determination of 
parent and fragment ions with high mass accuracy.  
4.2.4 Comprehensive two-dimensional gas chromatography – time-of-
flight mass spectrometry 
Despite high chromatographic resolution, overlapping peaks and coelutions are still 
observed in the analysis of complex samples by one-dimensional GC. Comprehensive 
two-dimensional GC (GC×GC) is a powerful analytical tool to tackle this problem and its 
application to metabolomics has been recently reviewed [42]. It uses two columns with 
orthogonal separation characteristics that are connected via a modulator. Typically, a 
nonpolar/polar column combination is employed. Hence, separation on the first column 
is essentially driven by differences in vapor pressure. Subsequent resolution of isovola-
tile sample components in the second dimension arises from the different strengths and 
types of polar interactions with the stationary phase. A number of different modulators 
are available that mostly employ thermal modulation. For example, the dual-stage four- 
jet modulator from LECO Corporation (St. Joseph, MI, USA) uses alternatingly nitrogen-
cooled cold jets for the periodic trapping of effluent from the first column in small seg-
ments that are then transferred to the very short second column upon hot jet remobiliza-
tion. Commonly, because of their high data acquisition rate, TOF mass analyzers are 
used to record the narrow peaks (peak widths of 50 – 200 ms) created by the focusing 
step and the fast separation in the second dimension. Electron ionization is used to 
generate fragment mass spectra that are then matched against available spectral librar-
ies. GC×GC-MS chromatograms are displayed as so-called 2D contour plots. The first 
and second column retention times are represented on the x-axis and y-axis, respec-
tively, and a color code depicts the detector response. An exemplary GC×GC-MS 
chromatogram of a methanolic avocado pulp extract is given in Figure 4.5. Peak anno-
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tation was based on spectral matching to the NIST 05 library using a cut-off score of 
700.  
 
Figure 4.5 GC×GC-TOFMS chromatogram of an avocado sample. Avocado pulp (40 mg) was homoge-
nized and extracted using cold methanol, extract was dried, derivatized (methoximation/silylation), and 
analyzed by GC×GC-TOFMS [12]. For peak annotation spectral matching to the NIST 05 library was 
performed using a cut-off score of 700. Signals marked in italics refer to internal standards. C16, palmi-
tate; C18, stearate; C18:1, oleate. Reprinted with permission from K. Dettmer et al, in W. Weckwerth, G. 
Kahl (Editors), The Handbook of Plant Metabolomics, Wiley-VCH, Weinheim, 2013, p. 77.  
Comprehensive two-dimensional GC separations not only offer enhanced resolution 
and a multiplicative increase in peak capacity over conventional GC methods, but also 
narrower peaks due to modulation and, hence, improved detection sensitivity. The latter 
was demonstrated for a standard mixture of 43 metabolites that was analyzed by both, 
one-dimensional and comprehensive two-dimensional GC-TOFMS [17]. For most me-
tabolites, lower limits of quantification were at least one order of magnitude lower using 
GC×GC-TOFMS. Still in need of improvement are convenient and practicable ways of 
data analysis to make full use of GC×GC-TOFMS for metabolic fingerprinting. In a first 
step, the raw data is pre-processed, for instance, in LECO’s ChromaTOF software. This 
includes background subtraction, deconvolution, picking of peaks and their integration, 
as well as combining several modulations belonging to one compound. Further, align-
ment tools must be capable of correctly aligning chromatograms within and across 
batches. This requires correction for shifts in retention time to recognize the same ana-
lyte across different samples. In addition to shifts in retention time, incorrect peak 
recognition can be caused by poor mass spectral deconvolution. These effects can 
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result in missing values in the alignment table despite the presence of the peak in the 
chromatogram, which impedes discriminate analysis. Quantitative analysis using 
GC×GC-TOFMS data can also be time-consuming. Employing peak based quantifica-
tion tools, the peaks from all modulations must be integrated to determine the response 
of an analyte. Since the software may fail in the proper integration of minor subpeaks, 
manual inspection and correction of integrated peaks may be necessary [43].  
 
4.3 Atmospheric pressure chemical ionization for GC-MS 
In this subchapter, the fundamentals of GC-APCI-MS and recent applications are de-
scribed, with an emphasis on the role of clusters in atmospheric pressure ionization.  
4.3.1 Fundamentals 
Historical outline (taken from [44]) 
APCI was first introduced by Horning et al. in 1973 [1] using 63Ni as a beta-emitter for 
ionization that was later replaced by a corona discharge ion source [2,45]. A range of 
applications were described by then, such as GC-APCI-MS in negative ion mode for 
environmental studies [46] as well as APCI-MS for gas analysis [47]. However, the 
technique was not widely used, in part because of the expensive instrumentation and 
due to already commercially available “plug and play” EI and CI GC-MS systems.  
APCI again attracted attention during the 1980s, when the introduction of electrospray 
ionization for LC-MS [48] caused a breakthrough in the development of LC-MS ion 
sources for generating ions at atmospheric pressure. Unlike previous LC-MS interfaces, 
such as particle beam or thermospray, where ions were generated under vacuum condi-
tions, molecules are ionized at atmospheric pressure in ESI and APCI. However, APCI 
was initially only used as an ionization interface for LC-MS.  
The renaissance of atmospheric pressure ionization techniques for GC-MS started just 
recently, when both McEwen and McKay [4] and Schiewek et al. [3] modified an API 
source on a commercial LC-MS instrument to enable an easy switch between various 
 
 19
 
 
 
ionization modes and to use both LC and GC with one certain mass spectrometer. The 
exciting potential of the latter investigations has led to the development of commercially 
available APCI sources that allow the hyphenation of GC to high-resolution TOF or 
QTOF mass spectrometers and tandem mass spectrometers that were previously only 
coupled with LC.  
Hence, distinctly lower quantification limits than previously obtained with quadrupole 
instruments can be achieved and features such as accurate mass measurements for 
chemical formula determination of unknown analytes can be exploited. A further ad-
vantage of GC-MS is the ability to observe compounds of low polarity that are not ame-
nable to LC-MS. These benefits are especially important in the study of complex mix-
tures as in the field of metabolomics. A major drawback remains the lack of convenient 
libraries [44]. 
 
GC-APCI-TOFMS instrumental setup 
One of the first successful attempts to couple GC to TOFMS was made by Erickson et 
al. in 1990 [49] by applying time array detection, which yielded data acquisition rates of 
up to 20 spectra/s and, hence, the optimization of chromatography for speed of analysis 
with no loss in chromatographic resolution or analyte detectability. Furthermore, the 
more widespread use of GC-TOFMS was fostered by the introduction of soft ionization 
techniques [4,50-53] for the determination of the elemental composition of unknown 
analytes and analog-to-digital converters distinctly increasing the dynamic range of 
TOFMS instruments [5].  
In the following, the GC-APCI I-TOFMS instrumental setup employed in this thesis is 
described (adapted from [44]).  
The first APCI source (APCI I) commercialized by Bruker Daltonics consists of a rectan-
gular aluminium chamber with five different ports A-E (compare Figure 4.6, [3]). Port A 
is mounted on the ion source mounting flange of the Bruker MS. The GC is connected 
to the ion source via a heated transfer line assembly at port B opposite to port A. The 
transfer line is fixed and heated externally by a controller to prevent compound conden-
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sation. Port E, located at the top of the ion source, contains the LC vaporizer stage, 
which is used for external hot nitrogen supply (illustrated in yellow in Figure 4.7) in case 
of GC to compensate for the relatively large pumping speed of the MS and to generate 
the heat required for the APCI process. Ports C and D are both arranged perpendicular 
to the longitudinal axis of the GC transfer line. Port C is sealed with an optical window 
and the corona needle assembly is mounted on Port D. This places the needle tip in 
close vicinity to the GC effluent and sheath gas flow. Figure 4.7 shows a general 
scheme of the GC-APCI-TOFMS setup. A sheath gas flow (nitrogen, illustrated in or-
ange in Figure 4.7) is introduced through coaxial holes around the outlet of the GC 
capillary and envelopes eluting analytes on their way through the source. Moreover, it 
directs the generated ions towards the MS. The source is purged with a clean dry gas 
(N2) to prevent reduction of ions by contaminants [3]. However, part of the dry gas is not 
directed into the APCI source but soaked into the transfer capillary (illustrated in red in 
Figure 4.7), which causes gas turbulences in front of the end plate of the capillary. 
Furthermore, the vaporizer gas is a major source of the overall extensive gas turbulenc-
es in the APCI I source, so that is was omitted for the second-generation APCI II source 
(see section 8.2.2). With regard to the ionization several APCI source parameters have 
to be optimized for a specific application namely drying gas (nitrogen) temperature and 
flow rate, vaporizer temperature and gas (nitrogen) pressure, current of corona needle 
discharge and capillary end plate voltage (compare Figure 4.7).  
 
Figure 4.6 Scheme of the APCI I source body. Reprinted with permission from [3].  
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Figure 4.7 GC-APCI-TOFMS setup and ion species present during the ionization procedure [3,4,45]. The 
flow direction of sheath gas, vaporizer gas, and dry gas is indicated by orange, yellow, and red arrows, 
respectively. Modified and reprinted from [15] with permission from Elsevier.  
In addition to the ionization in the APCI source, different stages of the ion transfer are 
crucial for the quality of the obtained APCI mass spectrum and have to be pointed out. 
Since analytes are ionization at atmospheric pressure, but ion separation in the mass 
analyzer is achieved under high vacuum conditions, pressure has to be reduced step-
wise in consecutive stages within the mass spectrometer. As discussed by Klee et al. 
[54,55] up to seven different domains can be distinguished within the overall ion genera-
tion and detection process. For the microTOF (Bruker Daltonics) employed here, this 
includes regions of primary and secondary ion generation, ion transfer to the MS, three 
different vacuum pumping stages and ion optics. The domains are characterized by 
varying chemical composition, temperature and pressure, which lead to rapid switching 
of the dynamic entity of analyte ions and surrounding matrix.  
Apart from the GC-MS approach followed in this thesis, APCI has been used for analyz-
ing compounds from solid or liquid surfaces. A detailed overview of AP surface sam-
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pling/ ionization techniques for mass spectrometry was compiled by van Berkel et al. 
[56], including Atmospheric-pressure Solids Analysis Probe (ASAP) and Direct Analysis 
in Real Time (DART), which make use of a hot nitrogen gas stream and excited helium 
atoms for vaporization and desorption of the sample, respectively, and subsequent 
ionization by APCI. Krieger et al. [57] developed a Direct Inlet Probe (DIP)-APCI ion 
source with temperature-programmed heating of the sample to separate analytes based 
on boiling point differences and, hence, reduce ion suppression. While DART and DIP-
APCI sources are used for analyzing solid samples and small amounts of liquid sam-
ples, the APCI source for LC-MS, in comparison to that of GC-MS, has an extra heated 
APCI nebulizer unit used for efficient nebulization and desolvation of the LC effluent. 
 
APCI ionization mechanism (partly taken from [44]) 
As stated above, APCI gained in importance first in LC-MS as an alternative to ESI, 
which is well suited for polar compounds and, especially, for large biomolecules. APCI, 
in comparison, is mostly used whenever small and medium-polar molecules are investi-
gated. Both ionization modes generate mainly protonated molecules with very little 
fragmentation. In case of ESI, evaporation of the eluent and ion formation from micro 
droplets through Coulomb explosions can be considered as top down processes, 
whereas APCI in the gas phase is mediated through proton-bound solvent clusters that 
are build bottom up from primary ions. “In positive-ion mode, APCI is initiated by corona 
discharge through application of a high voltage (2-6 kV) to a sharp metal electrode 
(corona-discharge electrode). The high electric field at the tip of the electrode attracts 
electrons and the surrounding nitrogen gas is ionized by electron ionization. This leads 
finally to plasma formation and together with traces of water vapour from air or nitrogen 
the following reactions (Figure 4.8) [45] occur in the plasma region.“ [44]  
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Figure 4.8 Ion molecule reactions in positive atmospheric pressure chemical ionization mode [45].  
This series of reactions leads to the formation of clusters, which are typically proton-
bound water clusters in GC-MS, whereas proton-bound LC solvent or mixed wa-
ter/solvent clusters are present in LC-MS. These clusters finally lead to the dominantly 
observed protonated molecules as described later in this section.  
It should be noted that gas-tight API interfaces have been designed in the context of 
ionization mechanism studies that favor charge exchange rather than protonation [58]. 
Furthermore, formation of molecular radical cations depends on the type of analyte. For 
instance, it was observed in the analysis of pesticides by means of GC-APCI-QTOFMS 
[59]. However, N2 transfer conditions resulting in the formation of M▪+ species [59] did 
not apply to the instrumental setup and analytes investigated in this thesis. The proto-
nated molecule, however, was always formed (termed as “proton transfer conditions” 
[59]). 
It should be mentioned that APCI in negative ion mode is also possible [6], but this was 
of no practical relevance in the context of the current thesis.  
Furthermore, among the different API techniques, both direct and dopant-assisted at-
mospheric pressure photo ionization (APPI/DA-APPI) and atmospheric pressure laser 
ionization (APLI/DA-APLI) are applied to medium- to nonpolar and aromatic nonpolar 
analytes, respectively. Both LC-MS [54] and GC-MS [3,60] applications have been 
reported. Unlike in APCI, primary reagent ions are formed from photons instead of elec-
trons, but, importantly, ionization of analytes is also based on chemical ionization by 
proton-bound cluster species [54,61]. Hence, it appears appropriate to derive universal 
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conclusions from the role of clusters in API and their fate in the ion transfer process 
from individual APCI, APPI or APLI studies.  
 
APCI conditions  
Atmospheric pressure chemical ionization takes place under completely different physi-
cal and chemical conditions than CI and especially EI. Hereinafter, given that the de-
scribed ionization conditions and processes in analyte ion generation are common to 
APCI, APPI and APLI, the expression API was used as a general term.  
Most relevant to the analytical chemist is the reduced degree in fragmentation in API 
and a concomitant increase in protonated molecules [M+H]+. The benefit of APCI for 
metabolite identification is shown in Figure 4.9 that depicts mass spectra of fructose-
1MeOx-5TMS acquired with GC-EI-qMS and GC-APCI-TOFMS, respectively. Infor-
mation on the entire molecule is only preserved in the latter case, and very few frag-
ments are observed, e.g. resulting from the loss of a neutral Si(CH3)3OH (m/z 90) 
group. Protonated molecules preferentially transfer excess energy to neutral molecules 
through collision processes lowering fragmentation (“collisional deactivation”) [62], 
whereas unimolecular decay reactions occur under vacuum conditions due to much 
lower densities of neutral molecules. Furthermore, source residence times of ions in API 
may reach up to several hundred miliseconds [55,63] and their transfer to the MS is 
dominated by gas flow instead of electric fields [64]. As opposed to that, ions formed 
under vacuum conditions are transported out of the source region within less than one 
micro-second by the applied electric fields [55]. Due to the prolonged residence time of 
ions in the APCI source, the formation of a silylation adduct was observed in my initial 
GC-APCI-TOFMS study [17], which was formed only in case of compounds with a car-
boxylic group and, thus, helped to strengthen a putative identification, e.g., nonanoate-
1TMS (Figure 4.9C) showed adduct formation as opposed to glycerol-3TMS (Figure 
4.9D), which lacks a carboxylic group. 
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Figure 4.9 GC-MS mass spectra of standards (62.5 M) using hard and soft ionization techniques as 
described elsewhere [17]. Identification of fructose-1MeOx-5TMS requires spectral libraries for GC-EI-
qMS (A) or can be achieved starting from the protonated molecule in case of GC-APCI-TOFMS (B), 
where structure-dependent adduct formation may serve as plausibility check as exemplified for (C) nona-
noate-1TMS and (D) glycerol-3TMS with the latter showing no adduct formation as it lacks a carboxylic 
group. MeOx, group introduced by methoximation; TMS, trimethylsilyl group; [M+73]+, silylation adduct of 
analyte M. [16] – Reproduced by permission of The Royal Society of Chemistry.  
Considering the long residence times of ions in the source compared to typical ion-
molecule reaction rates and the great numbers of neutral molecules as potential reac-
tants (typically nitrogen, oxygen and water molecules in GC-MS), chemical (bi- and 
termolecular) reactions inevitably occur in API sources. Under such conditions, as re-
cently pointed out by several authors [55,61], chemical processes are typically thermo-
dynamically controlled, i.e. the minimum of the Gibbs function G of the reaction system 
is reached within the dwell time of ions in the source. Hence, ionization at atmospheric 
pressure leads to thermally equilibrated ion populations, whereas ionization under vac-
uum conditions is kinetically driven [63]. However, equilibrated ion populations may 
drastically change en route to the detection system, not only because of interactions 
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with neutral molecules that reach the first ion transfer stages but also due to association 
and dissociation reactions of the ion-bound cluster systems.  
In order to establish optimum API conditions, the ion-bound clusters increasingly be-
came the focus in API mechanistic studies [54,55], because they were found to play a 
more complex role in the generation of protonated molecules than originally assumed. 
For instance, mainly [M+H]+ ions were detected in DA-APPI- and DA-APLI-MS even 
when aprotic dopants were used [54,65]. Previously, the difficulty in elucidating API 
ionization mechanisms lay in the fact that clusters are typically not observed using 
commercial API mass spectrometers, because cluster dissociation occurs due to the 
electrical voltages applied in the ion transfer.  
Water plays a major role in cluster ion chemistry. Due to its polar nature, cluster for-
mation with other reactants is energetically efficient and, furthermore, water is omni-
present in API sources above levels of 1 ppmV even if the latter sources are purged 
with ultrapure nitrogen for several days. Numerous working groups have provided kinet-
ic and thermodynamic data on the proton-bound water cluster system [66-69]. It has to 
be pointed out that LC solvents such as methanol or acetonitrile participate in clusters 
as well, but this was irrelevant in the context of the current thesis. The water cluster 
system consists of different H+(H2O)n species, with a varying number of n water mole-
cules bound to a core cluster, which reach a thermal equilibrium in the API source. The 
equilibrium cluster size distribution of the system is typically between n = 3-9 with a 
maximum between n = 4-6, depending on the temperature and water content in the 
source [70]. In fact, with an increase in the background water concentration the maxi-
mum of the latter distribution shifts towards a higher number of bound water molecules 
[54]. The water cluster system is highly dynamic and clusters undergo numerous colli-
sions in the source and also in the different stages of the ion transfer to the MS, where 
changes in pressure and ion temperature also affect cluster size and, hence, reactivity. 
This applies to the entire high or intermediate-pressure regions down to between 10-4 
and 1 mbar [54,55].  
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Analyte ion generation 
Proton-bound water clusters interact with analyte molecules to yield the dominantly 
observed protonated molecules. Previously, it was assumed that these clusters proto-
nate molecules with gas-phase basicities higher than that of water in bi-molecular reac-
tions in the API source [69]. Recently, an initial analyte capture by water ion cluster 
ligand exchange / association reactions followed by dissociation of water molecules 
further downstream yielding bare [M+H]+ ions has been proposed [54,71]. The unlikeli-
ness of direct acid-base-type protonation reactions is supported by the low gas-phase 
acidity of typically occurring water ion clusters with at least four water molecules. In fact, 
clusters of that size have been considered as essentially unreactive toward analytes 
with moderate gas-phase basicity [71]. For instance, mixed analyte-water ion clusters 
instead of the [M+H]+ ions of N,N-diisopropylethylamine were formed under thermal 
equilibrium in DA-APLI [54], demonstrating that even an amine with a high gas-phase 
basicity rather participates in ligand exchange/ association reactions than being directly 
protonated.  
Analyte molecules with suitable chemical and physical properties such as polarity/dipole 
moment can be captured as ligands in cluster equilibra [54]. All matrix components act 
as potential competitors in the cluster/ligand association reaction and the impact in-
creases with increasing matrix concentrations. Higher concentrated matrix species, 
even if less suitable in terms of polarity, may prevent analyte molecules from entering 
the cluster equilibria. Vice versa, omnipresent dopants in DA-API-MS that show a low 
tendency towards ligand exchange / association reactions (e.g., toluene) may lead to 
more efficient analyte protonation than those with a high tendency (e.g., anisole). Using 
toluene and anisole as dopants in DA-APPI-MS analysis, testosterone was ionized 
more efficiently through proton-bound water clusters in the case of toluene [72].  
As ligand exchange between clusters and background matrix is highly dynamic, analyte 
molecules may be replaced by other matrix molecules before cluster activation, i.e. the 
reduction of the number of cluster ligands to finally obtain protonated molecules. Ana-
lyte elimination from clusters may occur throughout ion generation and passage along 
the detection pathway from the ionization source to the intermediate-pressure region 
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down to between 10-4 and 1 mbar, where the number of collisions is still high enough to 
induce changes in the existing ion population. Klee et al. [54,55] distinguished up to 
seven different domains in API MS instruments, namely corona discharge region, ther-
malized region within the API source, ion sampling port and transfer to the MS, three 
consecutive pressure reduction stages and the vacuum analyzer region. The turbulent 
flow within the API source and ion transfer to the MS causes strong mixture of all sys-
tem components, followed by gas expansion and concomitant cluster growth and re-
equilibration in the first vacuum pumping stage with a sustained background pressure of 
a few mbar. Ions are further guided to the analyzer region by electrical fields, whereas 
neutral molecules are continuously removed. The applied electrical fields also lead to 
increasing kinetic energies of the ions, which in turn results in enhanced collisions and, 
hence, ion activation. Furthermore, fragmentation may occur in the case of fragile ana-
lyte ions as another consequence of the increased number of collisions. Apart from 
electrical field mediated collision-induced dissociation (CID) of analyte-water ion clus-
ters, stepwise CID of equilibrated water ion clusters may be a minor pathway leading to 
protonated molecules. In the process, smaller, more acidic water ion clusters are 
formed, which then protonate neutral analytes that reach the first pressure reducing 
stages [54,71]. The two above described mechanisms of ion activation are a favorable 
side effect of ion guiding to the mass analyzer, but the aim of ion guiding is a high ion 
transmission rather than controlled ion activation. Keeping that in mind, an ion activation 
stage (IAS) for controlled ion activation has been recently introduced [61]. In fact, the 
prevailing water-ion cluster distribution can be shifted towards reactive species for sub-
sequent analyte protonation by the IAS, which still awaits a systematic evaluation of its 
practical relevance.  
In summary, according to Klee et al. [54], critical prerequisites for efficient generation of 
[M+H]+ ions include analyte properties that favour participation in ligand exchange/ 
association reactions, e.g. polarity. This must be accompanied by the ability of the ana-
lyte molecule to be retained as a ligand in the cluster system until the very final stages 
of cluster activation to end up as a bare protonated molecule. As direct protonation of 
analytes by thermally equilibrated water ion clusters appears negligible in comparison to 
cluster mediated protonation, thermodynamic properties, such as gas-phase acidity and 
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basicity of the analyte are probably less relevant for predicting the formation of [M+H]+ 
ions than its polarity. However, several further analyte properties, e.g., steric hindrance, 
certainly play a role in the overall ionization efficiency, requiring more research and 
evaluation in the future [54].  
4.3.2 Review of GC(×GC)-APCI-MS applications  
This section focuses on applications in positive APCI mode over the last decade. Here-
inafter, metabolomics studies are discussed in detail (partly taken from [44]) and a brief 
overview on GC(×GC)-APCI-MS studies of environmental samples, foodstuffs, pharma-
ceutical impurities, pesticides, steroids and VOCs is provided in Table 12.1 in the ap-
pendix. In summary, recent publications have demonstrated the advantages of GC-
APCI-TOFMS with regards to the range of amenable compounds, detection sensitivity, 
compound identification and the provision of complementary information compared to 
conventional GC-MS approaches.  
Only few metabolomics studies employing GC-APCI-MS have been published so far. 
Ishimaru et al. in 2008 [11] used APCI for headspace GC-MS to reduce complexity of 
mass spectra of volatile metabolites in bacterial samples. Three different bacterial spe-
cies (Escherichia coli, Streptococcus pneumoniae and Staphylococcus aureus) were 
included in the study, which revealed 156 out of 163 peaks detected in total (95.7%) to 
be species specific. However, the potential of GC-APCI-MS for the rapid identification of 
pathogens might be compromised by a low repeatability of the presented approach, or 
the identified peaks might not have originated from the bacterial species. In fact, only 
54.7% to 75.3% (on average 68.0%) of detected peaks overlapped in the analyses of 
the three strains upon repeated cultivation, which was not further addressed in the pa-
per. In addition to that, the peaks that were thought to be specific to one of the bacterial 
species were selected according to visual judgement rather than statistical analysis of 
an adequate number of biological replicate samples [11].  
“In 2009, Carrasco et al. [9] tested GC-APCI coupled to a Bruker microTOF mass spec-
trometer using a standard mixture with 31 compounds from diverse chemical classes 
(amino acids, organic acids, alcohols, etc.). The complete analytical procedure, includ-
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ing source and instrument parameters, was optimized and evaluated with respect to 
characteristic analytical parameters. LODs were within 11.8 to 72.5 nM, which is con-
siderably lower than previously published for the determination of these compounds by 
GC-EI-qMS. LOQs were in the sub-micromolar range (between 0.05 and 0.24 µM) and 
the linear range extended over three orders of magnitude. Furthermore, good interday 
repeatabilities below 7% (RSD) were achieved. The developed method was applied to 
the analysis of human cerebrospinal fluid samples. Adequate values of mass error and 
sigma value (below 2 mDa and 10, respectively) made it possible to identify more than 
300 distinct features in cerebrospinal fluid (CSF) samples [9].  
Pacchiarotta et al. (2010) applied the well-known concept of parallel detection for 
metabolomics studies using APCI-TOFMS and FID [10]. Since APCI works at ambient 
pressure, parallel detection is fairly straightforward while parallel detection with conven-
tional EI-MS detectors requires restriction capillaries in order to maintain proper column 
flow to both detectors. In this study, MS combined with APCI ionization provided high 
detection sensitivity with LOQs of silylated amino acids of about 0.5 µM and additional 
structural information. In contrast to that, FID appeared to be more robust, and provided 
a wider dynamic range that is especially helpful for quantification of compounds present 
at concentrations above saturation of the MS detector. Furthermore, FID covers all 
organic peaks, some of which might be missed by GC-APCI-MS, but it ideally requires 
baseline-resolved analytes, which is often not achieved by one-dimensional GC for 
complex biological samples. Nevertheless, the authors claim that MS and FID provided 
complementary information that might be helpful to expand the set of analyzable com-
pounds in metabolic profiling studies [10].” [44] 
The results of my master thesis were compiled in the beginning of my doctoral thesis 
and published in 2011 [17]. In this work, GC-APCI-TOFMS was compared to GC×GC-
EI-TOFMS, GC-EI-TOFMS, GC-CI-qMS and GC-EI-qMS in terms of repeatability, dy-
namic range, limit of detection and quantification using a mix of 43 metabolites and 12 
internal standards. Lower limits of quantification for GC-APCI-TOFMS ranged between 
0.06 and 7.81 µM, and relative standard deviations for calibration replicates were be-
tween 0.4 and 8.7%. For all compounds and techniques, except in four cases, R square 
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values were above 0.99. With regards to limits of quantification, GC-APCI-TOFMS was 
only inferior to GC×GC-EI-TOFMS, but outperformed all other techniques tested. GC-
APCI-TOFMS was further applied to metabolic fingerprinting of E. coli wt strain MG1655 
and the double-mutant PntAB-UdhA. The latter mutant lacks two genes encoding for 
two transhydrogenase isoforms that are involved in the electron transfer from NADH to 
NADP+ and vice versa. It was reported that this leads to a substantial re-routing of the 
metabolic flux from glycolysis to the pentose-phosphate pathway to meet the cellular 
demand for NADPH [73]. Out of 45 features that differed significantly (false discovery 
rate <0.05) between the two E. coli strains, 25 metabolites, mainly from the Krebs Cycle 
and related pathways, were identified due to highly accurate and reproducible mass 
measurement (m±SD below 5mDa over m/z 190-722). Starting from the protonated 
molecule, six additional metabolites were identified that had not been found in a previ-
ous study using GC×GC-EI-TOFMS and the NIST 05 mass spectral library for identifica-
tion purposes. In fact, identification based on their EI spectra was not possible because 
the derivatives of dihydroorotate, N-acetylneuraminate and N-acetylputrescine were 
contained in neither the used NIST 05 nor the commercial Fiehn metabolite library. 
Silylation adducts formed in the APCI source helped the identification of unknown com-
pounds as its formation proved to be structure-dependent as it was not observed for 
compounds lacking a carboxylic group. It was concluded that GC-APCI-TOFMS is a 
potentially useful tool for metabolomics. However, ionization at atmospheric pressure 
was influenced by multiple factors. For example, moisture content in the source was 
highly variable and correlated to the humidity in the laboratory. This requires future 
investigations to evaluate and optimize factors influencing reproducibility during GC-
APCI-TOFMS analysis. This might benefit lower limits of quantification, as well as more 
consistent results in comparative studies in metabolic fingerprinting.  
Part of the reason why APCI has not been more widely adopted in GC-MS based 
metabolomics is the lack of commercial mass spectral libraries. Pacchiarotta et al. 
(2013) addressed this issue by building a web-based 150-component GC-APCI-QqTOF 
spectral library [74], which also proved to be useful in the current thesis (see chapter 8). 
Compounds most commonly found in biofluids and/or food specimens were initially 
included in the library, such as amino acids, fatty acids, organic acids and sugars. Chal-
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lenges in the GC analysis of above mentioned metabolite classes with their common 
fragmentation patterns are described in the article, which also provides a protocol for de 
novo identification of unknowns on a routine basis comprising the steps of (1) spectra 
calibration, (2) calculation of elemental formulas considering the isotopic distribution, (3) 
MSn experiments to reduce the number of putative candidates, and (4) verification with 
an analytical standard if available [74]. The spectral library and de novo identification 
protocol were employed in follow-up studies on avocado fruit extracts [75,76] and hu-
man urine specimens [77] by the same authors. GC-APCI-TOFMS proved as comple-
mentary tool to GC-EI-qMS in the characterization of the avocado fruit metabolome, 
with a wider range of amenable compounds in terms of polarities and molecular weights 
that could be analyzed. However, this might be partly explained by the different intrinsic 
detection capabilities of the employed mass analyzers. In fact, GC-APCI was coupled to 
an orthogonal-accelerated Qq-TOF MS, whereas a single quadrupole was used for GC-
EI-MS analysis [75]. Untargeted metabolomics by GC-APCI-TOFMS was further per-
formed in two studies to either investigate the effects of ripening degree and fruit varie-
ties on the metabolic profile of avocado fruits [76] or urinary tract infection (UTI)-induced 
changes of the human urinary metabolome [77]. Two-class PLS-DA models were built 
first using the information on the degree of avocado ripening and the infectious status of 
the E. coli UTI patients, either diseased on the day of enrolment or recovered after 30 
days, as sample class characteristic. This was followed by the allocation of peaks that 
accounted for the observed group separation in each case. Several of the identified 
metabolites could be corroborated by previous studies and information on new possibly 
relevant metabolites was gained, demonstrating, according to the authors, the useful-
ness of the applied GC-APCI-MS platform in exploratory studies for these applications. 
However, a major limitation was the incomplete annotation of important group discrimi-
nating peaks, which might improve with the future expansion of the employed GC-APCI-
MS spectral library [76,77].  
GC-APCI-MS has also been exploited as a complementary tool to GC-EI-MS for un-
known metabolites that had escaped previously identification using EI libraries. 
Strehmel et al. (2014) derived a strategy for the pair-wise assignment of GC-EI-qMS 
and GC-APCI-QTOFMS mass spectra based on 102 known components in MeOx-TMS 
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derivatized extracts of Arabidopsis thaliana [78]. GC separation was achieved under 
almost identical conditions, which facilitated establishing a prediction model for GC-
APCI-QTOFMS retention times based on GC-EI-qMS data. Furthermore, in order to 
identify the corresponding APCI spectrum of an unidentified EI spectrum in the GC-
APCI-QTOFMS data, the mass of the protonated molecule could be hypothesized for 
80% of the reference compounds. This was based on the EI molecular and/or [M-CH3]+ 
ion, or a pair of consistent EI and APCI fragment ions. From the protonated molecule 
elemental formulas were then calculated and additional information from experiments 
with deuterated derivatization reagents and CID mass spectra was incorporated, ulti-
mately leading to 14 structural hypotheses for a total of 25 unknown compounds [78]. A 
similar strategy for the pair-wise assignment of GC-APCI-TOFMS and GC×GC-EI-
TOFMS mass spectra was applied in chapter 8 in the current thesis. Moreover, Jaeger 
et al. employed GC-APCI-TOFMS and the above-mentioned concept of retention time 
prediction / elemental formulae calculation to confirm putatively annotated metabolites 
by GC-EI-MS in the study of global metabolomic changes in Caenorhabditis elegans 
lifespan mutants [79]. The number of metabolites identified by APCI was found to be 
comparable to EI, with a total of 95% (108 of 114) primary GC-EI-MS annotations con-
firmed by the elemental sum formulas obtained from high-resolution APCI-TOFMS data. 
Importantly, this included several metabolites with a low EI spectral match factor or high 
RI deviation relative to the library reference compound. In the further course of the 
study, PCA, hierarchical clustering and ANOVA followed by post-hoc testing were per-
formed on the GC-EI-MS data, revealing a critical role of peroxisomes in aging [79].  
 
4.4 Experimental design and data analysis in metabolomics 
A metabolomics study comprises several experimental steps, subsequent data analysis, 
and, finally, biochemical interpretation of the results. Sampling, quenching, extraction of 
metabolites and derivatization have to be performed. Samples are further analyzed 
using optimized and validated analytical methods. Common data analysis steps include 
data pre-processing, (optionally) manual peak integration, statistical analysis, identifica-
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tion of metabolites, and validation of the results. Finally, the study outcome has to be 
interpreted in the particular biological context. In such a study, the observed variability 
of an acquired data set results from biological, pre-analytical and analytical sources. 
The latter two are preferably reduced to a minimum. Established protocols for quench-
ing, extraction of metabolites and derivatization were used to cope with pre-analytical 
variability as described in chapter 5 and the experimental sections of the following chap-
ters. In this subchapter, strategies are described that were applied in this thesis to elim-
inate analytical variability. Furthermore, an overview on data analysis is given, with an 
emphasis on the evaluation of high-resolution GC-APCI-TOFMS data.  
4.4.1 Setting up an analysis 
Proper priming of the analytical system is a key factor in obtaining data of high quality. 
Whenever parts of the GC system (e.g., ferrules, connectors, pre-column) are ex-
changed, the system has to be checked for leaks and the oven temperature should be 
ramped stepwise to the maximum temperature tolerated by the stationary phase to 
clean and equilibrate the system. It is also advisable to start a sequence with a blank 
sample containing, e.g., the derivatization reagents to equilibrate the system. A test 
mixture can be used to check proper and expected performance of the system. GC 
column performance should be monitored on a regular basis because contamination of 
the column or column bleeding over time may deteriorate chromatographic separation. 
Some degradation of the stationary phase, typically more pronounced for thick film 
stationary phases, is unavoidable. It is mainly visible as an elevated baseline at higher 
column temperatures, which is caused by the formation of linear and cyclic polysilox-
anes in case of siloxane-based stationary phases. In particular oxygen in the carrier gas 
in combination with higher column temperatures will increase column bleeding. This 
background noise negatively affects the quality of MS spectra and the limit of detection. 
Nowadays, most manufacturers offer low bleed column that are suitable for GC-MS.  
In case of GC-MS instruments with nominal mass resolution, tuning of the mass scale 
and ion intensities is performed with perfluorotributylamine (PFTBA) on a regular basis 
using automated routines in the MS software. For high-resolution MS, however, tuning 
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is more elaborate. Initial external calibration with a vendor standard mixture that con-
tains masses in the range of the planned application is advised. Ions monitored for 
calibration should not go into saturation, and experimental masses should not deviate 
more than 1 ppm from their theoretical values. In addition, mass spectra should be 
recalibrated after every analysis, because mass accuracy of high-resolution TOFMS 
and qTOFMS instruments suffers from slight drifts in temperatures and/or voltages 
between runs. This can be accomplished by the addition of standards to each sample 
(for details see section 5.4.3). Moreover, a lock mass that is present in every spectrum 
can be used to recalibrate the mass scale afterwards.  
Samples should be analyzed in random order. Blanks, quality control samples such as 
pools of individual samples, and calibration controls should be interspersed. The addi-
tion of blanks helps to identify contamination peaks that originate from solvents, extrac-
tion solutions, impurities from internal standards or the column. The blanks should un-
dergo the complete analytical procedure. Quality control samples are helpful especially 
in case of large sample sets that cannot be analyzed in a single batch. Between-block 
effects, also called batch effects, are most critical in metabolic fingerprinting. Quality 
control samples that are repeatedly measured may be used to correct for variance in-
troduced by instrumental drifts. Calibration controls should also be included to ensure 
proper quantitation across a batch. They may contain two to three calibration standards 
well in the linear range of the calibration curves of the target compounds and are used 
to calculate recoveries.  
An important aspect of metabolomics is the generation of quantitative data. In order to 
account for matrix effects and to achieve required levels of accuracy and precision, SIL-
ISs are commonly included in quantitative analysis. Ion suppression or enhancement in 
case of the stable isotopically labeled analogue is expected to be equal to that of the 
sample analyte given the almost identical chromatographic and ionization behavior. One 
should note that deuterated internal standards, depending on the number of deuterium 
atoms incorporated, might show a partial separation from the unlabeled analyte. Using 
unique quantification traces, the mass spectrometer is capable of distinguishing analyte 
and labeled analogue. For quantification, the response [peak area normalized by the 
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corresponding internal standard (IS) peak area and internal standard concentration: 
peak area × IS concentration/IS peak area] is plotted instead of the peak area value. At 
the initial stage of method development, it is important to evaluate matrix effects, which 
have been reported mostly for LC-MS [80,81], but also for GC-APCI-MS [82]. Spike-in 
experiments should be performed to reveal ion suppression [83]. Definite amounts of 
the studied analyte are added to the extracted samples. Plotting the response values of 
calibrators and spiked sample extract against each other should yield a linear curve with 
a slope of one and an intercept of zero. However, possible over-quantification may go 
unnoticed in spike-in experiments [39]. For that reason, absolute amounts obtained by a 
novel method should always be validated by an established technique or the analysis of 
certified reference materials.  
Furthermore, the addition of standards before extraction and injection, respectively, 
allows the detection of extraction losses and/or problems with sample injection. The 
addition of a homologous series of standards further enables the calculation of retention 
indices. In their plant metabolomics studies, Gullberg et al. [84] included 11 SIL-ISs 
representing different compound classes and optimized their extraction and derivatiza-
tion protocols using a design-of-experiments approach. Koek et al. [41] distinguished 
three performance classes of silylated metabolites and recommended the inclusion of 
representative compounds from each class, preferably labeled with stable isotopes, for 
method optimization and validation. This classification was based on derivatization 
efficiency, analytical repeatability and reproducibility, linear range and quantification 
limits. Sugars and organic acids, which showed the best performance, were classified 
as group I compounds, followed by metabolites containing amine or phosphoric func-
tional groups (group II compounds), whereas those with amide, thiol or sulfonic func-
tional groups (group III compounds) were regarded as the most critical to analyze [41].  
However, SIL-ISs are expensive and their availability is limited. In addition, they can 
complicate several data processing steps, such as deconvolution, peak picking and 
integration, especially in the case of GC×GC-MS [43]. Lien et al. [85] employed 
deuterated MSTFA as a derivatizing reagent (d9-MSTFA) for a mixture of standard 
compounds to overcome the limited number of available SIL-ISs. This deuterated 
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standard mix was then spiked into MSTFA derivatized samples prior to GC-MS/MS 
analysis. However, this strategy does not correct for metabolite losses during sample 
preparation and derivatization. Alternative approaches to overcoming the lack of com-
mercially available SIL-ISs include the use of d3-MCF/d3-MeOH to generate stable 
isotopically labeled methyl chloroformate derivatives [86] and the in vivo biosynthesis by 
feeding microorganisms stable isotopically labeled substrates [87]. However, such ap-
proaches will cover only parts of more complex metabolomes observed for example in 
plants and mammals. 
4.4.2 Data analysis workflow 
Analysis of the acquired mass spectral data depends on the intended strategy. For a 
quantitative method, mass traces (quantifier and qualifier ions) of the target compounds 
have to be specified, along with their retention time, and an internal standard has to be 
assigned for each analyte that is ideally the labeled analogue. Concentration levels of 
the standards have to be defined, further parameters may be defined (e.g. 1/x weighing 
for linear regression analysis or smoothing), and finally calibration curves can be calcu-
lated and integrated together with the samples. If SIL-ISs are used, isotope dilution 
analysis can be performed for quantification.  
For comparative analysis of multiple sample groups in an untargeted approach, data 
files are pre-processed first, e.g., baseline correction, recalibration of the mass scale, 
deconvolution and peak picking are performed, and then peaks across chromatograms 
are aligned in one data matrix that contains their m/z values, retention times and area 
integrals. In the process of data processing and alignment, one has to be aware of 
several pitfalls, such as batch effects or missing values in the data matrix. The latter can 
be imputed by dedicated software algorithms provided that they are missing completely 
at random [88]. Prior to multivariate analysis, it is important to minimize contributions 
from unwanted biases and experimental variance by using normalization methods. The 
simplest of these would be normalization to an appropriate internal standard or the sum 
of all integrals in the sample, whereas more advanced methods include quantile normal-
ization or variance stabilization approaches in the absence of significant between-group 
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differences in total signal intensity. Depending on the nature of specimens analyzed, 
further normalization may be conducted to correct for undesired biological variance, 
such as normalization to creatinine concentration in case of urine specimens as a con-
sequence of differences in fluid intake or to the number of cells or protein content in the 
analysis of cell extracts. Since the number of peaks, features, or “dimensions” that a 
given dataset represents may number in the hundreds, dimension reduction techniques 
such as principal component analysis (PCA) are commonly used to reduce data com-
plexity and, thus, facilitate visualization of differences between samples. Selection of 
differential features for subsequent assignment to metabolites using different strategies 
for identification (see subchapter 4.5) could be initially based on two-sided t-tests or 
analysis of variance (ANOVA) followed by post-hoc tests. In case of large feature num-
bers correction for multiple testing is needed, for example, by controlling the false dis-
covery rate [89]. The ultimate goal is the reliable detection of features (biomarkers) and 
corresponding pathways that distinguish a group. In recent years, a number of different 
classification algorithms, such as nearest neighbour, linear discriminant analysis and 
classification trees, have been developed and applied to the classification of samples 
based on transcriptome data [90]. Their applicability and performance for LC/MS- or 
GC/MS-based metabolite fingerprinting data still awaits systematic evaluation. Recent 
work performed in our laboratory on 1H NMR-based metabolite fingerprints of different 
physiological fluids from different species compared Elastic Net, Nearest Shrunken 
Centroids, Partial Least Squares-Discriminant Analysis (PLS-DA), Random Forests, 
Top scoring pairs, and Support Vector Machines (SVM) as classification tools [91]. 
Random Forests and SVM combined with t-score based feature filtering were found to 
be overall the best suited techniques for classification of samples [91]. 
To facilitate the biological interpretation of results, multiple databases are available. 
Major metabolite databases are the Human Metabolome Database (HMDB) [23], the 
Madison Metabolomics Consortium Database (MMCD) [92], Metlin [25], and LIPID 
MAPS [24]. They contain huge numbers of fully annotated metabolite entries tailored to 
studies on specific compound classes/pathways, e.g. lipid metabolism, or a particular 
organism. These databases incorporate many sources of information. The HMDB, for 
example, includes chemical, clinical, and molecular biology/biochemistry data for over 
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7900 fully annotated metabolites. It also contains spectra information for more than 800 
compounds. Search entries are linked to other databases, e.g. KEGG, and still more 
dedicated software and search algorithms have been added to the latest version  
(V 2.5). However, each of the mentioned databases only covers a fraction of the metab-
olome. Therefore, one should search multiple databases. Zhou et al. [93] recently im-
plemented a web-based software tool, which searches the four major metabolite data-
bases listed above, and finally combines the results for a more comprehensive 
coverage of possible candidates for mass-based metabolite identification. In addition to 
searching databases, mapping of identified metabolites to corresponding metabolic 
pathways is helpful. In a recent work by Leader et al. [94], the authors described a freely 
available tool called “Pathos”, which uses as input raw m/z values or KEGG IDs, if the 
metabolites have been already identified, to search the KEGG database. Apart from 
returning a pathway map with the identified metabolites highlighted, it can also visualize 
changes in their experimental abundance if relative quantification data under different 
experimental conditions is provided. This allows the scientist to obtain a quick survey 
over regions of metabolism of potential interest. Finally, metabolomics data can be 
combined with results from other –omics fields to yield a global picture of the biological 
entity under study.  
4.4.3 Recalibration of high-resolution GC-APCI-TOFMS data and cal-
culation of elemental formulas 
Especially in the case of GC-high-resolution MS (GC-HRMS), mass recalibration can be 
difficult. For external calibration, the APCI source can be replaced with an ESI source 
and calibration can be performed using an ESI tune mix. Alternatively, FAMEs can be 
infused from the top of the APCI source at the beginning of each analytical run. Howev-
er, post-acquisition recalibration of mass spectra is not as straightforward as in LC-MS. 
Internal standards that are added to every sample prior to analysis can be used for 
internal calibration, which was carried out in this thesis (compare section 5.4.3). 
Accurate mass measurements are especially beneficial for compounds that are not 
included in spectral libraries. In that case, soft ionization methods coupled to HRMS 
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yield protonated molecules, from which elemental formulas can be derived and data-
bases searched after elimination of groups that have been introduced by derivatization. 
This concept has been applied in the current thesis and is described in more detail in 
section 5.4.4. Nevertheless, high mass accuracy suffices rarely to achieve an unambig-
uous assignment of a single molecular formula to an unknown, especially in higher 
mass regions, where the number of elemental combinations for a given mass and the 
defined mass error is many times higher. Therefore, isotopic pattern matching is re-
quired as an orthogonal filter to remove false candidate formulas. Kind and Fiehn in 
2006 [95] demonstrated via query of over 1.6 million elemental formulas that an MS with 
3 ppm mass accuracy and 2% error for isotopic abundance patterns outperforms a 
hypothetical mass spectrometer with 0.1 ppm mass accuracy that does not take isotope 
information into account.  
Tools for calculating elemental formulas from accurate mass measurements, e.g. the 
SmartFormula tool from Bruker Daltonics, consider chemical and heuristic rules as 
proposed by Kind and Fiehn in 2007 [96] in addition to comparing the isotopic patterns, 
which is assessed by the mSigma value (between 0 in case of perfect match and 1000 
in case of no match). These rules include, among others, constraints on number and 
ratio of elements as well as LEWIS and SENIOR rules, and their application has result-
ed in correct metabolite annotations with 98% probability for 6,000 compounds in target 
databases [96]. For calculating elemental formulas, the search space can be reduced 
by assuming a lower experimental mass error. But, the correct formula may be missed, 
whereas if a larger mass error is tolerated, hit lists become more extensive and are 
more likely to include hits that are closer to the experimental data than the correct for-
mula. SmartFormula3D additionally relies on the accurate mass and isotope pattern of 
the fragments from a parent ion in MS/MS experiments. Accordingly, parent ions that 
cannot be related to the fragments are excluded, thus restricting the search space dras-
tically up to a single remaining elemental formula in some cases. In summary, in the 
identification process of unknowns from high-resolution GC-APCI-TOFMS data still a lot 
of manual intervention is required as reported in section 5.4.4. 
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4.5 Identification of metabolites 
Recent years have seen great progress in the identification of spectral features, still 
considered one of the biggest bottlenecks in metabolomics (see 
http://fiehnlab.ucdavis.edu/staff/kind/Metabolomics-Survey-2009/). For targeted metabo-
lomics, only very few peaks are of interest, so-called “known unknowns” that have been 
either described in the literature or included in databases, but have not been reported 
for the organism and/or type of sample at hand. Their identification is typically accom-
plished by means of commercial standards. In semi-targeted or untargeted metabolom-
ics, the use of reference compounds for the identification of features becomes cumber-
some as the number of features recorded in a single run may easily run into the 
hundreds. Therefore, routines for automatic feature annotation and identification of so-
called “unknown unknowns” are required. The rapid progress in MS technologies and 
resulting improvement in detection sensitivity has revealed a vast number of such com-
pounds that still await positive identification. This holds especially true for secondary 
metabolites of plants and fungi, whose metabolomes have been estimated to contain 
tens of thousands of individual metabolites [27]. However, these numbers are only 
rough estimates [97].  
In 2007, Sumner et al. [26] proposed four levels of metabolite identification depending 
on the amount of information collected on a feature of interest. The authors distin-
guished between positively (level 1) and putatively (level 2) identified compounds, com-
pounds that are putatively assigned to a class of compounds (level 3), and unknown 
compounds (level 4). For positive identification (level 1), matching two independent 
parameters, such as retention time index and mass spectrum, relative to an authentic 
standard is required, which emphasizes the need for chromatography as an additional 
dimension to MS. Several excellent reviews have appeared in recent years on advanc-
es in metabolite identification by means of chromatography and MS [98-101]. 
4.5.1 Gas chromatography 
Separation of analytes in a time dimension constitutes added value to the identification 
process. GC-MS retention times are very stable and, therefore, of great benefit to identi-
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fication. Typically, retention time of a compound is given relative to a reference com-
pound within the chromatogram to exclude variation due to slight instrument changes in-
between consecutive analyses and make retention times more comparable to other 
laboratories. In 1958, Kováts introduced the concept of calculating retention indices 
(RIs) [102] based on a series of alkanes as reference compounds for isothermal GC. 
This concept was later modified and applied to temperature-programmed GC by Van 
den Dool and Kratz [103]. Temperature programmed RIs are often referred to linear 
retention indices. Retention indices are a normalized measure of retention time. They 
are calculated relative to compounds from a homologous series of alkanes or fatty acids 
that are added to every sample. In temperature-programmed GC, members of a homol-
ogous series show a linear increase in retention time with increasing number of carbon 
atoms for a given stationary phase. Per definition, members of the homologous series 
are assigned a retention index by multiplying the respective carbon number with 100. 
The linear retention index I of an analyte x is calculated using the following formula: 
 
t R(x)   Retention time of the analyte 
t R(n)   Retention time of the reference compound eluting before the analyte 
t R(n+1)   Retention time of the reference compound eluting after the analyte 
n  Carbon number of the reference compound eluting before the analyte 
 
Traditionally, n-alkanes have been used as RI markers [104,105], albeit fatty acid me-
thyl esters (FAMEs) [106] or any other homologous series can be used. Selection of the 
reference system depends on column polarity, e.g. n-alkanes are poorly dissolved in 
polar stationary phases, and the detector used, e.g. n-alkanes evade ionization using an 
APCI source for GC-MS. Retention indices are partly reported in MS databases, such 
Ix = 100n + 100
tR(x) –tR(n) 
tR(n+1) –tR(n) 
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as NIST, HMDB [23], Golm Database [107], and Fiehn Metabolome Database [106]. 
Physicochemical properties of not yet annotated metabolites are collected in the Golm 
DB as mass spectral tags (MSTs), which were introduced recently [108,109] in analogy 
to expressed DNA sequence tags (ESTs). MSTs now await their structural elucidation.  
For databases to be useful, they need to be updated regularly. Insufficient resources for 
database curation still limit the utility of HMDB and Golm DB. Hence, NIST is still the 
most widely used database. The latest NIST 14 version contains EI-MS spectra for over 
242,000 unique compounds, and for more than 56,000 compounds RI values are pro-
vided. However, the majority of entries do not refer to metabolites.  
In the absence of RI values for metabolites of interest, they may be predicted. In 2011, 
Kumari et al. [110] introduced a workflow for re-identifying 29 trimethylsilylated metabo-
lites from accurate mass GC-CI-TOFMS. Elemental formulas were derived from the 
protonated molecules in an initial step, followed by in-silico derivatization and prediction 
of RIs using the NIST RI algorithm with a correction factor for TMS groups [111]. In a 
subsequent step, accurate mass EI spectra were predicted for remaining structures and 
scored against experimental spectra. As a result, the correct structure was obtained in 
73% within the top-5 hits of the proposed candidates [110]. Earlier, Mihaleva et al. [112] 
made use of multiple linear regression (MLR) and support vector regression (SVR) 
models for RI prediction, which cut the hit lists obtained from matching experimental 
spectra of the NIST 05 MS library in half.  
The concept of RIs has also been transferred to GC×GC [113], but it is not used rou-
tinely. Nevertheless, GC×GC facilitates identification of compounds belonging to differ-
ent chemical classes as they occupy different regions within the 2D separation space. 
Hence, structure-retention relationships serve as plausibility check for the identification 
of unknown signals in the chromatogram. Quantitative structure-retention relationship 
(QSRR) models have also been developed to correlate molecular structures to their 
retention times [114]. In summary, retention times are essential in compound identifica-
tion, especially in case of isomers, which cannot be distinguished by their mass spec-
trum only. To check for plausibility, one should not only rely on the mass spectrum, but 
also consider chromatographic retention of a putatively identified metabolite.  
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4.5.2 Mass spectrometry 
Mass spectrometry is the method of choice in the identification of unknown metabolites. 
Matching EI fragment patterns to spectral libraries has been traditionally performed in 
MS-based metabolite identification. A second strategy involves the use of soft ionization 
techniques in conjunction with high-resolution MS. Elemental formulas are derived from 
the accurate mass and isotopic pattern of the protonated molecules in an initial step, 
groups introduced by derivatization are removed, and curated formulas can be fed into 
databases for a putative identification (compare section 5.4.4).  
Successful identification of known unknowns based on mass spectral libraries requires 
mass spectra of high quality, powerful spectral matching algorithms to reveal significant 
degrees of spectral convergence and, particularly, comprehensive and reliable refer-
ence spectra libraries. Successful library identification strongly depends on the quality of 
the input spectrum. Spectral quality suffers often from poor deconvolution, ion source 
overload and/or varying acquisition parameters. Mass spectral deconvolution has to be 
performed in case of mixed mass spectra originating from unresolved peaks. Local peak 
maxima are analyzed for all ion traces and ions that share a peak maximum (retention 
time) are combined in one mass spectrum. This process gives a “pure” mass spectrum 
that can be matched against reference spectra. Of course, deconvolution is only suc-
cessful if overlapping peaks display a slight difference in peak maxima and if enough 
data points across the peak are available to distinguish these slight differences. Un-
doubtedly, deconvolution software packages such as AMDIS supplied with the NIST 
library, ChromaTOF (LECO), or AnalyzerPro (SpectralWorks) constitute an added value 
for proper analysis of highly complex samples. However, deconvolution may generate 
outright false or impure spectra. In 2008, Lu et al. [115] evaluated the performance of 
AMDIS, ChromaTOF and AnalyzerPro using a mixture of 36 endogenous compounds, 
which exhibited varying chemical structures and concentrations. Numerous failures of 
AMDIS and ChromaTOF occurred, which resulted in incorrect identifications [115], 
emphasizing the need for further improvements or novel approaches.  
For spectral matching, several algorithms such as INCOS, probability-based matching 
(PBM) and dot-product scoring have been described [116]. In case of INCOS and PBM, 
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the number of mass/intensity pairs of library spectra considered for matching is restrict-
ed, which might result in failure to retrieve as first hit the correct library entry for a 
searched full spectrum of an unknown. The dot-product algorithm, in contrast, is first 
carried out on condensed spectra before finally considering entire spectra for definite 
metabolite identification. Stein and Scott in 1994 [117] found dot-product scoring supe-
rior (75% accuracy) to four other algorithms (Euclidean distance, absolute value dis-
tance, PBM and Hertz et al. similarity index) based on matching test spectra against the 
NIST library, which contained 12,592 spectra of about 8,000 unique compounds at that 
time.  
The library search delivers a match factor, which is a measure for the agreement be-
tween search and library spectrum. A NIST search delivers both, a match factor (direct 
match) and a reverse match factor. The reverse search algorithm compares the library 
spectra against the search spectrum and non-matching peaks in the submitted spec-
trum are ignored. Match factors above 900 indicate an excellent match with 999 being a 
perfect match. Match factors above 800 are still considered good, while match factors 
below 700 have to be considered with care. In general, top candidates from the hit list 
should be checked for plausibility by considering information on retention indices, or 
reference standards should be run for verification.  
It is also possible to create custom libraries with commercial standards as accomplished 
by Smart et al. for methyl chloroformate derivatives [118]. In silico mass spectral frag-
mentation routines can be used if reference spectra are not available. However, in 
2009, Schymanski et al. [119] tested three commercial programs for in silico generation 
of mass fragments and concluded that available software was not practical yet. 
Alternatively, efficient and sensitive identification of metabolites may be accomplished 
by soft ionization techniques, accurate mass measurement and tandem MS. GC-APCI-
MS principles and applications (subchapter 4.3) as well as data analysis strategies 
(subchapters 4.4 and 5.4) including (re-)calibration of the mass scale and calculation of 
elemental formulas are reported elsewhere. Furthermore, GC-CI-TOFMS has also been 
employed for metabolite identification [50,110]. Abate et al. [50] reported, that higher ion 
intensities improved accurate mass and isotopic abundance measurements and thus, 
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allowed the determination of elemental formulas with higher confidence. In these GC-
CI-TOFMS studies, high-mass tuning [50] as well as the careful selection of the reagent 
gas [110] proved critical in obtaining higher ion intensities.  
According to Sumner et al. [26], two independent/orthogonal parameters, e.g. retention 
index/mass spectrum or accurate mass in combination with MS/MS information, relative 
to a commercial standard are required to positively identify compounds. Whenever 
standards are not available, confidence in a putative identification can be increased by 
the use of isotope labeling to distinguish background ions from ions that originate from a 
true biological source. Furthermore, with the commercial availability of fraction collectors 
for GC, compound isolation for metabolite identification by NMR spectroscopy has be-
come feasible. However, stability of derivatized metabolites is critical while collecting 
fractions by cold trapping and a huge discrepancy exists between amounts that are 
subjected to GC-MS analysis and those required for NMR analysis. Once a single or 
several metabolites have been identified, proper biological or medical interpretation is 
promoted by metabolic pathway databases such as the Kyoto Encyclopedia of Genes 
and Genomes (KEGG) database [120].  
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5 Experimental section 
5.1 Materials  
The mixture of fatty acid methyl esters (FAMEs #CRM47885) in methylene chloride was 
purchased from Supelco (Belafonte, PA, USA). Compounds included in the metabolite 
standard mixtures used in chapters 6, 7, and 8, except for glycerol, as well as citric acid, 
aminoadipic acid, malic acid, tryptophan, lysine, threonine, cysteine, histidine, tyrosine, 
arginine, asparagine, lauric acid, myristic acid, stearic acid, serine, ornithine, glycine, 
palmitic acid, N-acetyl-L-aspartic acid, odd-numbered, saturated straight-chain fatty 
acids (C9-C19), pyridine, methyl chloroformate (MCF), methoxylamine hydrochloride, 3-
picoline, propyl chloroformate, fetal bovine serum, L-glutamine, sodium dodecyl sulfate, 
the FluoroProfile kit for determination of protein content in cell pellets, the disodium salt 
of D/L racemate of 2-hydroxyglutarate, disodium D- and L-2-hydroxyglutarate, (R)-5-
oxotetrahydro-2-furancarboxylic acid, formic acid, 3-trimethylsilyl-2,2,3,3-
tetradeuteropropionate (TSP) in D2O, ethanol (ACS reagent grade), urease type III 
(#U1500), [U-13C]glucose, [2H7]trans-cinnamic acid, norvaline, [U-13C]β-hydroxybutyric 
acid, [2,4,4,4-2H4]citric acid, and alkane standard solutions (C8-C20 and C21-C40) were 
from Sigma-Aldrich/Fluka (Taufkirchen, Germany). N-Methyl-N-(trimethylsilyl)-
trifluoroacetamide (MSTFA) was purchased from Macherey-Nagel (Dueren, Germany), 
sodium dihydrogen phosphate monohydrate, tri-sodium phosphate dodecahydrate, di-
potassium hydrogenphosphate trihydrate, potassium dihydrogen-phosphate, and chlo-
roform (analytical grade) from Merck KGaA (Darmstadt, Germany), and [U-13C, U-15N] 
cell-free amino acid mix, [U-13C]lactic acid, sodium [U-13C]pyruvate, [U-13C]fumaric acid, 
and [U-2H]succinic acid from Euriso-top (Saint-Aubin Cedex, France). [4,6,7-2H3]5-
hydroxyindole-[2H2]acetic acid, D/L-[2,3,3-2H3]malic acid, and the disodium salt of D/L-
[2,3,3-2H3]2-hydroxyglutarate were delivered from C/D/N Isotopes Inc. (Quebec, Cana-
da), and [U-13C]lactose from Omicron Biochemicals (South Bend, IN, USA). Methanol 
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(MeOH; LC-MS grade), ethyl acetate (analytical grade), methylene chloride (LC-MS 
grade) and propanol (LC-MS grade) were from Fisher Scientific GmbH (Ulm, Germany), 
and glycerol, isooctane and acetonitrile (HPLC grade) from BDH Prolabo (VWR Interna-
tional, Vienna, Austria). Purified water from a PURELAB Plus system (ELGA LabWater, 
Celle, Germany) was used in all experiments. MiaPaCa-2 pancreatic cancer cells 
(ATCC #CRL-1420) were obtained from ATCC (Manassas, VA, USA). DMEM medium, 
glucose, and phosphate-buffered saline (PBS) were purchased from PAA Laboratories 
GmbH (Coelbe, Germany), and penicillin/streptomycin from Invitrogen (Karlsruhe, Ger-
many). The Hsp90 inhibitor 17-DMAG was obtained from Invivogen (Toulouse, France).  
A surrogate solution was prepared containing the 12 internal standards [2,2,4,4-
2H4]citrate, [U-13C]fumarate, [U-13C]glucose, [U-13C]-hydroxybutyrate, [U-13C]lactate, 
[2,3,3-2H3]malate, [U-13C]pyruvate, [U-2H]succinate, [2H7]trans-cinnamate, [U-
13C]lactose, [4,6,7-2H3]5-hydroxy-indole-[2H2]acetate and norvaline at 1 mM each in 
methanol. The odd-numbered, saturated straight-chain fatty acids (C9-C19) were dis-
solved in isooctane, and combined, hereinafter referred to as fatty acid mixture (1 mM of 
each compound). 
 
5.2 Sample preparation 
5.2.1 Preparation of calibration and cell culture samples  
For the acquisition of calibration curves in chapter 8, 75 or 100 µL of a metabolite 
standard and 10 µL of the surrogate solution of ISs were combined in a 2-mL vial with a 
400-µL glass insert and evaporated, respectively, only surrogate solution or 100 µL of 
pure methanol was dried in case of blank samples. Subsequently, MeOx-TMS derivati-
zation was performed. To assess derivatization repeatability, a calibration standard at a 
concentration of 31.25 µM was derivatized in quintuplicate. 
MiaPaCa-2 pancreatic cancer cells were grown in 75 cm2 cell culture flasks (PAA La-
boratories GmbH) in 25 mL of DMEM medium supplemented with 15% (v/v) fetal bovine 
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serum and enriched with 2 mM glutamine, 25 mM glucose, and standard penicil-
lin/streptomycin solution. Cells were cultured in a humidified incubator at 37°C with 5% 
CO2. For assessing the effect of 17-DMAG on cell metabolism, 1 × 106 cells were plated 
into 10-cm Petri dishes and treated for 72 h with either medium containing 100 nM 17-
DMAG or control medium only. Cells were washed thrice with cold PBS. For quenching 
of cell metabolism as well as combined cell harvesting and extraction of metabolites, 
direct solvent scraping in MeOH/H2O (80:20, v/v) [121] was performed on ice and with 
cold solutions. The aforementioned experiments were carried out by Dr. Maria My-
cielska from the Department of Surgery/University Hospital Regensburg.  
Pellets were re-extracted twice more with 500 µL of MeOH/H2O (80:20, v/v). The super-
natants were combined and fully evaporated. Dried extracts were redissolved in 200 µL 
of MeOH/H2O (80:20, v/v), and 60 µL were taken for MCF derivatization in chapter 6 
(N=5 biological replicates per group). For the determination of cellular protein content 
according to the instructions provided with the FluoroProfile kit from Sigma-Aldrich, 
protein pellets were dissolved in 1 mL of a 20 mM sodium dihydrogen phosphate buffer, 
pH 4.5, supplemented with 1% (v/v) sodium dodecyl sulfate and diluted 1:50 (v/v) with 
water.  
Cell culture supernatants from the above-described experiment of MiaPaCa-2 pancreat-
ic cancer cells grown for 72 hrs under standard conditions (N=3 biological replicates) 
were used in chapter 8. Hundred µL of each supernatant sample were further prepared 
as follows: Ten µL of 1 mM [2H7]trans-cinnamate were added to 100 µL of supernatant. 
Proteins were precipitated with 600 µL cold methanol, centrifuged for 6 min at 4°C and 
9500 × g and the supernatant was collected. The protein pellet was washed twice with 
200 µL of methanol. The supernatants were combined and the solvent was evaporated. 
MeOx-TMS derivatized cell culture supernatant samples were diluted 50:50 (v/v) in 
pyridine prior to injection. 
5.2.2 Methoximation–trimethylsilylation 
A two-step MeOx-TMS derivatization protocol was applied to dried standards (chapters 
6, 7, and 8), spiked serum samples (chapter 6), spiked matrix samples (chapter 7), and 
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cell culture supernatants (chapter 8). Fifty µL of 20 mg/mL methoxylamine hydrochloride 
in pyridine were transferred to the dried residues and incubated at 60°C for 60 min. 
Prior to silylation, 10 µL of the fatty acid mixture were added, for internal recalibration of 
GC-APCI-TOFMS mass spectra as well as the calculation of retention indices. Silylation 
was carried out by the addition of 50 µL of MSTFA, and again incubating for 60 min at 
60°C. Derivatization was carried out manually. 
5.2.3 Methyl chloroformate/methanol derivatization 
Manual MCF derivatization was performed in chapters 6 and 9 based on a modified 
MeOH/MCF protocol published previously [39]. Depending on the experiment, water 
was added to the standard, IS, and sample or sample extract already containing the IS, 
to obtain a final volume of 275 µL of aqueous phase. For the analysis of sample ex-
tracts, the mixture was dried and reconstituted in 275 µL of water. Next the aqueous 
phase was fortified with 167 µL of MeOH, and 34 µL of pyridine, followed by adding two 
times 20 µL of MCF vortexing for 10 s after each addition. Derivatives were extracted 
with 300 µL CHCl3 under vortexing for 10 s. After 30 s, extraction was completed and an 
aliquot of the lower chloroform phase was taken for GC analysis.  
 
5.3 Instrumentation 
5.3.1 GC-APCI-TOFMS 
A model 450-GC (Bruker Daltonics GmbH, Bremen, Germany) with an autosampler 
(model PAL COMBI-xt from CTC Analytics, Zwingen, Switzerland) for sample injection 
with a 10-µL Hamilton syringe was coupled to a microTOF orthogonal acceleration TOF 
mass spectrometer (Bruker Daltonics) via an APCI source. For separation of analytes, a 
Phenomenex ZB-AAA column (15 m × 0.25 mm i.d. × 0.1 µm film thickness, Torrence, 
CA, USA) was used with a 2 m deactivated pre- and a 0.5 m post-column of matching 
inner diameter (Agilent Technologies, Palo Alto, CA, USA). The oven temperature pro-
gram was started at 50°C and held for 1 min, and temperature was ramped at 8 K/min 
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to 300°C and held for 15 min. A sample volume of 1 µL was introduced by means of an 
1177 split/splitless injector at 280°C performing hot needle splitless injection (pre-
injection dwell of 1 s) with a splitless time of 1 min. Helium served as the carrier gas at a 
constant flow rate of 1 mL/min. The transfer line to the MS instrument was maintained at 
300°C, and the protrusion of the GC capillary from the exit of the transfer line was ap-
proximately 1 mm. The APCI source was operated as follows, with deviating parameter 
settings in chapter 7 in brackets: ionization mode, positive; drying gas (nitrogen) tem-
perature, 160°C; drying gas flow rate, 2.0 L/min; APCI vaporizer temperature, 300°C 
(450°C); nebulizer gas (nitrogen) pressure, 4.0 bar (1.7 bar); current of the corona dis-
charge needle, +3000 nA; capillary voltage, -2900 V; end-plate offset, 0 V. Water was 
introduced through the top ESI inlet into the APCI source by means of a syringe pump 
(KD Scientific Inc., Holliston, MA, USA) in chapters 6 and 9 unless otherwise stated in 
the text. Mass range for acquisition of spectra with a rate of 3 spectra/s was from 50 to 
1000 m/z. Initial external mass calibration was performed with an electrospray ionization 
tuning mix (Agilent) and an ESI source, and an additional post-acquisition processing 
routine was performed for internal recalibration of each mass spectrum (see section 
5.4.3).  
Diverging from the instrumental and operational settings above, an Agilent model 6890 
GC instrument equipped with an Auto Liquid Injector (model 7683B) was used in chap-
ter 7, and data were acquired with the “GC-APCI II” source from Bruker in chapters 8 (in 
addition to measurements with the APCI I source) and 9. Chromatographic separation 
was achieved using a Rxi-5MS capillary column (30 m × 0.25 mm i. d. × 0.25 µm film 
thickness, Restek, Bad Homburg, Germany) in chapters 7 and 8, whereas an Rt-
DEXsa (2,3-di-acetoxy-6-O-tert-butyl-dimethylsilyl gamma CD doped into 14% cy-
anopropylphenyl/86% dimethyl polysiloxane) column (30 m × 0.25 mm ID, 0.25 µm film 
thickness; Restek) was used in chapter 9. The flow rate of helium as carrier gas was set 
to 2 mL/min (constant flow) and the injector was kept at 250°C in chapter 9. In the same 
chapter, except for initial experiments to optimize the temperature ramp, the oven pro-
gram started at 70°C, held for 1 min, was then ramped at 5 K/min to 190°C, and finally 
held for 7 min. 
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The APCI II transfer line to the mass spectrometer was maintained at 290°C, and the 
post-column capillary was mounted flush with the outlet of the transfer line. APCI II 
source parameters were as follows: ionization mode, positive; drying gas (nitrogen) 
temperature, 150°C; drying gas flow rate, 2.0 L/min; nebulizer gas (nitrogen) pressure, 
2.5 bar; current of the corona discharge needle, +4000 nA; capillary voltage, -3000V; 
and end-plate offset, -500V. The APCI II source was kept at 300°C. No water was in-
fused into the APCI source in projects presented in chapters 7 and 8. 
Details on the “GC-APCI II” source setup are provided in section 8.2.2. The source 
parameters for APCI I and II were individually optimized using metabolite standards as 
part of my master thesis and the bachelor thesis by Thomas Hahn, respectively. 
5.3.2 Miscellaneous 
Solvents were evaporated to complete dryness by means of a vacuum evaporator 
(CombiDancer, Hettich AG, Bäch, Switzerland). Other lab equipment used in the course 
of this doctoral research work included a model MP220 pH meter from Mettler-Toledo 
GmbH (Greifensee, Switzerland) for the preparation of buffer solutions, a vortexer (lab 
dancer, IKA-Werke GmbH, Staufen, Germany), a heater with two heating blocks (Haep 
Labor Consult, Bovenden, Germany), a model GS-15R centrifuge (Beckman Coulter 
GmbH, Krefeld, Germany), and a FLUOstar OPTIMA multi-mode microplate reader 
(BMG Labtech, Ortenberg, Germany) for the determination of cellular protein content 
based on fluorescence measurements.  
 
5.4 Data analysis 
5.4.1 Software 
Bruker DataAnalysis versions 4.0 to 4.1 (Bruker Daltonics) were employed for pro-
cessing and manual inspection of GC-APCI-MS chromatograms and mass spectra, 
compound extraction, internal recalibration of mass spectra, and calculation of accurate 
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masses, elemental formulas and mSigma values. For peak integration and generation 
of calibration curves, exported data files were loaded into MassLynx V4.1 (Waters Inc., 
Milford, MA, USA), with m/z of [M+H]+ for standard compounds and internal standards 
(see Table 12.2, Table 8.2 and Table 9.1 referring to chapters 6, 8, and 9, respective-
ly), or m/z of a particular significant feature used as quantifier mass. ChemStation ver-
sion D.02.00.275 (Agilent) was used for manual inspection of GC-EI-qMS chromato-
grams (section 9.3.1). GC×GC-EI-TOFMS raw data were processed by ChromaTOF 
software version 4.50 from LECO Corp. (St. Joseph, MI, USA) for annotating com-
pounds in cell culture supernatants (chapter 8). Compounds extracted in DataAnalysis 
along with their retention times, experimental masses, area integrals, peak widths 
measured at half the peak height (wh), and S/N ratios were further exported into Excel 
(Microsoft Corporation, Redmond, WA, USA). Generation of bucket tables, feature 
extraction by means of the FMF algorithm, and alignment were performed in ProfileA-
nalysis V2.1 (Bruker Daltonics). Bucket tables were then exported into Excel for genera-
tion of ROC curves and fold change plots (chapter 6) as well as cumulative distributions 
of RSDs (chapter 8). Excel was also used to create Bland-Altman plots and to perform 
basic statistics, e.g. the calculation of relative standard deviations (RSDs) or paired 
student’s t tests. The statistical computing package R [122] was used to perform princi-
pal component analysis (PCA), the Kolmogorov-Smirnov test, Shapiro-Wilk testing, the 
Wilcoxon signed-rank test, ANOVA followed by post hoc tests using LIMMA [123], to 
impute missing values by MISSMDA [124], and to calculate false discovery rates 
(FDRs) according to Benjamini and Hochberg [89] using MULTTEST [125]. The partition 
coefficients of the MCF and MeOx-TMS derivatives of the standard compounds and 
fatty acids analyzed in chapter 6 were estimated using ACD/Laboratories V12.01 (Ad-
vanced Chemistry Development Inc., Toronto, Canada) and expressed as the  
log Poctanol/water, i.e., the logarithm of the ratio of the concentrations of the un-ionized 
solute in octanol and water, respectively. Retention indices were calculated in Excel on 
the basis of alkanes or fatty acid derivatives according to equation (8) from a previous 
work by van den Dool and Kratz [103]. 
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5.4.2 Calibration curves 
Peak areas of standards were normalized to those of their corresponding SIL-ISs or a 
closely eluting or structural similar IS (see Table 8.2 and Table 9.1). Hence, the re-
sponse (area*IS concentration/IS area) was plotted as a function of the absolute 
amount of standard to yield the calibration curve for each standard. 1/x weighting was 
applied. In case that multiple chromatographic peaks were obtained for a metabolite, 
due to a varied extent of silylation in case of amino acids or cis-trans isomers of meth-
oximated compounds, the most intense signal was exclusively evaluated. All data points 
that spanned the linear range of the calibration curve, determined by LLOQ and ULOQ, 
exceeded a peak S/N ratio of 8:1 and did not deviate more than 20% from the curve, 
according to the FDA Guide for Bioanalytical Method Validation [126]. The correlation 
coefficient R was obtained by linear regression analysis. To assess derivatization re-
peatability, response values from derivatization replicates were exported and RSDs 
calculated in Excel, which was also used to determine the order of magnitude of the 
linear concentration range based on a log-10 scale. For quantification, calibration 
curves were exported in MassLynx and subsequently used for sample processing.  
5.4.3 Recalibration of mass spectra  
Post-acquisition recalibration of APCI mass spectra was based on SIL-ISs and fatty 
acids that had been added to every sample prior to analysis. For recalibration, a previ-
ously in-house developed Visual Basic script was employed. Briefly, an average mass 
spectrum was created from regions within each chromatogram that corresponded to the 
internal standards nonanoate, [U-13C]fumarate, [2H7]-trans-cinnamate, undecanoate, [U-
13C]glucose, and [U-13C]lactose (Figure 5.1A). The mass scale was then recalibrated 
according to the theoretical masses of fragment ions, protonated molecules and ad-
ducts that originated from the standards (Figure 5.1B). In total, ten masses over a mass 
range from m/z 138.093 to m/z 960.507 were used in chapter 8. The entire procedure is 
illustrated in Figure 5.1. Internal recalibration improved mass accuracy for cis-aconitate 
from 22.9 mDa before recalibration to 4.0 mDa after recalibration (Figure 5.1C). In 
chapter 6, mass spectra were recalibrated using solely the m/z values of the [M+H]+ 
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ions of the odd-numbered, saturated fatty acid derivatives (C9-19), which are listed 
along with the corresponding retention times in Table 12.2.  
 
Figure 5.1 Internal mass recalibration of GC-APCI-TOFMS data. An average mass spectrum is generat-
ed from defined areas of the chromatogram containing internal standards (A). The average spectrum is 
used to recalibrate the complete run (B). The improvement in mass accuracy is shown for cis-aconitate in 
(C). Macc, (calculated) accurate mass of analyte M. Reprinted from [15] with permission from Elsevier. 
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5.4.4 Calculation of elemental formulas 
For the identification of features that were significantly differently regulated between 
sample groups (chapter 6) or to annotate features extracted from cell culture superna-
tants (chapter 8), the respective protonated molecule of a recalibrated data file was 
queried using the SmartFormula tool included in DataAnalysis [9,127]. Parameters for 
calculating elemental formulas were as follows for MeOx-TMS and MCF derivatives, 
respectively: positive adducts, M+H; m ≤ ±5 mDa; charge, 1; even electron number; 
filter H/C element ratio ≤3; and check ring plus double bonds from -0.5 to 40. Apart from 
C, H, N, O atoms, which are considered automatically by the algorithm, P (0-3), S (0-3) 
and Si (at least 1) atoms were included for calculation in the case of MeOx-TMS deriva-
tives, whereas the following restrictions were applied for MCF derivatives: 0 ≤ nN ≤ 5; 0 
≤ nP ≤ 1; 0 ≤ nS ≤ 2. Calculated formulas with an mSigma value below 50 were further 
considered. From the calculated elemental formula, the proton and possible groups 
introduced by derivatization had to be eliminated, such as trimethylsilyl groups as well 
as groups introduced by methoximation in the case of MeOx-TMS derivatization. The 
sum formula of the native metabolite was then searched in the HMDB [23]. The overall 
workflow is exemplified in Figure 5.2 for N-acetylaspartate [17]. Candidate metabolites 
that were obtained by database search were only kept if they possessed the functional 
groups for forming the derivatives that had been the basis for the identification process.  
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Figure 5.2 Scheme for initial steps towards identification of unknowns by GC-APCI-TOFMS. Reprinted 
from [15] with permission from Elsevier. 
 
However, identification of unknowns required manual intervention. The corresponding 
spectrum had to be reviewed for proper selection of the protonated molecule used to 
calculate an elemental formula. Accidentally subjecting masses of fragments or adducts 
to the elemental formula calculator would have resulted in significant errors or an incon-
clusive database search. As exemplified for N-acetyl-neuraminate-1MeOx-6TMS in 
Figure 5.3, putative annotation via calculation of elemental formulas and subsequent 
database search initially failed (step 3 on the left-hand side), because feature extraction 
routine and statistical analysis (step 2) performed in comparative metabolic fingerprint-
ing of wild type and double-mutant (PntAB-UdhA) E. coli strains [17] pointed to a frag-
ment mass instead of the mass of the protonated molecule. Manual review of the corre-
sponding mass spectra finally led to positive identification (step 3 on the right-hand 
side).  
 
 58
 
 
 
315.102
347.365
377.632
395.117
429.218
452.328
468.668
487.363
531.016 578.847
660.521680.567
704.772
771.373
N-Acetyl-Neuraminate-1MeOx-6TMS395.117
771.373
300 350 400 450 500 550 600 650 700 750 800 m/z
2.5
Intensity
×104
2.0
1.5
1.0
0.5
0.0
[M+H]+
O
Si
N
H
O
O
O
O
O
O
O
N
Si
Si
Si
Si
Si
O
no. m/z RT/min wild type 1 … mutant 1  … adjusted p value
1 182.1 9.3 0.194 … 0.105 … 0.000
2 190.1 10.2 1.457 … 0.102 … 0.026
3 154.0 10.3 0.237 … 0.034 … 0.041
4 204.2 11.4 1.934 … 0.268 … 0.002
5 385.2 11.7 0.046 … 0.071 … 0.037
: : : : : : : :
44 395.1 31.0 0.005 … 0.105 … 0.005
: : : : : : : :
1. Sample preparation and GC-APCI-TOFMS analysis 
2. Statistical analysis 
3. Calculation of elemental formulas and database search 
4. Verification with standards 
5. Comparison to other data and/or interpretation 
C30H71N2O9Si6
C12H22N2O9
„-H“
„-6•SiC3H8“Hit: N-Acetyl-
Neuraminate
„-NCH3“C11H19NO9
Database 
searching
No database hit! 
Proton
Silylation
MeOx
O
N
H
OH
O
HO
HO
HO
OH
OH
O
 
Figure 5.3 Manual review of GC-APCI-TOFMS mass spectra in the identification procedure of unknown 
features distinguishing wt and mutant (PntAB-UdhA) E. coli strains [17]. The example of N-acetyl-
neuraminate-1MeOx-6TMS is given, as it emphasizes the need for manual intervention. Annotation based 
on the accurate mass of a fragment ion that had been extracted by the feature extraction routine yielded 
initially no database match; manual selection of the protonated molecule finally led to positive identifica-
tion. [16] – Reproduced by permission of The Royal Society of Chemistry. 
Commercial standards were run on GC-APCI-TOFMS For tentatively identified metabo-
lites, and mass spectra and linear retention indices were compared for final confirma-
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tion, which required that a relative difference of 1.0% established by Strehmel et al. 
[128] was not exceeded.  
 
5.5 Validation methods 
5.5.1 ROC curve 
Receiver operator characteristic (ROC) curves were plotted in chapter 6 to assess the 
effect of water infusion on the ability of GC-APCI-TOFMS to detect concentration fold 
changes of metabolite standards that were spiked into extracts of human serum and 
derivatized afterwards. Initially, features were extracted and aligned into a single data 
matrix for each spike-in data set, e.g. all MCF-derivatized spike-in samples that were 
acquired by GC-APCI-TOFMS in the absence of water infusion. Features were as-
signed as true positives (TPs) or true negatives (TNs). Then the different spike-in levels 
were compared by t tests between all features, and the latter were listed in ascending 
order of P values. Features corresponding to spike-in compounds should appear at the 
top of the list. After each feature, starting from top to bottom, true positive rate (TPR or 
sensitivity) and, similarly, false positive rate (FPR or 1-specificity) were determined and 
plotted against each other in receiver operating characteristic (ROC) curves. The true 
positive rate is also referred to as sensitivity, i.e., the number of detected TPs up to a 
respective row compared to total number of TPs. In the ideal case, i.e., a perfect dis-
crimination of two different abundance levels, all features corresponding to spike-in 
compounds are ranked higher than signals from matrix compounds, and an area under 
the curve (AUC) value of 1 is obtained. Figure 5.4 depicts three ROC curves as an 
example, which were obtained from six spike-in compounds and six matrix compounds 
that were compared between two arbitrary abundance levels in each case. Discrimina-
tion of the two levels gets worse from (A) to (C) as indicated by a decreasing AUC value 
(Figure 5.4).  
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Figure 5.4 Example of three ROC curves based on six spike-in compounds and six matrix compounds 
that were compared between two arbitrary abundance levels in each case. AUC values decrease from (A) 
to (C) indicating that discrimination of the two levels gets worse. In (A) three data points of the curve are 
assigned to the underlying data matrix. FN, false negative; FP, false positive. Adapted and reprinted with 
permission from Bruker Daltonics. 
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5.5.2 Bland-Altman plot 
A Bland-Altman plot is a method of data plotting to determine agreement between two 
different analytical approaches. It can be also used to assess repeatability of a single 
analytical method or to compare measurements by two operators. It was introduced by 
Bland and Altman in the 1980s [129,130] as a better alternative to correlation and dis-
plays the difference in output variable c obtained by the two approaches A and B (y = 
cA-cB) against the corresponding average (x = (cA+cB)/2) for each sample. To allow a 
quick visual inspection, mean difference (đ) as well as upper and lower limits of agree-
ment (đ ± 1.96*SD) are represented as horizontal lines in the graph. The latter limits 
refer to the 95% confidence interval of the differences assuming normal distribution, 
indicating how far measurements by the two approaches were apart for most samples. 
According to Kaspar et al. [126], six different types of Bland-Altman plots can be distin-
guished based on absolute and relative mean differences as well as whether differ-
ences scatter randomly or proportionally with x (relative mean difference corresponds to 
the mean difference divided by the averaged mean of all couples and multiplied by 100). 
Ideally, absolute and relative mean differences are almost zero and ≤15%, respectively, 
and individual differences scatter randomly (type A, compare [126]).  
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6 Investigations on the effects of continuous water 
infusion on APCI of derivatized metabolites 
6.1 Introduction 
It has been recognized as early as 1976 that water promotes the formation of protonat-
ed molecules in APCI [45]. Notable improvements in peak abundance and selectivity 
achieved by the infusion of water into the APCI source have been demonstrated recent-
ly for gas chromatography-tandem mass spectrometry of underivatized pyrethroid insec-
ticides [82] and GC-APCI-TOFMS analysis of dissolved standards of methyl stearate, 
benzophenone, methyl palmitate, and cocaine [131]. Whether such improvements also 
hold true for derivatives of metabolites, and, moreover, are associated with better re-
producibility of APCI were the objectives of the present study. To that end, water was 
continuously infused from the top into the APCI I source and the effects of water infu-
sion on APCI-TOF mass spectra of MCF and MeOx-TMS derivatives of 20 standard 
compounds and the ability of GC-APCI-TOFMS to detect differences in metabolite con-
centration levels in a human serum extract were assessed. Subsequently, MCF derivat-
ization and GC-APCI-TOFMS were applied to the comparative metabolic fingerprinting 
of extracts of pancreatic cancer cells that had been cultivated in the absence and pres-
ence, respectively, of the Hsp90 inhibitor 17-DMAG. 
This chapter was published in [14].  
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6.2 Materials and methods 
6.2.1 Materials 
For each standard compound an individual stock solution was prepared in either meth-
anol, water, or a mixture thereof, except for the even-numbered (C12-C18), saturated 
straight-chain fatty acids, which were dissolved in propanol. The compounds from the 
fatty acid mixture (C9-19, compare subchapter 5.1) were used as retention index mark-
ers and for recalibration of the mass scale according to the procedure described in 
section 5.4.3. The spike-in mixture (Table 6.1) contained 20 compounds at a concentra-
tion of 1 mM each in MeOH. 
6.2.2 Sample preparation 
For the spike-in experiment aliquots of 10 µL of human serum were extracted with 50 µL 
of MeOH, according to an established protocol in our laboratory [132]. Extraction stand-
ards, were not added. Pellets were re-extracted twice more with 50 µL of methanol.  
Extracts were pooled and then split into aliquots for the preparation of spike-in samples. 
Amounts of 960 and 160 µL each were taken from the pool for MCF and MeOx-TMS 
derivatization, respectively, which corresponded to 60 and 10 µL of extracted serum. 
Since the final volume after MCF derivatization (300 µL) is three times as high as that 
after MeOx-TMS derivatization (100 µL), a three times higher extract volume was need-
ed assuming that efficiency of both derivatization strategies was comparable. In addi-
tion, the volume was doubled to obtain two times more concentrated MCF-derivatized 
serum compounds. A two-fold higher concentration for MCF-derivatized serum com-
pounds, which was also used for MCF-derivatized spike-in compounds, was required to 
detect a sufficient number of MCF -derivatized spike-in and matrix compounds in the 
absence of water infusion into the APCI source. 
Six different spike-in levels were prepared (N=5 derivatization replicates), ranging in 
final concentrations of the spike-in compounds from 133 µM to 200 µM, 267 µM, 333 
µM, 400 µM, and 467 µM, respectively, for MCF derivatization, and 67 µM to 100 µM, 
133 µM, 167 µM, 200 µM, and 233 µM, respectively, for MeOx-TMS derivatization. 
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Prior to derivatization, on the basis of the desired final standard concentration, the re-
spective volume of standard stock solution, spike-in mixture, or an appropriate dilution 
was transferred either to a 2-mL glass vial together with 20 µL of fatty acid mixture in 
case of MCF derivatization, or to a 2-mL glass vial with a 400-µL glass insert for MeOx-
TMS derivatization. For example, 120 µL and 20 µL, respectively, of a 0.5 mM standard 
stock solution were taken for preparation of 200 µM MCF- and 100 µM MeOx-TMS-
derivatized standard samples in initial experiments and for optimizing the water infusion 
rate. Depending on the sample set, cell extract or an aliquot of the serum extract pool 
was added as well, and the entire sample was then dried using a vacuum evaporator 
followed by either MCF or MeOx-TMS derivatization according to sections 5.2.2 and 
5.2.3. In the case of cell extracts and MCF derivatization, 250 µL of the chloroform 
phase were carefully dried and reconstituted in 50 µL of chloroform. 
6.2.3 GC-APCI-TOFMS analysis 
See subchapter 5.3. Spike-in samples along with blanks and cell extracts were meas-
ured in random order to avoid systematic error. A blank sample was always run be-
tween changes in water flow rates for equilibration of APCI source conditions.  
6.2.4 Cross-validation of amino acids 
Targeted quantification of amino acids was performed by high-performance liquid chro-
matography – electrospray ionization – tandem mass spectrometry (HPLC-ESI-MS/MS) 
in positive ionization mode as previously described [133]. Briefly, 10 µL of aqueous cell 
extract together with 10 µL of SIL-IS mix in water were subjected to propyl chlorofor-
mate (PCF) derivatization. Separation of PCF derivatives was carried out on a Phe-
nomenex EZ:faast 4u AAA-MS (250 × 3 mm i.d., 4µm, Torrence, CA, USA) reversed-
phase column using gradient elution with 10 mM ammonium formate and 0.1% (v/v) 
heptafluorobutyrate in water and methanol. One selective transition each for the unla-
beled and labeled amino acid was programmed for operating the MS/MS in MRM mode. 
For quantification, calibration curves were obtained from standards by plotting nominal 
concentration ratio (analyte/internal standard) against peak area ratio (analyte/internal 
standard), whereby the corresponding labeled analogue was included for each target 
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analyte as internal standard, with the exception of ornithine, for which labeled methio-
nine was used. Acquisition and analysis of data was carried out employing Analyst 
version 1.5.1 from AB Sciex (Darmstadt, Germany). 
6.2.5 Feature extraction and alignment 
For the analysis of data from the spike-in experiment, optimized Find Molecular Fea-
tures (FMF) algorithm and bucketing parameters for feature extraction and alignment 
within ProfileAnalysis were as follows for MCF/ MeOx-TMS derivatives, with deviating 
parameters for MeOx-TMS derivatives in brackets: S/N threshold, 2 (5); correlation 
coefficient threshold, 0.6 (0.7); minimum compound length, 8 (10); smoothing width, 2 
(3); additional smoothing, enabled; proteomics, enabled; bucketing basis, M+H. Reten-
tion time range, 8-25 min (8-17 min); mass range, m/z 100-250 (m/z 100-500); ad-
vanced bucketing tolerance parameters, 0.1 min (0.4 min) and 10 mDa for retention 
time and mass, respectively; split buckets with multiple compounds, disabled; value 
count of group attribute (spike level) within bucket as bucket filter, enabled at least 
three; and other parameters, always none or disabled.  
Each of the four different bucket tables (0.0 mL/h H2O/MCF, 0.4 mL/h H2O/MCF, 0.0 
mL/h H2O/ MeOx-TMS, and 0.4 mL/h H2O/ MeOx-TMS) listed features in rows with 
accompanying information on retention time and m/z value as well as the feature inten-
sities over all spike-in samples from entire spike-in levels. To reduce the number of zero 
values within the bucket table, bucket filtering was applied: at least three out of five area 
integrals had to be available for each spike-in level; otherwise the respective feature 
was excluded. Further data analysis proceeded in Excel as described in 6.3. 
For metabolite fingerprinting in cell extracts, individual data matrices were generated 
from GC-APCI/+H2O-TOFMS and GC-APCI/-H2O-TOFMS measurements of MCF-
derivatized cell extract samples of control and 17-DMAG -treated groups, applying with 
a few exceptions the same FMF and bucketing parameters as for the MCF spike-in 
experiment. Exceptions were as follows: the mass range for bucketing was extended to 
m/z 100-300, advanced bucketing tolerance parameter for retention time was increased 
to 0.15 min, and bucket filtering criteria allowed only the inclusion of features into the 
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bucket table, for which at least 3/5 area integrals were available in at least one group. 
Further data analysis was carried out in Excel as described in 6.3. 
 
6.3 Results and discussion 
6.3.1 Effects of continuous water infusion on APCI mass spectra of 
MCF and MeOx-TMS derivatives 
Initial experiments on the effect of continuous water infusion on APCI mass spectra of 
MCF and MeOx-TMS derivatives were performed at an infusion rate of 0.4 mL/h. Table 
12.2 lists the most prominent ions observed in APCI/+H2O mass spectra of MCF and 
MeOx-TMS derivatives of 20 standard compounds as compared to spectra acquired 
without water infusion (APCI/-H2O). Compounds included in the standard mixture were 
selected as to cover a variety of chemical classes, including organic acids, amino acids, 
and analytes containing amide and thiol functional groups, according to the three per-
formance classes introduced by Koek et al. [31] for silylated derivatives.  
APCI/-H2O mass spectra of MCF derivatives were typically dominated by fragment ions. 
The [M+H]+ ion constituted only a minor component with a relative intensity of <30% for 
12 of the 20 investigated compounds. Notably, the six MCF derivatives that exhibited 
[M+H]+ as the base peak were, aside from malonate and fumarate, the four aromatic 
compounds benzoate, hippurate, nicotinate, and phenylacetate, indicating that MCF-
derivatized aromatic compounds might be less prone to in-source fragmentation. In 
contrast, APCI/+H2O mass spectra exhibited dominant [M+H]+ ions for all MCF deriva-
tives. Major fragment ions of MCF derivatives could be attributed to neutral losses in-
cluding CH3OH (32.026 Da), [CH3OH + CO] (60.021 Da), and combinations thereof. 
Besides, [2M+H]+-type adduct ions (relative intensity <5%) for several amino acids and 
[M+H+H2O]+-type adduct ions for fumarate and the fatty acids were detected. The 
strongest effect of water infusion on suppression of in-source fragmentation and, con-
sequently, the formation of abundant [M+H]+ ions was noticed for dicarboxylic acids, as 
shown exemplarily for suberate in Figure 6.1. The APCI/-H2O mass spectrum of suber-
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ate was dominated by the [M+H-CH3OH]+ fragment ion, while the relative intensity of the 
[M+H]+ ion amounted only to 8%. Upon water infusion, [M+H]+ became the dominant ion 
species. Hence, APCI/+H2O provides softer ionization than conventional APCI, possibly 
due to an increased formation of [H(H2O)n]+ ion clusters of higher order, which exhibit a 
higher proton affinity [134,135]. However, in analogy to the use of two different reagent 
gases in GC-CI-MS metabolite profiling [136], APCI/-H2O and APCI/+H2O may com-
plement each other in the identification of unknowns. While APCI/+H2O is more likely to 
generate [M+H]+ ions of sufficient intensity for the calculation of sum formulas, fragment 
rich APCI/-H2O mass spectra will provide additional structural information and, thus, 
narrow the list of sum formulas generated from accurate mass measurements. Other 
than that, APCI/+H2O is more suited for quantification and the [M+H]+ ions may also 
serve as precursor ions for MS/MS analyses. In fact, protonated molecules have been 
preferred over EI fragment ions in terms of abundance and selectivity in previous me-
tabolite profiling studies [82,86].  
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Figure 6.1 GC-APCI-TOFMS mass spectra of the MCF derivative of suberate (conc = 200 M) acquired 
without (A) and with (B) infusion of water at 0.4 mL/h. Neutral losses yield a series of fragments in the 
case of APCI/-H2O as annotated in the left spectrum; [M+H]+ abundance is distinctly promoted by water 
infusion. Reprinted from [14]. 
Water infusion, interestingly, exerted almost no effect on MeOx-TMS derivatives, i.e., 
the [M+H]+ ions dominated for 19/20 compounds even in the APCI/-H2O mass spectra. 
Typical fragment ions were caused by neutral loss of C3H8Si [TMS] (72.040), C3H9SiOH 
[TMSOH] (90.050 Da), [TMSOH + CO] (118.045 Da), and combinations thereof. Over-
all, MeOx-TMS mass spectra were less rich in fragment ions compared to their MCF 
analogues (compare Figure 6.1, Figure 12.1 and Figure 12.2 for suberate and valine, 
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respectively). For some compounds, including benzoate, fumarate, and phenylacetate, 
a [M+H+TMS]+-type adduct was observed, as recently reported [78]. 
6.3.2 Optimization of water infusion rate 
Next the effects of different water infusion rates on the ionization behavior of both 
standard mixtures of 20 MCF- and MeOx-TMS -derivatized compounds were investigat-
ed, in 0.1 mL/h increments up to 0.5 mL/h. Details are presented in Table 12.3. The 
geometric means of fold changes in [M+H]+ peak area relative to no water infusion dif-
fered significantly (ANOVA, p <0.05) for MCF-derivatized spike-in standards (N=20) 
across water infusion rates of 0.1-0.5 mL/h. On average, peak areas increased the most 
for organic acids with increasing rates of water infusion, followed by amino acids, 
whereas (hetero) aromatic compounds yielded the smallest increases. In contrast, ge-
ometric means of RSD values were fairly similar across the water infusion rates tested, 
ranging from 16.3 % to 23.2%. Ultimately, a water infusion rate of 0.4 mL/h was chosen 
for all subsequent experiments, as it had yielded overall the highest fold change in 
[M+H]+ peak area (16.6-fold) and the lowest RSD (16.3 %), and [M+H]+ constituted the 
base peak for all 20 MCF derivatives. Figure 12.2 shows mass spectra of MCF-
derivatized suberate and valine acquired without and at five different rates of water 
infusion. The standard mixture was also spiked at 200 µM into a serum extract and 
analyzed without and with 0.4-mL/h water infusion, followed by normalization of the 
[M+H]+ area values against undecanoate. Relative standard deviations improved signifi-
cantly at 0.4 mL/h water infusion (Table 6.1), e.g. from 25.3% to 11.3% for isoleucine. In 
addition, an average 28-fold higher S/N ratio was observed for the [M+H]+ ions. 
On the other hand, in the case of MeOx-TMS derivatives only 6 of the 20 standard 
components were significantly affected over the different water infusion rates (ANOVA, 
p <0.05). Significant increases in fold changes in [M+H]+ peak area relative to no water 
infusion were limited to (hetero) aromatic compounds and adipate only. Some com-
pounds were even negatively affected as evidenced by a fold change <1 (Table 12.3). 
Overall, geometric means for fold-changes and RSDs did not differ markedly across the 
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water-infusion rates tested. Compared to MCF derivatives, RSDs for MeOx-TMS deriva-
tives were generally higher. 
Table 6.1 Impact of 0.4 mL/h water infusion on APCI of MCF derivatized spiked serum extracts. Mean 
fold changes in peak area and S/N ratio of [M+H]+ ions of the 20 standard compounds were obtained by 
comparing 0.4 mL/h water infusion to no water infusion. In addition, RSD values and average S/N ratio of 
[M+H]+ ions for APCI/-H2O and APCI/+H2O are given. For calculation of FCs and RSDs, peak areas were 
normalized to undecanoate. Water infusion increased [M+H]+ peak areas on average by 11-fold and 
significantly decreased RSD values. Standard concn = 200 µM; N=5 derivatization replicates; A=amide 
group; E=methyl ester group. Reprinted from [14]. 
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Adipate-2E 166.9 34.6 12.0 20 2955 147.7 
Ala-1A-1E 27.7 36.5 26.6 84 2257 26.9 
4-Aminobutyrate-1A-1E a a 7.3 a 259 a 
Asp-1A-2E 10.1 22.0 9.3 257 2408 9.4 
Benzoate-1E 1.3 33.9 11.2 2145 3370 1.6 
Fumarate-2E 0.6 38.8 13.3 1154 1041 0.9 
Glu-1A-2E 9.6 45.6 5.1 104 1494 14.4 
Hippurate-1E 5.1 23.6 15.3 713 5052 7.1 
Ile-1A-1E 14.5 25.3 11.3 290 4362 15.0 
Leu-1A-1E 11.0 19.8 16.5 416 5384 12.9 
Malonate-2E 44.0 17.1 10.6 28 1767 63.1 
Met-1A-1E 18.1 46.0 11.9 174 3892 22.4 
Methyl-malonate-2E 66.0 23.0 12.6 30 2387 80.1 
Nicotinate-1E 1.1 35.6 20.9 1170 1483 1.3 
Nval-1A-1E 18.6 32.5 24.3 132 2985 22.7 
Phe-1A-1E 9.3 45.9 9.8 367 5314 14.5 
Phenylacetate-1E 5.1 17.3 12.8 467 3161 6.8 
Pro-1A-1E 8.4 28.5 10.7 519 4606 8.9 
Suberate-2E 62.6 25.5 4.9 97 6868 71.0 
Val-1A-1E 17.3 24.0 21.4 254 3005 11.8 
a S/N of [M+H]+ of 4-Aminobutyrate below 20 in case of no water 
infusion. 
 
Ionization of analytes is not only due to direct protonation but also ligand switching [69], 
i.e., association of analytes with [H(H2O)n]+ water ion clusters followed by dissociation of 
water molecules. As evident from Table 12.2, log P values are significantly lower for 
MCF derivatives compared to their MeOx-TMS analogues, indicating that MCF deriva-
tives are more polar. This might facilitate the formation of MCF derivative-water ion 
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clusters and explain the observed increase in signal intensities upon infusion of water 
into the APCI source.  
6.3.3 Method evaluation via spike-in experiment 
Metabolic fingerprinting sets high requirements on quantitative precision as well as 
extraction and alignment of features. To test whether APCI/+H2O improves the detec-
tion of differences in metabolite concentration of MCF and MeOx-TMS derivatives, a 
serum extract was spiked with the 20 standard compounds at six different concentration 
levels (N=5 derivatization replicates) ranging from 133-467 M and 67-233 M, respec-
tively, thus generating a total of 15 concentration fold changes (FCs) between 1.17- and 
3.5-fold. A 2-fold higher concentration for MCF spike-in compounds and volume of se-
rum extract was chosen in comparison to the MeOx-TMS spike-in experiment to extract 
features for an increasing number of low-abundant MCF -derivatized spike-in com-
pounds in the case of APCI/-H2O. Four data matrices were obtained in total, and fea-
tures were assigned as true positives (TPs) or true negatives (TNs), by comparing se-
rum blank and individual standard samples. All multiple features of a single spike-in 
compound, e.g.,  protonated molecule, fragments, adducts, or different derivatives, were 
further considered as true positives, and ROC curves were obtained as described in 
detail in section 5.5.1. For MCF derivatives, 91 (53 TPs, 38 TNs) and 178 (97 TPs, 81 
TNs) features were obtained for APCI/-H2O and APCI/+H2O data matrices, respectively, 
with a maximum of 3% zero values after exclusion of one run each due to technical 
problems. Figure 6.2 shows how water infusion influences accuracy of detection of 
differential features by presenting ROC curves for 6 of the 15 possible FCs. AUC values 
were noticeably improved in the case of APCI/+H2O (compare Figure 6.2A,B and Table 
12.4). Furthermore, the AUC values of APCI/-H2O and APCI/+H2O for all 15 possible 
FCs were plotted against each other (Figure 6.3A). Higher AUC values for APCI/+H2O 
were found in almost all cases. Interestingly, the AUC value for an FC of 1.2 (spike-in 
levels 4 vs 5) in the case of APCI/-H2O distinctly exceeded the corresponding value for 
APCI/+H2O. Upon pairwise leaving out one of the five replicates for spike-in levels 4 and 
5 (25 combinations in total), a mean AUC value±SD of 0.66±0.08 and 0.47±0.05 was 
obtained for APCI/-H2O and APCI/+H2O, respectively. These greater relative standard 
 
 71
 
 
 
deviations implied that AUC values for an FC of 1.2 were less stable compared to a 
higher FC of 1.67 (spike-in levels 3 vs 5), for which AUC values of 0.76±0.04 (APCI/-
H2O) and 0.84±0.01 (APCI/+H2O) were obtained. Because lower FCs are more prone to 
error due to measurement fluctuations, the FC of 1.2 was regarded as random devia-
tion. Hence, only AUC values >0.7 were considered trustworthy. Using this cutoff, AP-
CI/+H2O proved more sensitive in the detection of discriminating features, as it suc-
ceeded in distinguishing an FC of 1.33 from the background, whereas AUC values 
exceeding constantly 0.7 were obtained for FCs of 1.67 and higher in the case of APCI/-
H2O (Table 12.4). In addition to that, no [M+H]+ ions were included in the data matrix in 
the case of APCI/-H2O for 11 spike-in compounds and no features at all were extracted 
for four analytes, which might complicate or entirely prevent the detection of discriminat-
ing MCF -derivatized metabolites without water infusion.  
While assigning features as TPs or TNs, the number of TNs was distinctly higher than 
that of TPs and therefore the retention time range for generation of the bucket table was 
reduced to 8-17 min in the MeOx-TMS spike-in experiment to decrease the number of 
TNs. Otherwise, in the case of an enormous excess of TNs over TPs, small P values for 
many TNs would have occurred by chance and these TNs appeared at random on top 
of the sorted list, which would have prevented similar fold changes from being distin-
guished by means of their ROC curves. Comparable AUC values for APCI/-H2O and 
APCI/+H2O were obtained in the case of MeOx-TMS derivatives. This was in accord-
ance with the observed lack of any influence of water infusion on RSD values. Table 
12.4 lists AUC values for both APCI/-H2O and APCI/+H2O of MeOx-TMS derivatives, 
and the respective AUC vs AUC plot is depicted in Figure 6.3B. It was concluded that 
water infusion held no advantage for APCI-MS of MeOx-TMS derivatives in metabolite 
fingerprinting. 
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A B0.0 mL/h 0.4 mL/h
 
Figure 6.2 Impact of water infusion on the detection of concentration differences of MCF -derivatized 
metabolites illustrated by receiver operating characteristic (ROC) curves. Twenty known compounds were 
spiked at six different concentrations (133-467 µM) into aliquots of serum extract and analyzed by GC-
APCI-TOFMS without (A) and with water infusion (B). Water infusion increased area under the curve 
(AUC) values. Hence, it improved the ability to distinguish genuine changes in metabolite concentration 
from background signals of the serum matrix. Reprinted from [14]. 
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Figure 6.3 Impact of water infusion on the detection of differential MCF and MeOx-TMS derivatized 
features illustrated by area under the curve comparison plot. AUC values from the corresponding ROC 
curves for all pairwise fold changes are compared for MCF (A) and MeOx-TMS (B) derivatives. ROC 
curves were generated from 20 compounds spiked at six different concentrations into aliquots of a serum 
extract, followed by derivatization (N=5 derivatization replicates per spike level), and GC-APCI-TOFMS 
analysis without and with water infusion at 0.4 mL/h. AUC values were overall increased by water infusion 
in the case of MCF derivatives, whereas those corresponding to MeOx-TMS derivatives were not signifi-
cantly affected. Reprinted from [14]. 
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6.3.4 Evaluation of fold changes and mass and isotope accuracy 
Next the accuracy and repeatability of FCs detected with MCF derivatives under water 
infusion was studied. To that end, following subtraction of blank feature area integrals, 
all possible pairwise FCs from area integrals of preferentially the [M+H]+ ion of a specific 
compound within the spike-in data matrix were plotted against their expected FCs, as 
shown exemplarily for benzoate in Figure 6.4. Then univariate linear regression analy-
sis was performed. The respective slopes and intercepts of the regression equations, 
regression coefficients, and mean RSDs over all FCs are listed in Table 12.5. Upon 
water infusion, accuracy and repeatability of FCs were distinctly enhanced, with ranges 
of regression coefficients and mean RSDs improving from 0.350-0.945 (median value of 
0.774) to 0.709-0.944 (0.883) and 19.5-67.2% (34.3%) to 15.9-29.9% (22.5%), respec-
tively.  
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Figure 6.4 Linear dependency between expected and observed fold changes for the MCF derivative of 
benzoate. Blank feature area values had been subtracted as “background” from area integrals of [M+H]+ 
of benzoate (m/z 137.0597 Da) for generation of FC plots derived from analyses of spiked serum extracts 
acquired at a water infusion rate of (A) 0.0 mL/h, and (B) 0.4 mL/h. All possible fold changes are plotted, 
and the respective linear regression equation, regression coefficient, and mean RSD value over all fold 
changes are given in the graphs. Accuracy and repeatability of FCs were distinctly improved by water 
infusion. Reprinted from [14]. 
Reliability of accurate mass measurements was verified by means of retrieving ele-
mental formulas from known MCF-derivatized standards spiked into serum extracts at a 
concentration of 200 µM each. Results are listed in Table 12.6. Upon internal recalibra-
tion excellent mass accuracy over a mass range of 133-238 m/z for all spike-in com-
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pounds was obtained irrespective of water infusion, as confirmed by Wilcoxon signed-
rank test for each spike-in compound except 4-aminobutyrate, with absolute mean mass 
errors (±SD) of 0.64 (±0.72) mDa and 0.66 (±0.68) mDa, respectively, for APCI/-H2O 
and APCI/+H2O at 0.4 mL/h. In general, the absolute mass error was below 3 mDa for 
all measured ions. In contrast, isotope patterns of [M+H]+ ions were markedly enhanced 
by water infusion because of the increased signal intensities (Table 12.6). In the case of 
APCI/-H2O, mSigma values, which decrease with increasing goodness-of-fit between 
the theoretical and experimental isotope pattern, were inadequate, ranging from 33-80. 
Further, for more than half of the compounds, the first isotope of the [M+H]+ ion was not 
detectable. Upon water infusion, the mean mSigma value was 10.0±1.0. As a conse-
quence, given the relevance of isotopic patterns for the exclusion of incorrect elemental 
combinations and the selection of the correct formula among the top-hits [50,95], aver-
age rank of correct formula within all calculated formulas was 2.7 and 1.9 for APCI/-H2O 
and APCI/+H2O, respectively. APCI/+H2O yielded excellent isotope ratio accuracies for 
the first isotope with a mean error of 0.66±0.68%. According to our own results and 
those of previous studies [50,78] for MeOx-TMS derivatives that had been investigated 
by means of GC-APCI-QTOFMS [78] as well as GC-EI-TOFMS and GC-CI-TOFMS 
[50], there is a dependency of isotopic pattern accuracy on ion abundance in contrast to 
mass accuracy. Nevertheless, for both APCI/-H2O and APCI/+H2O, the correct ele-
mental formula was always derived, except for 4-aminobutyrate whose [M+H]+ ion had 
not been detected by APCI/-H2O. In conclusion, APCI/+H2O yielded a number of nota-
ble improvements in the quantification and identification of MCF derivatives that might 
benefit metabolite fingerprinting. 
6.3.5 Analysis of metabolic fingerprints of cancer cell extracts 
As a proof of principle, MCF derivatization and GC-APCI-TOFMS were applied to meta-
bolic fingerprinting of pancreatic cancer cells treated with 17-DMAG. The latter is an 
inhibitor for Hsp90, which acts as a molecular chaperone for many oncoproteins and 
thus has become a target in clinical trials. However, little is known about whether Hsp90 
has a direct impact on cancer cell metabolism. As evidenced by the overlaid total ion 
current (TIC) chromatograms in Figure 6.5, ionization efficiency was distinctly en-
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hanced by water infusion. Feature extraction and alignment yielded a total of 217 and 
211 features for APCI/-H2O and APCI/+H2O, respectively. In the latter case, one would 
expect an increase in detectable [M+H]+ ions, which should benefit metabolite identifica-
tions. For instance, this was the case for malate, which eluted at 14.9 min in the chro-
matogram depicted in Figure 6.5B (peak no. 9). Twenty of the metabolites identified in 
extracts of untreated pancreatic cancer cells are represented in Figure 6.6A, with mean 
[M+H]+ areas ± SD given in the graph. With the exception of the fatty acid derivatives, 
which formed water adducts at the expense of [M+H]+ ions under water infusion, all 
metabolites showed an increase in mean [M+H]+ area. Furthermore, SDs were lower for 
most metabolites. Importantly, of the four metabolites that could solely be identified by 
water infusion (Figure 6.6), malate, serine, and aminoadipate were found to show sig-
nificant discrimination between control and 17-DMAG treated cell extracts.  
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Figure 6.5 Impact of water infusion on ionization efficiency as exemplified by the overlay of 10 min sec-
tions of the TIC chromatograms (A) and enlarged sections deriving therefrom (B, C) acquired by GC-
APCI-TOFMS without (chromatogram in black) and with (0.4 mL/h) water infusion (chromatogram in gray) 
for an MCF-derivatized metabolite extract of untreated pancreatic cancer cells. Metabolites, whose abun-
dance was found by means of GC-APCI/+H2O-TOFMS to be significantly different in 17-DMAG -treated 
cells versus controls, are annotated, with asterisks indicating metabolites found to be discriminating 
irrespective of water infusion. Experimental details are given in chapter 5. As a result, ionization efficiency 
was distinctly enhanced by water infusion. Peak identification: 1, lactate; 2, alanine; 3, glycine; 4, valine; 
5, leucine; 6, isoleucine; 7, laurate; 8, threonine; 9, malate; 10, proline; 11, myristate; 12, serine; 13, 
methionine; 14, aminoadipate; 15, palmitate; 16, aspartate; 17, citrate; 18, N-acetyl-L-aspartate. Reprint-
ed from [14]. 
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Figure 6.6 Influence of water infusion on magnitude and repeatability of signal intensities of selected 
MCF-derivatized metabolites and on the clustering of biological replicates in principal component analy-
sis. (A) Arithmetic means ± SD of peak areas of [M+H]+ ions of selected metabolites detected in MCF-
derivatized cell extracts (N=5) from the control group without and with water infusion. (B, C) Principal 
component analysis of metabolic fingerprints of MCF-derivatized cell extracts from control and 17-DMAG 
-treated pancreatic cancer cells (N=5 biological replicates) acquired (B) without and (C) with water infu-
sion at 0.4 mL/h, respectively. [M+H]+ abundance of identified compounds was distinctly promoted by 
water infusion, except for the fatty acid derivatives, and technical variability overall reduced as indicated 
by tighter clustering of the biological groups. A, amide group; MC, methoxycarbonyl group; E, methyl 
ester group. Reprinted from [14]. 
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6.3.6 Comparative analysis of control and 17-DMAG -treated sample 
groups 
Following extraction and alignment of features for both control and 17-DMAG -treated 
cells that had been acquired by APCI/-H2O and APCI/+H2O, respectively, peak area 
integrals were normalized against protein content followed by log 2 transformation, and 
missing values were imputed. Further, FDRs according to Benjamini and Hochberg [89] 
assuming equal variances in control and treated groups were calculated. A total of 18 
and 77 significant features (FDR <0.05) that distinguished control from 17-DMAG -
treated cells were obtained by APCI/-H2O and APCI/+H2O, respectively. To minimize 
false positive features, areas of significant features were reintegrated manually using 
MassLynx to exclude incorrect feature integration by the automated data analysis rou-
tine. Furthermore, GC-MS [M+H]+ features for amino acids that were also independently 
quantified by HPLC-MS/MS (Table 6.3) as well as [M+H]+ features of metabolites dis-
played in Figure 6.6A were included in the final bucket tables, in case the features had 
not been extracted previously by the routine. Final bucket tables contained in total 218 
(APCI/-H2O) and 195 (APCI/+H2O) features after the exclusion of retention index mark-
ers at this stage. Data analysis was repeated, leaving 35 and 64 significant features, 
respectively, for APCI/-H2O and APCI/+H2O with an FDR <0.05 and an S/N ratio >20 for 
corresponding peaks across all samples of at least one group. For visualization, princi-
pal component analysis was performed based on the final bucket tables. While a group 
separation between control and 17-DMAG -treated cell extracts along PC1 was ob-
tained based on both APCI/-H2O- and APCI/+H2O-TOFMS data, variability within the 
two biological groups was distinctly reduced in the latter case, as presented in Figure 
6.6B,C. Among the top loadings of PC1, features corresponding to cysteine, threonine, 
alanine, glycine, and proline were always found, irrespective of water infusion.  
The identities of discriminating features were determined whenever possible. One has 
to keep in mind that the number of detected features does not necessarily equal that of 
metabolites, as features corresponding to isotopes, adduct and fragment ions might 
have been included as well. Eventually, 27 out of 35 (APCI/-H2O) and 41 out of 64 (AP-
CI/+H2O) significant features could be assigned to 13 and 23 metabolites, respectively. 
 
 80
 
 
 
Table 6.2 lists all discriminating metabolites along with figures of merit from the identifi-
cation procedure. Because, according to Sumner et al. [26], at least two independent 
and orthogonal data derived from a standard are required for the definite (level 1) identi-
fication of an unknown, van den Dool retention indices (RIs) were compared in addition 
to the mass spectra. Differences in RIs (RI) were between 0 and 6 index units corre-
sponding to relative RIs of 0-0.5%. This was below the established threshold of 1.0% 
for transferring RIs between different methods by Strehmel et al. [128], who had found 
RI to increase with retention time and, therefore, had suggested to use relative rather 
than absolute RIs values. Significant features from APCI/+H2O analysis were either not 
detectable with APCI/-H2O or not extracted by the FMF routine despite a S/N threshold 
of 2. Further reasons for the smaller number of significant features from APCI/-H2O 
analysis included missing values within group attributes of extracted features, which 
entailed exclusion of the respective features, as well as insufficient repeatability of peak 
areas. With a rapid turnover of intracellular metabolites, biological variances are in-
creased, thus putting even higher requirements on analytical precision. Water infusion 
made it possible to extract features with overall better repeatability, e.g., RSDs for peak 
areas of lysine (m/z [M+H]+: 277.1394 Da) in control and treated samples improved 
from 32% and 53% to 21% and 24%, respectively, thus enabling its identification as a 
metabolite differing in abundance between untreated and treated cells. The same held 
true for ornithine and methionine with fold changes <2, that had been missed by APCI/-
H2O. Finally, the identity of four significant metabolites could not have been revealed in 
the case of APCI/-H2O. Malate (Figure 6.7), serine, and aminoadipate only formed an 
[M+H]+ ion under water infusion, whereas for ornithine, mSigma values >50 obtained 
from APCI/-H2O mass spectra would have entailed exclusion of the correct elemental 
formula during the identification procedure.  
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Table 6.2 Figures of merit for the metabolites identified by GC-APCI/+H2O-TOFMS that showed signifi-
cant discrimination (FDR <0.05) between control and 17-DMAG treated pancreatic cancer cells (N=5 
biological replicates). Compounds marked with an asterisk (*) were revealed by GC-APCI-TOFMS irre-
spective of water infusion. Water infusion almost doubled the number of significantly regulated metabo-
lites that were identified to a total of 23. A, amide group; MC, methoxycarbonyl group; E, methyl ester 
group. Reprinted from [14]. 
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Gly-1A-1E* C5H10NO4+ 10.87 -2 148.0610 -0.6 6.4 0.0015 3.9 
Trp-1A-1E* C14H17N2O4+ 27.74 e 277.1173 1 12.0 0.0015 1.9 
Leu-1A-1E* C9H18NO4+ 13.25 -3 204.1230 0.0 7.9 0.0023 2.4 
Ala-1A-1E* C6H12NO4+ 10.51 -5 162.0764 -0.3 7.3 0.0030 3.5 
Pro-1A-1E* C8H14NO4+ 15.00 -3 188.0913 0.4 7.4 0.0033 3.5 
Cys-1A-1MC-1E* C8H14NO6S+ 19.17 1 252.0532 0.5 8.9 0.0033 7.5 
Phe-1A-1E* C12H16NO4+ 19.09 -4 238.1067 0.7 10.0 0.0060 2.8 
Thr-1A-1E* C7H14NO5+ 14.45 -1 192.0863 0.4 9.0 0.0070 3.7 
His-2A-1E* C11H16N3O6+ 24.07 e 286.1025 0.9 14.0 0.0077 2.7 
lactate-1MC-1E* C6H11O5+ 9.08 e 163.0600 0.1 7.8 0.0103 3.9 
laurate-1E* C13H27O2+ 14.22 0 215.2000 0.6 15.6 0.0116 2.4 
Val-1A-1E* C8H16NO4+ 12.13 -3 190.1067 0.7 9.8 0.0196 2.5 
Ile-1A-1E* C9H18NO4+ 13.41 -3 204.1229 0.1 9.1 0.0214 2.0 
stearate-1E C19H39O2+ 21.09 2 299.2938 0.6 9.2 0.0003 3.3 
Tyr-1A-1MC-1E C14H18NO7+ 24.96 e 312.1085 -0.7 3.3 0.0018 2.6 
Lys-2A-1E C11H21N2O6+ 23.08 e 277.1390 0.5 12.0 0.0020 2.5 
myristate-1E C15H31O2+ 16.67 0 243.2311 0.7 9.9 0.0057 2.2 
palmitate-1E C17H35O2+ 18.94 3 271.2624 0.7 5.1 0.0061 2.7 
Orn-2A-1E C10H19N2O6+ 21.96 6 263.1217 2.1 15.1 0.0270 1.9 
Met-1A-1E C8H16NO4S+ 17.65 -3 222.0777 1.7 4.1 0.0323 1.9 
Ser-1A-1MC-1E C8H14NO7+ 16.95 -1 236.0766 -0.1 11.1 0.0128 1.3 
aminoadipate-1A-2E C10H18NO6+ 18.80 1 248.1123 0.5 14.3 0.0334 1.7 
malate-1MC-2E C8H13O7+ 14.90 -1 221.0643 1.3 22.2 0.0442 1.8 
a Difference between fatty acids-based RI in a standard and sample. b Difference between predict-
ed and measured mass. c False discovery rate according to Benjamini and Hochberg [89]. 
d Calculation after manual integration of respective [M+H]+ as quant mass that exhibited a peak-to-
peak S/N >20. e Not calculable. 
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Figure 6.7 Influence of water infusion on detectability of [M+H]+ of MCF-derivatized malate in a cell 
extract sample from the control group acquired by GC-APCI-TOFMS (a) without and (b) with 0.4 mL/h 
water infusion. [M+H]+ was not formed in the absence of water infusion, thus impeding positive identifica-
tion of this metabolite. Reprinted from [14]. 
6.3.7 Cross-validation of discriminating amino acids 
To confirm that amino acids identified by metabolite fingerprinting to discriminate be-
tween control and 17-DMAG -treated cells reflect true differences in abundance of those 
amino acids, targeted analysis by means of HPLC-ESI(+)-MS/MS was performed using 
SIL-ISs. Concentration levels were normalized by the protein content of the respective 
cell pellet, which was 3.1±0.2 mg and 1.5±0.4 mg for the control and the 17-DMAG 
group, respectively. As displayed in Table 6.3, significant amino acids in metabolic 
fingerprinting were confirmed in all cases by HPLC-MS/MS, except for valine and cyste-
ine, whose content could not be determined by the targeted approach. In addition to the 
discriminating amino acids already identified by the fingerprinting approach, HPLC-
MS/MS revealed arginine and asparagine as significantly regulated. In the case of argi-
nine this came as no surprise, as it is thermally instable and, therefore, not amenable to 
GC-MS. Furthermore, the 1.3-fold difference in abundance of asparagine between the 
two groups detected by the untargeted approach was too small to reach significance 
due to the lower repeatability of GC-APCI/+H2O-TOFMS in the absence of SIL-ISs. The 
FCs obtained by GC-APCI/+H2O-TOFMS deviated less than 20% from HPLC-MS/MS 
results for 15 out of 17 amino acids (Table 6.3), emphasizing that the presented GC-MS 
approach was capable of reproducing fold changes in a quantitative manner.  
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Table 6.3 Comparison of fold changes in free amino acid abundance in 17-DMAG -treated cell extracts 
relative to controls determined both by GC-APCI/+H2O-TOFMS and HPLC-ESI-MS/MS, respectively. 
Protein levels in cell pellets for normalization of concentration levels were determined by means of the 
FluoroProfile kit from Sigma-Aldrich. Amino acids marked with an asterisk (*) were found to discriminate 
control from treated cells irrespectively whether GC-APCI-TOFMS was performed without or with water 
infusion. Both approaches were well in accordance with each other. Reprinted from [14]. 
Amino acid GC-APCI/+H2O-TOFMS HPLC-ESI-MS/MS Fold GC-MS/  
Fold HPLC-
MS/MS 
 Significant (Adjusted 
p-valuea<0.05) 
Foldb Significant (Adjusted 
p-valuea<0.05) 
Fold 
      
Arg Not detected x 1.4 - 
Gln Not detected Not determinedc - 
Val* x 2.5 Not determinedc - 
Cys* x 7.5 Not determinedc - 
Gly* x 3.9 x 2.8 1.4 
Thr* x 3.7 x 3.0 1.2 
Ala* x 3.5 x 2.6 1.4 
Pro* x 3.5 x 3.0 1.2 
His* x 2.7 x 2.4 1.1 
Trp* x 1.9 x 2.1 0.9 
Leu* x 2.4 x 2.3 1.0 
Phe* x 2.8 x 2.5 1.1 
Ile* x 2.0 x 2.4 0.8 
Tyr x 2.6 x 2.5 1.0 
Ser x 1.3 x 1.4 1.1 
Met x 1.9 x 2.0 1.0 
Lys x 2.5 x 2.3 1.1 
Orn x 1.9 x 1.8 1.1 
Asn  1.3 x 1.1 1.2 
Asp  1.0  1.1 0.9 
Glu   1.0   1.1 1.1 
a False discovery rate according to Benjamini and Hochberg [89]; b Calculation after manual 
integration of respective [M+H]+ as quant mass that exhibited a peak-to-peak S/N >20 and nor-
malization of peak areas to the protein content of the respective cell pellet; c Co-eluting com-
pound present in case of Gln and Val, Cys was not detected in 17-DMAG treated samples and 
therefore a p value was not calculated. 
 
 
6.4 Conclusions 
The present study showed that the continuous infusion of water enhanced not only the 
efficiency but also the repeatability of APCI of MCF-derivatized metabolites, while exert-
ing almost no or at times even a deleterious effect on APCI of MeOx-TMS derivatives. A 
likely explanation for the different behavior of the MCF and MeOx-TMS derivatives is 
the more polar nature of the former, which facilitates the formation of analyte-water ion 
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clusters. Overall, the beneficial effect of water infusion was most pronounced for car-
boxylic acids, less so for amino acids, and the least for (hetero) aromatic compounds. 
Water infusion was also found to improve the ability of GC-APCI-TOFMS to detect, 
determine, and identify metabolites, whose abundance changed significantly upon 
treatment of cancer cells with the Hsp90-inhibitor 17-DMAG. This was due to reduced 
in-source fragmentation of MCF-derivatized metabolites and a concomitant increase in 
[M+H]+ ions, that improved not only detection sensitivity but also facilitated elucidation 
of elemental composition of discriminating metabolites, which also benefitted from the 
improved isotope patterns seen upon water infusion. Finally, the ability of metabolite 
fingerprinting based on MCF derivatization and GC-APCI/+H2O-TOFMS to detect true 
differences in metabolite abundance could be confirmed by targeted HPLC-MS/MS 
analysis employing SIL-ISs. In summary, APCI/+H2O provides softer ionization than 
conventional APCI, with reproducible formation of [M+H]+ being favored over fragment 
ions for MCF derivatives, especially in the case of organic acids, thus extending the 
range of compounds amenable to metabolic fingerprinting. 
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7 Assessment of matrix effects in GC-APCI-MS 
7.1 Introduction 
As concluded in my master thesis, GC-APCI-TOFMS can be used for the quantitative 
analysis of metabolites. However, a major obstacle in the development of accurate and 
reliable quantitative methods for complex samples is the matrix effect, i.e., “the com-
bined effect of all components of the sample other than the analyte on the measurement 
of the quantity” [137].  
Matrix effects were examined in detail for LC-MS. Although less discussed, matrix ef-
fects are also found in GC-MS, e.g. in pesticide analysis [138,139]. Either suppression 
or enhancement of the analyte signal is possible. Electrospray ionization (ESI) and 
APCI are common ionization techniques in LC-MS, and both were found to be suscepti-
ble to matrix effects, although to different degrees [80,81,140]. Different mechanisms 
are currently discussed for the occurrence of matrix effects. Ion suppression may result 
in the liquid phase due to an altered efficiency of droplet formation or droplet desolva-
tion caused by less volatile compounds or matrix co-eluting with the analyte of interest 
[141], In turn, this affects the number of ions in the gas phase that enter the MS. Fur-
thermore, other possible mechanisms are proposed that take place in the gas phase 
such as depletion of charge of the analytes by interfering species. In summary, as 
pointed out by several authors [80,141], many potential causes rather than only one 
may lead to the observed matrix effect. The effects may vary greatly among different 
sources and ionization modes [142].  
Matrix effects occurring solely during ionization have been less of a concern in GC-MS 
compared to LC-MS. Since the mobile phase is a gas, mobile phase additives and the 
analyte transfer in the gas phase during ionization are irrelevant. Furthermore, GC pro-
vides enhanced analyte resolution, and, hence, a lower number of co-eluting analytes 
and matrix compounds are expected. Nevertheless, biological samples are highly com-
 
 86
 
 
 
plex, and co-elution is commonly observed even in GC-MS. In addition to that, APCI for 
LC-MS and GC-MS is based on similar principles, because analyte ionization in the gas 
phase is initiated by corona discharge, which might be a source of ion suppression in 
the case of co-eluting species. So far, only few authors evaluated matrix effects in GC-
MS with EI [37,143] and APCI [8,82] sources. For instance, Portoles et al. [82] found 
decreased signals of pesticides spiked into various food matrices in comparison to pure 
standard solutions. The authors concluded that this was due to a combined effect of the 
ionization and the injection [82]. Indeed, blocking of active sites in the liner by matrix 
compounds resulting in ionization enhancement of the analyte has been already de-
scribed in the field of pesticide analysis [144].  
The aim of this project was to investigate matrix effects in GC-APCI-TOFMS. It should 
be noted that the study only aimed at revealing potential matrix effect but the underlying 
mechanisms were not further studied. Three different matrices that are typically encoun-
tered in metabolomics were spiked with a mixture of 15 metabolites and recovery rates 
were determined for these analytes. In addition to that, possible interferences between 
three pairs of co-eluting analytes in standards were studied, which not only allowed the 
evaluation of defined amounts of possibly interfering compounds but also a closer look 
into whether APCI might be an actual source of ion suppression or enhancement. 
The results of this chapter will be part of a manuscript in preparation. 
 
7.2 Materials and methods 
7.2.1 Spike-in experiment 
Preparation of E. coli, serum and urine pool samples 
The aqueous-methanolic E. coli BL21 extract was the same as described in a previous 
study by Almstetter et al. [12]. Sample volumes of 10 and 20 µL of serum and urine, 
respectively, were used according to established protocols in our laboratory [132]. Forty 
aliquots of 10 µL of human serum were precipitated with 50 µL of cold methanol and 
 
 87
 
 
 
then centrifuged at 3375 × g for 5 min. The supernatants were collected and pellets re-
extracted twice with 50 µL of methanol. All supernatants were combined in a pool sam-
ple. Forty aliquots of 20 µL of human urine were incubated with 20 µL of a 2U/µL solu-
tion of urease in PBS at 37°C for 15 min. The reaction was stopped with 200 µL of eth-
anol, and all aliquots were pooled.  
 
Preparation of standards and matrix samples  
Since endogenous metabolite concentrations varied among the three matrices, individ-
ual spike-in mixtures were prepared in methanol from individual aqueous or methanolic 
stock solutions of the spike-in compounds (N=15). Their composition and the respective 
concentrations of the spike-in compounds are given in Table 12.7. Aliquots of 10 and 40 
µL were taken for further preparation of spike-in standards to determine the amounts of 
spiked metabolites via the same calibration curves (see below) as for the matrix sam-
ples for calculating recovery rates. For the generation of the spiked matrix samples, 100 
µL of E. coli extract, 150 µL of pooled serum extract and 240 µL of pooled pre-treated 
urine, respectively, were used, followed by the addition of 0, 10, 20, 30, 40, 50, and 60 
µL of the respective spike-in mixture. The matrix samples contained amounts between 
0.08-24.24 nmol absolute of the spike-in metabolites. Each matrix sample and spike-in 
standard was prepared in five replicates in a 2-mL glass vial with a 400-µL glass insert. 
They were then fortified with 10 µL of internal standard surrogate solution, vortexed, 
and evaporated to complete dryness, followed by manual MeOx-TMS derivatization 
including the odd-numbered, saturated fatty acids (C9-C19) prior to silylation. To check 
accuracy of the calibration curves, two standard samples were prepared as previously 
described [17] at a concentration of 125 and 15.63 µM, respectively. 
 
Determination of endogenous and spiked levels of spike-in metabolites, and recovery 
GC-APCI-TOFMS calibration curves from an existing quantitative method [17] were 
used for quantification of spike-in metabolites in spiked and unspiked matrix samples, 
and spike-in standards. For quantification the internal standards specified in Table 12.7 
were used. Recovery rates were determined in Excel for each spiked matrix sample 
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according to the following equation, which includes absolute amounts of spiked analytes 
that were calculated from those of the spike-in standards:  
 
Values higher or lower than 100% indicate ion enhancement or suppression, respective-
ly.  
Spiked and unspiked matrix samples as well as spike-in standards were measured in 
random order by GC-APCI-TOFMS. 
7.2.2 Co-eluting analyte pairs  
Two standard mixtures were prepared from separate stock solutions. Mixture A con-
tained glycerol, glycine and phenyllactate, whereas mixture B comprised phosphate, 
succinate and phenylpyruvate at a concentration of 1 mM each in methanol. Both were 
serially diluted over a concentration range of 0.98-1000 µM.  
According to the expected linear range of the calibration curves of the six analytes, one 
set of calibrators consisted of eight and six calibration samples that were prepared in 
triplicate from dilutions of mixtures A and B, respectively. Hundred µL or 75 µL of the 
respective diluted standard were transferred into a 2-mL glass vial with a 400-µL glass 
insert. Absolute amounts of 0.195, 0.391, 0.781, 1.172, 1.563, 3.125, 4.688 and 6.25 
nmol of analytes in mixture A, respectively, and 0.098, 0.781, 1.563, 3.125, 6.25 and 
12.5 nmol of analytes in mixture B were used. To study the slopes of the analytes’ cali-
bration curves in the absence of co-eluting compounds and their presence at three 
different concentration levels, four sets of calibrators were prepared in total. Then abso-
lute amounts of 0, 1, 10, and 100 nmol of mixture B were added to the calibration sam-
ples from mixture A and vice versa. Further, all calibration samples were fortified with 20 
µL of a 0.5 mM mixture of [2H7]trans-cinnamate and [U-13C]fumarate, vortexted, evapo-
rated to complete dryness, and manual MeOx-TMS derivatization was performed, with-
out the addition of fatty acids.  
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For calibration, glycerol, phenyllactate and phenylpyruvate were normalized by 
[2H7]trans-cinnamate, whereas [U-13C]fumarate was used for normalization of glycine, 
phosphate and succinate. The [M+H]+ ion was chosen as quantifier for all analytes. 
Retention times of the analytes and internal standards are shown in Figure 7.4. 
 
7.3 Results and discussion 
7.3.1 Selection of internal standards for quantification of spike-in me-
tabolites 
At the initial stage of the evaluation of matrix effects an existing quantitative method 
including 43 analytes from different chemical classes [17] was used to determine the 
endogenous concentrations of these compounds in E. coli, serum, and urine. For the 
selection of spike-in compounds the ULOQs of the calibration curves were considered 
in addition to the determined endogenous levels. Concentration fold changes (FCs) of 
1.5- to 4-fold of the endogenous levels were thought to be suitable to be spiked into the 
matrix samples. According to Annesley [145], analyte concentrations similar to those 
under real conditions should be used to evaluate ion suppression. Therefore, for in-
stance, amino acids were not chosen because of their endogenous concentrations in 
the high micromolar range in E. coli. On the other hand, FCs lower than 1.5-fold might 
be too small for a correct evaluation. Furthermore, for analytes with endogenous con-
centrations below the LLOQ, 0.75 nmol absolute were used for spike-in level 1, and FCs 
between 2 and 6 for the higher spike-in levels. Table 12.7 lists all the compounds in-
cluded in the spike-in mixtures and their concentration levels.  
Evaluation of matrix samples initially resulted in surprisingly high recoveries of up to 
174% for glycerate and phenyllactate in E. coli extracts, and for homovanillate, phos-
phoglycerate and hydroxyphenylpyruvate both in serum and urine. This was caused by 
an internal standard recovery ([U-13C]lactate, [U-2H]succinate and [2,2,4,4-2H4]citrate) of 
less than 75% in these matrices (Figure 7.1). A decrease of 25% or more in peak area 
has been previously regarded as indicator for ion suppression [81]. The other 4 internal 
 
 90
 
 
 
standards deviated less than 25%, but recoveries ranged between 76.1-113.4% (Table 
12.7). Matrix pre-treatment steps are ruled out as a possible source for the observed 
analyte losses, because matrix aliquots were spiked post-extraction with internal stand-
ards. Hence, it was assumed that the poor IS recovery is due to the high endogenous 
concentrations of lactate and succinate in E. coli, and citrate in serum and urine, which 
might have suppressed their co-eluting stable isotope-labeled analogues. In fact, the 
actual concentration levels of these three endogenous metabolites could not be deter-
mined in these matrices because the ULOQ of the respective calibration curves had 
been exceeded. Another explanation in the case of labeled citrate in a urine matrix 
might be complexation of labeled citrate with bivalent calcium cations, because no pre-
cipitation step was included in urine pre-treatment. Similarly for LC-MS with ESI and 
APCI sources, Remane et al. [140] reported enhanced ion suppression for 14 ISs with 
increasing concentration levels of the native analogues, which was evaluated in the 
context of multi-analyte procedures to quantify drugs and poisons in clinical and forensic 
toxicology.  
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Figure 7.1 Mean recoveries ±SD of critical internal standards in E. coli, serum, and urine in the spike-in 
experiment. These internal standards exhibited more than 25% deviation in peak area in at least one of 
the biological matrices (N=30 spiked matrix samples each) in comparison to standard samples (N=12). 
The black solid lines indicate mean recoveries of 75% and 125%, respectively. Student’s t test was per-
formed on the area integrals of [M+H]+ in the spiked matrix samples (N=30) versus those in standards 
(N=12) *P value <0.05; **P value <0.001.  
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A decreased IS signal caused by co-eluting endogenous analytes might cause severe 
problems especially if only a limited number of ISs are available in a study. Hence, use 
of SIL-ISs for quantification of analytes other than their native analogues may result in 
inaccurate quantification.  
As a consequence of the poor recoveries of [U-13C]lactate, [U-2H]succinate and [2,2,4,4-
2H4]citrate, endogenous concentrations of glycerate, phenyllactate, homovanillate, 
phosphoglycerate and hydroxyphenylpyruvate were recalculated using calibration 
curves based on different SIL-ISs (listed in bold in Table 12.7). The recalculated values 
differed from the original data. Since the calculation of the spike-in amounts was based 
on the original data, the resulting actual fold changes are slightly different and therefore 
fold changes are not consistent for all spike-in metabolites.  
7.3.2 Recovery rates of 15 spiked metabolites in three different matri-
ces 
Mean recoveries over all spike-in levels of the 15 spike-in compounds were determined 
in the three different matrices. Results are presented in Figure 7.2. Most metabolites 
yielded recovery rates between 75-125%. One of the exceptions was methylmalonate in 
E. coli with a mean recovery of 68%. However, this was probably due to incorrect peak 
integration since valine (m/z [M+H]+: 262.1653 Da) was partially co-eluting (~ 25% peak 
overlap) with methylmalonate (m/z [M+H]+: 263.1129 Da), and an extraction width of 
±0.1 Da for the quantifier turned out as too wide to distinguish methylmalonate and the 
first isotope of valine based on their mass. High recoveries up to 142% were seen for 
phenylacetate in serum and urine in the presence of threonine as co-eluting matrix 
compound. Among the matrices no obvious differences were recognized. For most 
spike-in compounds high mean RSD values of up to 30% were obtained. This is at-
tributed to missing corresponding SIL-ISs for 13 out of 15 spike-in analytes. RSD values 
for fumarate and pyruvate, for which a corresponding SIL-IS was included, were dis-
tinctly lower (below 9% in all cases).  
Next, mean recoveries of individual spike-in levels were compared, because it has been 
pointed out in LC-MS that the degree of ion suppression can depend not only on the 
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total amount of co-eluting matrix but also the matrix/analyte ratio [145]. Even though no 
consistent fold changes had been generated for all analytes, as described in the previ-
ous section, a total of 12 spike-in metabolite – matrix combinations could be evaluated. 
Only combinations with comparable spiked FCs in the specified matrix were considered. 
As shown in Figure 7.3, no big differences were seen among the different spike-in 
levels, except for methylmalonate in E. coli and urine, and pyruvate in urine (ANOVA, p 
<0.05), which exhibited significantly decreased recoveries for the lowest spike-in level. 
In the case of pyruvate this was surprising, as no co-eluting matrix compound was rec-
ognized in the chromatogram. Hence, this might be caused more likely due to a slightly 
over-estimated endogenous pyruvate level in urine that had the largest impact on the 
calculation of recovery rates for low spike-in levels.  
Previously, Garcia-Villalba et al. [8] investigated matrix effects in GC-APCI-TOFMS for 
phenolic compounds in extra virgin olive oil. The authors compared peak areas of ana-
lytes spiked post-extraction into the oil matrix to those in a neat solution, but did not 
report any significant differences [8]. In contrast, Portoles et al. [82] studied insecticides 
in various food matrices by means of GC-APCI-MS/MS, and found a distinct decrease 
in the analyte signal in most of the investigated matrices, which was on average 55% of 
that in standard solutions. The authors concluded that such effects resulted from com-
bined effects of the ionization and the injection [82]. The latter is well known as a source 
for ion enhancement in the analysis of pesticides by GC [144]. Accordingly, the outcome 
of matrix evaluation experiments may strongly depend on the type of matrix.  
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Figure 7.2 Mean recoveries over all spike-in levels ±SD of the 15 metabolites spiked into E. coli, serum, and urine. Six spike-in levels (N=5 derivatization replicates 
each) were generated using absolute spiked amounts between 0.08-24.24 nmol. Spike-in levels were based on the endogenous concentration of the spike-in me-
tabolites determined from unspiked matrix samples and the ULOQ of the respective calibration curves. The black solid lines indicate mean recoveries of 75% and 
125%, respectively. For the majority of spike-in compounds mean recovery rates ranged between 75-125% indicating that matrix compounds hardly interfered.  
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Figure 7.3 Mean recoveries of individual spike-in levels ±SD of 12 spike-in metabolite – matrix combinations with comparable fold changes based on the endoge-
nous analyte concentration in the specified matrix. The black solid lines indicate mean recoveries of 75% and 125%, respectively. Differences among individual 
spike-in levels were small indicating that the matrix-to-analyte ratio is rather not crucial for the onset of matrix effects. EC, E. coli; S, serum; U, urine, *, ANOVA,  
p <0.05 in at least one comparison to a higher spike-in level. 
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Another explanation for the rather minor effects seen for the 15 spike-in compounds 
might be insufficient matrix amounts. Heller [146] by means of API-LC/MS studied vary-
ing amounts of co-injected matrix in the analysis of drug residues in animal tissue ex-
tracts. It was concluded that a critical matrix concentration exists for the onset of matrix 
effects [146]. This might also be valid in GC-MS. Nevertheless, typical volumes of sam-
ple were used for the experiments described above, according to established protocols 
in our laboratory. Furthermore, MeOx-TMS derivatization was used, which is considered 
as most versatile among common derivatization strategies in metabolomics; therefore, a 
comparably high number of matrix compounds was expected to be derivatized. On the 
other hand, urease pre-treatment in the case of urine removed urea, which would have 
yielded a broad peak and might have caused alterations in the ionization efficiency of 
co-eluting spike-in compounds.  
7.3.3 Slopes of calibration curves of six analytes in the presence of 
co-eluting compounds 
Apart from interferences by matrix compounds, ion suppression and enhancement tests 
should be performed for co-eluting analytes. Using calibrators that include at least two 
of the latter might hamper the quantitative determination of them in real samples in the 
absence of co-elution, and vice versa. Therefore, the effect of co-eluting analytes on the 
slopes of calibration curves of five metabolites and phosphate was studied by addition 
of defined amounts of co-eluting analytes to the calibrator samples. Figure 7.4 depicts 
the TIC chromatogram of a standard containing the six investigated compounds and two 
internal standards included in the experiment. The three co-eluting pairs, namely glyc-
erol/phosphate, glycine/succinate and phenyllactate/phenylpyruvate, gave rise to mixed 
APCI-TOFMS mass spectra as shown at the bottom of Figure 7.4. These compounds 
might co-exist in real samples as well, e.g., complete removal of phosphate in cell cul-
ture samples is virtually not possible; hence, phosphate might interfere with the quanti-
tative analysis of glycerol.  
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Figure 7.4 Gas chromatographic separation of the six analytes and two internal standards included in the 
co-elution experiment as well as APCI-TOFMS mass spectra of the three pairs of co-eluting compounds. 
Experimental details are given in chapter 5. 
According to the linear range of their calibration curves [17], analytes were combined in 
two mixtures. Calibration curves were acquired in the absence of co-eluting analytes 
and their presence at three different amounts (1, 10, and 100 nmol absolute). As exam-
ple Figure 7.5 shows a glycerol calibration without and with phosphate at 100 nmol 
absolute being present in the calibrators.  
Conc
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Figure 7.5 Calibration curves for the example of glycerol in the absence of co-eluting phosphate and its 
presence at 100 nmol absolute. The slope of the latter curve was distinctly decreased.  
Further, the slopes of all calibration curves were normalized by those obtained in the 
absence of a co-eluting compound. The data is illustrated in Figure 7.6 including aver-
aged figures of merit of the four calibration curves of each analyte. As indicated by the 
two black solid lines spanning from 75% to 125% of normalized slopes, slopes of cali-
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bration curves in the presence of 100 nmol of co-eluting analytes were distinctly de-
creased in all cases. Whereas those of glycine (80%) and phenylpyruvate (77%) were 
slightly above the established threshold of 75%, they were much lower for the other four 
analytes ranging between 29-57%. Furthermore, slopes of phosphate (81%) and suc-
cinate (76%) were remarkably decreased even in the presence of intermediate (10 
nmol) levels of co-eluting analytes. In general, due to the presence of co-eluting ana-
lytes, mean RSDs over all triplicates and calibration points were quite high (Figure 7.6 
at the bottom), especially in the case of glycine (39%).  
These results are in good accordance with those in the previous subsection on the 
suppression of stable isotopically labeled lactate, succinate, and citrate in the presence 
of high concentrations of their native analogues. The effects observed in the co-elution 
experiment, however, are more likely solely due to ion suppression because only stand-
ards were used and no biological matrix was present. Furthermore, only calibrators well 
in the linear range of the analytes were used, so that saturation of the TOFMS could be 
excluded. In summary, alterations in ionization efficiency were found within all three co-
eluting analyte pairs, emphasizing the importance of corresponding SIL-ISs for quantita-
tive analysis.  
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Figure 7.6 Normalized slopes of calibration curves of six analytes in the presence of three different levels 
of their respective co-eluting compound. Depending on the analyte, the calibration curves were based on 
calibrator levels between 0.98-125 µM (N=3 derivatization replicates per calibration level) with 0, 1, 10, or 
100 nmol absolute of respective co-eluting compound added to each calibration sample. The three co-
eluting analyte pairs are arranged adjacent to each other in the figure. Normalization was based on the 
slope obtained in the absence of co-elution. Figures of merit of the calibration curves listed at the bottom 
correspond to the averaged values from the four curves of each analyte. The black solid lines indicate 
normalized slopes of 75% and 125%, respectively. While slopes of calibration curves were distinctly 
decreased in all cases in the presence of 100 nmol of co-eluting compounds, this was also seen for 
phosphate and succinate in the presence of intermediate (10 nmol) levels of co-eluting analytes. Counts, 
number of included calibration points; OOM, order of magnitude of the linear range on the basis of a log-
10 scale; RSD, average mean relative standard deviation in peak area over all individual RSDs of calibra-
tion triplicates. 
 
7.4 Conclusions 
The experiments presented in this chapter clearly indicate the presence of matrix effects 
or interferences due to co-eluting analytes, which result at least in part from the ioniza-
tion in the APCI source. In the spike-in experiment, recovery of three out of the seven 
internal standards was below 75% in at least one of the three biological matrices in 
comparison to standard samples. This was attributed to suppression by their respective 
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unlabeled analogue that was present at a high concentration, which was reinforced by 
the fact that co-eluting analyte pairs in standards suppressed each other at concentra-
tions of 1000 µM of the co-eluting compound. It emphasizes the need for careful selec-
tion of internal standards used for several analytes with respect to possibly occurring 
ionization interferences.  
Recoveries of the 15 spike-in compounds in the three biological matrices were within 
75-125% in most cases, which does not indicate severe matrix effects. Nevertheless, 
the situation might be different if higher concentrated samples or other matrices are 
analyzed, or different derivatization strategies such as MCF derivatization are em-
ployed. Furthermore, the matrix-to-analyte ratio did not prove as critical for the onset of 
matrix effects, albeit only a small number of matrix – spike-in compound combinations 
were evaluated. A clear dependence on the concentration level of the interfering analyte 
for the onset of ion suppression was observed for three analyte pairs. In fact, depending 
on the analyte, 100 or 1000 µM of interfering compound led to at least 20% suppression 
of the slope of the analyte’s calibration curve. This points to the ionization in the APCI 
source as cause for suppression since no matrix was present in that experiment.  
In summary, during quantitative method development matrix effects should always be 
evaluated. They may be reduced by sample cleanup. Alternatively, an analyte’s altered 
ionization may be corrected by its corresponding SIL-IS, or selectivity may be tuned. 
The latter can be achieved by choosing a GC column of different polarity or modification 
of the temperature program in such a way that co-elution with the target analytes be-
comes negligible.  
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8 Performance evaluation of a redesigned APCI 
source  
8.1 Introduction 
Following APCI source commercialization for GC-MS, an increasing number of success-
ful applications has been realized in various fields, as summarized in section 4.3.2. 
Nevertheless, weaknesses such as unstable ionization conditions remained and 
spurred further development and modifications of the source design. In 2006, Östman et 
al. introduced an APCI microchip that exhibited good repeatability [135]. Klee et al. [71] 
reported the development of a novel capillary APCI (cAPCI) ionization source for GC 
making use of liquid instead of metal corona discharge point electrodes. The authors 
observed controlled and very stable conditions during source operation, which was 
partly attributed to the continuously replenished surface of the point electrode by the 
liquid flow. Recent applications with a conventional source design relied more and more 
on the addition of water as a modifier to provide a well-defined humidity inside the APCI 
source for controlled ionization [14,82,131]. Continuous infusion of water into the APCI 
source clearly enhanced efficiency as well as repeatability of APCI in the case of MCF-
derivatized metabolites, as presented in chapter 6, but this was not observed for MeOx-
TMS derivatives. Hence, the second generation “GC-APCI II” design from Bruker Dal-
tonics, which was introduced during my doctoral thesis and supposedly addressed 
shortcomings of the original GC-APCI I source, was further tested with regard to its 
performance for the latter class of derivatives.  
The improved design claims to minimize gas turbulences in the source and to better 
shield the ionization chamber against uncontrolled gas exchange with the outside air, 
thereby reducing chemical background and providing better control over humidity in the 
source. In the present study, the novel GC-APCI II source coupled to HRTOFMS analy-
sis was compared to its first-generation predecessor (“GC-APCI I”) for the application to 
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metabolomics. Its performance was initially compared over the entire chromatographic 
run using a homologous series of fatty acid methyl esters. Furthermore, calibration 
curves of 20 MeOx-TMS derivatized metabolite standards were used to compare figures 
of merit for metabolic profiling, such as linear range and derivatization repeatability. 
Finally, to comparatively assess the qualitative output, features were extracted and 
identified from APCI I and II mass spectra from analyses of cell culture supernatants.  
Preparation of calibration and cell culture supernatant samples, as well as partial evalu-
ation of calibration curves was carried out by Thomas Hahn as part of his bachelor 
thesis under my guidance. This chapter was published in [13].  
 
8.2 Materials and methods 
8.2.1 Materials 
A 1:100 (v/v) working dilution of the FAME mixture in methylene chloride was prepared, 
yielding concentrations of 5-13 µM of the 19 individual compounds that were finally 
evaluated. The metabolite mix contained 20 metabolites (compare Table 8.2) in metha-
nol at 1 mM each, prepared from separate stock solutions in water, methanol or a mix-
ture thereof. The mix was serially diluted to generate 20 calibration points from 0.002 
μM to 1000 μM. MeOx-TMS derivatized calibration standards were generated as de-
scribed in subchapter 5.2.  
8.2.2 Instrumentation 
APCI II source setup 
The “GC-APCI II” source (Bruker Daltonics GmbH, Bremen) consists of an atmospheric 
pressure chemical ionization source chamber equipped with a corona discharge needle 
assembly and a flexible heated GC transfer line. A scheme of the APCI II source is 
shown in Figure 8.1. In contrast to its predecessor, the vaporizing unit had been re-
moved because it caused excessive turbulences in the APCI I source (compare Figure 
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4.7 and section 4.3.1 on the GC-APCI-TOFMS instrumental setup). Instead, the heat for 
the APCI ionization process is now generated at the head of the GC transfer line by an 
external heating device. Further reductions in gas turbulences are accomplished by 
generating a hot laminar flow from the head of the GC transfer line, illustrated in orange 
in Figure 8.1. This laminar gas flow guides the carrier gas towards the MS inlet. Oppo-
site to the head of the GC transfer line a modified spray shield assembly is mounted at 
the entrance of the transfer capillary of the mass spectrometer. This spray shield ar-
rangement has 2 functions. It produces an optimized electrical gradient to direct the ions 
into the MS inlet capillary and it generates an optimized laminar dry gas flow, illustrated 
in red in Figure 8.1, outside of the inner guiding gas flow. According to simulations 
performed by the manufacturer, both counter-directed laminar gas flows do not disturb 
each other and do not generate turbulences (personal communication, Dr. Thomas 
Arthen-Engeland, Bruker Daltonics Bremen, Germany).  
Both gas flows shield and maintain the heat in the inner APCI ionization area. This 
prevents contamination, which reduces the chemical background and excludes uncon-
trolled gas exchange with the outside air thereby controlling the water content in the ion 
source. This is further supported by the airtight design of the source chamber. Finally, in 
contrast to the original design, the heat required for the APCI process is now generated 
in close vicinity to the ionization region and hence generates higher temperatures in the 
APCI ionization region. 
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Figure 8.1 Scheme of the GC-APCI II ion source: 1 head of the GC transfer line; 2 GC capillary outlet 
and heated nitrogen gas guiding the eluting analytes towards the MS inlet; 3 APCI electrical shield with 
outer ring cover enclosing the APCI ionization area and guiding both gas flows into and from MS; 4 inlet 
mass spectrometer; 5 dry gas flow direction; 6 corona needle. The GC effluent is delivered by a flexible 
GC transfer line into the APCI region of the ion source. Mechanical design, gas flows, heat distribution 
and electrical fields were optimized for efficient AP chemical ionization and ion transfer into the MS inlet. 
The illustration is reprinted from [13] with permission from Bruker Daltonics GmbH, Bremen. 
 
GC×GC-EI-TOFMS 
Instrumental settings for the employed LECO Pegasus 4D GC×GC-EI-TOFMS instru-
ment are described in detail elsewhere [17,147]. The first-dimension GC column was 
identical to the one used for GC-APCI-TOFMS in the current chapter and chapter 7. The 
temperature program was only slightly different with 50°C for 0.2 min, raised at 8°C/min 
to 265°C, and held for 10 min. Analyte fractions were transferred in 4-second intervals 
from the first- onto the second-dimension column by means of a dual-stage, quad-jet 
thermal modulator. An RTX-1701 (2 m × 0.1 mm i. d. × 0.1 µm film thickness, Restek) 
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was employed as second dimension column, and kept at a positive offset of 5°C relative 
to the first-dimension column. Splitless injection of 1.5 µL was performed by means of a 
PTV injector (set at 50°C for 0.5 min, ramped at 12°C/s to 250°C, held for 1 min). EI 
ionization under standard 70 eV electron ionization parameters at 200°C was used. 
Data were acquired 40-600 m/z at a rate of 100 spectra/s. The solvent delay was 8 min.  
8.2.3 Data analysis 
8.2.3.1 FAMEs 
For automatic peak integration, the “Find Compounds – Chromatogram” version 3.0 
peak finder in DataAnalysis was applied to the extracted ion chromatograms (EICs) of 
[M+H]+ ions of all investigated compounds (see Table 1) using an extraction width of 
±0.02 Da. Peak finder parameters were as follows: sensitivity: 90%; area threshold: off; 
intensity threshold: 1000; minimum peak valley: 30%; and mass spectrum calculation 
settings: default. Peak identification of investigated FAMEs was based on the accurate 
mass of each compound, common elution rules [148], as well as peak abundance in 
case of C18:1n9c and C18:1n9t, as the concentration of the former is twice as high in 
the FAME mixture.  
8.2.3.2 Cell culture supernatant samples 
For compound identification, the “Find Compounds – Dissect” peak-finding algorithm 
implemented in DataAnalysis was used. This deconvolution algorithm combines all ions 
with a similar chromatographic profile into one compound. Dissect compounds were 
extracted over a chromatographic range of 9-37 min of recalibrated data files using the 
following parameters: internal S/N threshold: 20; maximum number of overlapping com-
pounds: 3; mass spectrum calculation parameters: default; and advanced settings: 
enabled chromatographic resolving power of 0.3. Identification of metabolites was 
achieved in several ways: (1) m/z values of extracted dissect compounds were 
searched in the GC-APCI-HRMS online database established by Pacchiarotta et al. [74] 
and retention indices compared when available in the database. (2) Accurate masses 
and retention indices were matched against an in-house GC-APCI-HRTOFMS database 
 
 105
 
 
 
of 100 metabolite standards including sugars, fatty acids, organic acids, alcohols, amino 
acids and amino acid metabolites (compare Table 12.8). (3) GC×GC-EI-TOFMS raw 
data were processed using the ChromaTOF software as previously described [147] with 
a S/N threshold of 100 for peak detection in the first dimension and a S/N threshold of 
30 for second-dimension subpeaks. Peaks were combined in the second-dimension 
separation using a spectral matching factor of 500. Annotation of deconvoluted mass 
spectra was carried out by mass spectral matching to the NIST 05 library (based on a 
match >500 in forward search mode) and an attempt was made for annotated metabo-
lites to find the accurate masses of corresponding [M+H]+ ions in the APCI-HRTOFMS 
data. (4) For additional confidence in identified metabolites according to (1)-(3), ele-
mental formulas were calculated using the SmartFormula tool implemented in DataA-
nalysis (compare section 5.4.4). 
In addition to the Dissect algorithm, the FMF algorithm, which is recommended for 
quantitative analyses, was used to extract features from the chromatograms and com-
pare cumulative distributions of RSDs of peak areas. The following settings were ap-
plied for extraction and bucketing of FMF features: S/N threshold, 20; correlation coeffi-
cient threshold, 0.6; minimum compound length, 15; smoothing width, 5; additional 
smoothing, enabled; proteomics, enabled; bucketing basis, M+H. Retention time range, 
9-37 min; mass range, m/z 100-650; advanced bucketing tolerance parameters, 0.1 min 
and 10 mDa for retention time and mass, respectively; other parameters, always none 
or disabled. The bucket table was exported into Excel, features were normalized to the 
area integrals of [2H7]trans-cinnamate, and the RSDs calculated for all APCI I and II 
FMF features. 
For the qualitative assessment of technical variability, a single supernatant sample was 
injected trice and overlaid EICs were manually inspected. 
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8.3 Results and discussion 
8.3.1 GC-APCI-HRTOFMS analysis of FAMEs with the APCI I and II 
sources 
The general performance of APCI II in combination with HRTOFMS was investigated 
with a commercial 37-component FAME mixture and compared to that of APCI I-
HRTOFMS. The two data sets were acquired using identical chromatographic condi-
tions (Figure 8.2).  
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Figure 8.2 Overlaid extracted ion GC-APCI I and II-HRTOFMS chromatograms of FAMEs. A subset of 
N=19 components of a commercial FAMEs mixture were investigated in four subsequent replicate runs 
by means of GC-HRTOFMS equipped with an (a) APCI I and (b) APCI II ion source, respectively. Ex-
tracted masses of protonated molecules are listed in Table 8.1. An average 4.4-fold increase in peak 
areas was observed and peak apices aligned better in case of APCI II. (Concentration range: 5-13 µM. 
EIC = 20 mDa). Peak identification: 1, C11:0; 2, C13:0; 3, C14:1; 4, C15:1; 5, C15:0; 6, C16:1; 7, C17:1; 
8, C17:0; 9, C18:1c; 10, C18:1t; 11, C18:0; 12, C20:1; 13, C20:0; 14, C21:0; 15, C22:1; 16, C22:0; 17, 
C23:0; 18, C24:1; 19, C24:0. Reprinted from [13]. 
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The FAME mixture was used, because repeatability of retention time, peak width and 
ionization efficiency can be evaluated for compounds of widely different volatility. More-
over, FAMEs are alternative reference compounds for the calculation of retention indi-
ces instead of alkanes, which evade ionization in APCI(+) mode [78]. Keeping the use 
of FAMEs as reference compounds in mind, we opted not to use a dedicated FAME 
capillary GC column but rather the general-purpose Rxi-5MS column, though it is not 
well suited for the separation of complex FAME mixtures. Especially, unsaturated 
FAMEs with C18 and C20 backbones are not baseline resolved [148]. However, sepa-
ration of even- and odd-numbered, saturated and monounsaturated FAMEs was suffi-
cient. The FAMEs C4:0 and C6:0 eluted with the solvent and C8:0, C10:0, C12:0, 
C14:0, and C16:0 were excluded from this subset because they were in detector satura-
tion with GC-APCI II-HRTOFMS already at concentrations of 25 µM in the diluted mix-
ture. Consequently, 19 FAMEs remained that were used for comparison. Very stable 
retention times across four injection replicates were obtained with an average relative 
standard deviation of 0.01% for all 19 FAMEs. Signal intensities (peak areas) of the 
protonated molecules of the 19 FAMEs were on average 4.4-fold greater with the APCI 
II than the APCI I source, most likely due to the more efficient ion transfer to the MS 
inlet in the APCI II source (Table 8.1). This is also reflected in the S/N ratios that were 
on average 2.6-fold higher (Table 12.9). Furthermore, RSDs of peak areas obtained 
with APCI II were drastically reduced from 24.3% with APCI I to 4.6%. This low value is 
the more impressive as peak areas had not been normalized to an IS. Equally impres-
sive were the symmetric GC peaks with fairly uniform and highly repeatable (average 
RSD of 1.5%) peak widths at half height (wh) of approximately 2 s that could be ob-
served over the entire elution range with GC-APCI II-HRTOFMS (Figure 8.2, Table 
8.1). In contrast, for APCI I, values of wh increased for late-eluting FAMEs (compare 
Figure 8.3), most likely due to adsorption of the higher boiling analytes to cold spots in 
the ionization chamber, and were generally less repeatable (13.0%). The excellent 
repeatability of the peak area and wh observed with the APCI II source resulted from the 
generation of less ragged peak profiles as a consequence of the reduction in gas turbu-
lences in the APCI II source accomplished by the modified spray shield and the removal 
of the vaporizing unit.  
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Table 8.1 Statistical results for quadruplicate analyses of FAMEs (N=4) by GC-HRTOFMS with the APCI I and APCI II source, respectively. Given are the retention 
times and the m/z values of the protonated molecules of the nineteen FAMEs examined. Student’s t-tests with correction for multiple testing according to Benjamini 
and Hochberg [89] were performed on the peak areas and peak widths at half height (wh). The average 4.4-fold increase in peak area obtained with APCI II was 
significant for all evaluated FAMEs (p <0.05). APCI II also outperformed APCI I in terms of repeatability of peak area and wh and yielded similar peak widths over the 
entire retention time range. A paired t-test was performed to compare mean area RSDs. For comparison of the not normally distributed wh RSDs, the Wilcoxon 
signed-rank test was used. Reprinted from [13]. 
FAME GC-APCI II-
HRTOFMS  
ret.time (min) 
   
m/z APCI 
[M+H]
+ 
ion 
Fold change 
mean  
peak area 
APCI II/I
GC-APCI I-HRTOFMS GC-APCI II-HRTOFMS
 
Area RSD 
(%) 
Mean wh 
 (s) 
wh RSD  
 (%) 
Area RSD 
(%) 
Mean wh
 (s) 
wh RSD  
(%)  
  
C11:0 16.61 201.18 3.4 13.6 1.9 17.7 2.2 2.0 0.6
C13:0 19.50 229.22 3.8 17.4 2.1 9.7 3.5 2.0 0.8
C14:1 20.70 241.22 5.3 20.0 2.0 10.7 3.8 1.9 1.1
C15:1 22.00 255.23 5.0 21.7 2.0 6.6 4.0 2.0 2.5
C15:0 22.12 257.25 4.3 29.4 1.9 11.4 5.2 2.0 0.5
C16:1 23.13 269.25 5.0 40.9 1.9 12.9 4.5 1.9 0.7
C17:1 24.32 283.26 4.9 25.0 1.9 4.3 5.2 1.9 2.3
C17:0 24.53 285.28 3.4 22.7 1.8 15.1 4.3 1.9 1.2
C18:1c 25.39 297.28 4.3 16.6 1.8
a
5.2 4.5 2.1
a
0.6
C18:1t 25.45 297.28 4.6 43.3 2.0 31.6 4.9 2.0 2.3
C18:0 25.65 299.29 3.5 10.0 2.0 8.4 3.8 2.2 2.1
C20:1 27.54 325.31 4.8 23.0 1.9 11.4 4.5 2.0 1.6
C20:0 27.78 327.33 3.5 20.7 2.1 8.7 3.5 2.2 2.6
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Table 8.1 continued. 
FAME GC-APCI II-
HRTOFMS  
ret.time (min) 
   
m/z APCI 
[M+H]
+ 
ion 
Fold change 
mean  
peak area 
APCI II/I
GC-APCI I-HRTOFMS GC-APCI II-HRTOFMS
 
Area RSD 
(%) 
Mean wh 
 (s) 
wh RSD  
 (%) 
Area RSD 
(%) 
Mean wh
 (s) 
wh RSD  
(%)  
  
C21:0 28.79 341.34 4.5 18.5 2.2 8.9 5.1 1.9 1.1
C22:1 29.55 353.34 5.7 37.3 2.4
a
8.7 5.6 2.0
a
0.8
C22:0 29.77 355.36 3.9 31.1 2.1 10.3 3.7 2.2 1.0
C23:0 30.71 369.37 4.7 26.5 2.4 32.8 7.1 2.0 2.3
C24:1 31.43 381.37 5.7 22.9 2.9 19.8 7.2 2.1 2.4
C24:0 31.64 383.39 4.0 20.6 3.4
a
12.5 4.7 2.3
a
2.8
Mean   4.4 24.3b 2.1 13.0c 4.6b 2.0 1.5c
a
 padj <0.05 (Student’s t-test, corrected for multiple testing). 
b
 p <0.05 (Students t-test). 
c
 p <0.05 (Wilcoxon) 
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Figure 8.3 Peak widths (Wh) of late-eluting FAMEs obtained from GC-APCI-TOFMS measurements with 
APCI I (left) and APCI II (right) ion sources. APCI II yielded distinctly narrower peaks in comparison to 
APCI I. 17, C23:0; 18, C24:1; 19, C24:0.  
 
8.3.2 Comparison of GC-APCI-HRTOFMS calibration curves 
The quantitative performance of GC-APCI II-HRTOFMS was assessed by comparing 
the standard calibration curves of 20 metabolites to data acquired with an APCI I 
source. The chosen set of metabolites included compounds from various chemical 
classes, including amino acids; amines; mono-, di-, tri-, and aromatic carboxylic acids; 
2-oxo-acids; and sugars. The linear range determined by the lower limit of quantification 
(LLOQ) and upper limit of quantification (ULOQ), its order of magnitude on a log-10 
scale, and the RSD of the area response for derivatization replicates (N=5) of a single 
calibration point (31.25 µM) are given in Table 8.2 together with the GC-APCI II-
HRTOFMS retention times, m/z values of [M+H]+ ions, and the ISs used for normaliza-
tion. Retention times, m/z values, and RSDs of the non-normalized peak areas of the 
ISs are listed in Table 12.10. Employing the APCI II source, the analytical performance 
for the MeOx-TMS derivatized metabolite standards was distinctly enhanced. The RSD 
of the area response of the 31.25 µM calibration point decreased more than twofold 
compared to APCI I, from 7.5 to 3.4%. The calibration point was well within the linear 
range of all compounds for both the APCI I and the APCI II source, except for GABA-
3TMS, which slightly exceeded the ULOQ of GC-APCI II-HRTOFMS. Similarly, RSD 
values determined for the non-normalized peak areas of the ISs were slightly lower for 
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the APCI II measurements (Table 12.10). LLOQs decreased on average more than 
threefold from 1.5 to 0.45 µM. Considering the median rather than the average LLOQ, a 
more than fourfold decrease from 0.61 to 0.15 µM was observed. The median LLOQ 
provides a more appropriate evaluation of the data, as the LLOQ of 4-methyl-2-
oxovalerate (3.91 µM) was much higher than the LLOQs of the other analytes, which 
ranged from 0.002 – 0.73 µM. The linear concentration range was significantly in-
creased from 2.4 to almost three orders of magnitude, with R² values above 0.99 in all 
cases. The increase was achieved through better repeatability and, thus, inclusion of 
lower calibration points with less than 20% deviation from the curve. Increased detecta-
bility also contributed to the broader linear range as indicated by a distinctly lower medi-
an LLOQ in comparison to the median limit of detection (LOD) previously obtained for 
GC-APCI I-HRTOFMS (0.15 versus 0.24 µM) [17]. A drastic improvement in LLOQ from 
1.46 µM to 0.045 µM was observed for lactose, due to the generation of narrower peaks 
for high-boiling compounds using the APCI II source. Even greater improvements in 
LLOQ were achieved for GABA and glycine, with all amino acids yielding consistently 
LLOQs in the submicromolar range and a linear range over at least three orders of 
magnitude in five out of seven cases, including the non-proteinogenic GABA. As report-
ed previously by our group [17] and others [37], amino acids are difficult to analyze by 
silylation and more suitable derivatization strategies have been recommended [37,38]. 
Using GC-APCI II-HRTOFMS, RSDs were below 5% for all amino acids except Ala-
2TMS (8.6%), but in general lower than previously reported data obtained by GC-MS 
with EI and CI sources [17]. This constitutes a major improvement especially if one 
takes into account that derivatization was performed manually in the present study. 
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Table 8.2 Figures of merit for quantitative profiling of 20 metabolites after MeOx-TMS derivatization and GC-HRTOFMS analysis with the APCI I or APCI II source. 
RSDs of response values were determined for a concentration level of 31.25 µM (N = 5 derivatization replicates). APCI II outperformed APCI I in terms of lower 
LLOQs, broader linear ranges, and better repeatability. (TMS derivatization status and isomer elution number are given for metabolites yielding multiple peaks after 
derivatization). Reprinted from [13]. 
Compound GC-APCI II-
HRTOFMS 
ret.time 
(min)
m/z  
[M+H]
+
ion
Corresponding IS 
GC-APCI I-HRTOFMS GC-APCI II-HRTOFMS
  LR (µM) Order of 
Magnitude
RSD
 
(%) LR (µM) Order of Magnitude RSD
 
(%) 
        
Lactate 10.88 235.12 [U-
13
C]lactate 0.12 - 500 3.6 1.7 0.12-187.5 3.2 9.3
Ala-2TMS 11.56 234.13 Nval-2TMS 0.98 - 375 2.6 15.9 0.18-250a 3.1b 8.6
2-Hydroxybutyrate 12.02 249.13 [U-13C]3-hydroxybutyrate 0.24- 93.75 2.6 4.9 0.12-375 3.5b 4.5
3-Hydroxybutyrate 12.55 249.13 [U-13C]3-hydroxybutyrate 0.12 - 500 3.6 4.3 0.12-250 3.3 2.9
4-Me-2-oxovalerate 13.46 232.14 [U-13C]3-hydroxybutyrate 7.81 - 500 1.8 2.0 3.91-500 2.1 3.7
Val-2TMS 13.53 262.17 Nval-2TMS 0.37 - 125 2.5 13.5 0.73-93.75 2.1 1.2
Leu-2TMS 14.44 276.18 Nval-2TMS 0.73 - 125 2.2 15.9 0.73-187.5a 2.4b 2.3
Ile-2TMS 14.81 276.18 Nval-2TMS 1.95 - 125 1.8 15.6 0.12-187.5a 3.2b 2.0
Pro-2TMS 14.89 260.15 Nval-2TMS 3.91 - 375 2.0 3.0 0.49-500a 3.0b 1.7
Gly-3TMS 15.04 292.16 [U-2H4]succinate 0.12 - 62.5 2.7 9.0 
≤ 0.002-
46.88a 4.4
b 2.5 
Succinate 15.05 263.11 [U-
2
H4]succinate 0.18 - 46.88 2.4 6.3 0.09-46.88
a 2.7 1.6
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Table 8.2 continued. 
Compound GC-APCI II-
HRTOFMS 
ret.time 
(min)
m/z  
[M+H]
+
ion
Corresponding IS 
GC-APCI I-HRTOFMS GC-APCI II-HRTOFMS
  LR (µM) Order of 
Magnitude
RSD
 
(%) LR (µM) Order of Magnitude RSD
 
(%) 
        
Glycerate 15.41 323.15 [U-
13
C]fumarate 0.06 - 46.88 2.9 14.7 0.12-46.88 2.6 1.5
Fumarate 15.55 261.10 [U-
13
C]fumarate 0.12 - 93.75 2.9 2.4 0.37-187.5 2.7 0.8
Adipate 17.97 291.14 [U-
2
H4]succinate 2.93 - 187.5 1.8 10.4 0.37-46.88 2.1 2.2
GABA-3TMS 18.43 320.19 [U-13C]fumarate 0.37 - 46.88 2.1 2.5 
≤ 0.002-
15.63a 3.9
b 2.8c 
cis-Aconitate 21.35 391.14 [
2
H7]trans-cinnamate 0.49 - 62.5 2.1 6.5 0.09-62.5 2.8 4.4
Homogentisate 22.52 385.17 [U-
13
C]glucose-1 5.86 - 250 1.6 4.6 0.73-31.25 1.6 2.3
Hydroxyphenylpyruvate 23.36 354.16 [U-13C]glucose-1 0.73 - 500 2.8 11.6 0.24-375a 3.2b 6.8 
5-HIAA-2TMS 26.79 336.15 [4,6,7-
2
H3]5-HI-[
2
H2]AA 1.46 - 500 2.5 3.0 0.49-46.88 2.0 1.1
Lactose-1 31.86 948.47 [U-
13
C]lactose-1 1.46 - 93.75 1.8 2.5 0.045-375 3.9 5.0
Arithmetic mean    1.50-230d,e 2.4f 7.5g 0.45-191d,e 2.9f 3.4g
a LLOQ lower than previously for GC×GC-EI-TOFMS [17]. b Broader linear range than previously for GC×GC-EI-TOFMS [17]. c Standard concen-
tration above ULOQ. d p (Wilcoxon, LLOQ) = 0.002. e p (Wilcoxon, ULOQ) = 0.365. f p (t test) = 0.014. g p (Wilcoxon) = 0.005. 
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The excellent overall quantitative performance of the APCI II source and, in particular, 
the improvements observed for analytes without a corresponding IS are striking even in 
comparison to GC×GC-EI-TOFMS, which had performed the best in a previous study 
[17]. GC-APCI II-HRTOFMS yielded lower LLOQs and broader linear ranges than 
GC×GC-EI-TOFMS [17] for eight of the investigated metabolites. The respective me-
tabolites are marked with superscript a indicating a lower LLOQ and b indicating a 
broader linear range (Table 8.2). Overall, the median LLOQ was comparable to that of 
GC×GC-EI-TOFMS (0.15 versus 0.12 µM). The average linear range was slightly less 
wide for GC-APCI II-HRTOFMS (2.9 versus 3.2 orders of magnitude) because of detec-
tor saturation for higher calibration points.  
8.3.3 Analysis of cell culture supernatants 
To assess the performance of GC-APCI II-HRTOFMS in the analysis of complex biolog-
ical matrices, we measured MeOx-TMS derivatized cell culture supernatants from three 
replicate MiaPaCa-2 pancreatic cancer cell cultures. In total, 275 peaks (dissect com-
pounds) were extracted over a chromatographic window of 9-37 min from the APCI II 
data using an S/N threshold of 20. In comparison, only 127 peaks were extracted from 
the APCI I data applying the same “Find Compounds – Dissect” peak finder parameters. 
The difference in extracted peaks is illustrated in Figure 8.4 showing the dissect com-
pounds from the same supernatant sample for both APCI sources. Particularly impres-
sive is the approximately 8-fold gain in extracted peaks for compounds eluting after 25 
minutes. The increased number of extracted peaks with the APCI II source is mainly 
attributed to the improved detection sensitivity but also to the improved, less ragged 
peak shapes that facilitate peak detection by the peak finding algorithm. This is again 
discussed at the end of this section. Furthermore, late eluting peaks are narrower, 
which enhances peak detection. In addition, the improved heating of the source reduces 
potential adsorption of late eluting high boiling analytes, which may also contribute to 
the higher number of detected late eluting analytes. 
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Figure 8.4 Features extracted from GC-APCI I-HRTOFMS (a) and GC-APCI II-HRTOFMS (b) base peak 
chromatograms of a representative supernatant sample of MiaPaCa-2 pancreatic cancer cells. The “Find 
Compounds – Dissect” peak finder was applied with an internal S/N threshold of ≥20 over the chromato-
graphic range of 9-37 min. On average 127 and 275 features were extracted from the APCI I and APCI II 
data, respectively. The gain in extracted signals was the greatest for analytes eluting after 25 minutes; it 
was approximately eightfold higher for the APCI II than the APCI I source. Reprinted from [13]. 
Eliminating signals also present in blank samples and multiple signals found within a 
retention time and mass window of 0.1 min and 10 mDa, a revised total of 96 and 251 
dissect compounds was obtained from the APCI I and APCI II data, respectively. It 
should be noted that these numbers do not equal individual metabolites. Certain metab-
olites yield multiple GC peaks such as partly silylated amino acids or cis-trans isomers 
of methoxime derivatives of carbonyl compounds (see Table 8.3).  
a 
b 
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For compound identification different strategies were pursued. Accurate masses were 
initially searched in the GC-APCI-HRMS online database established by Pacchiarotta et 
al. [74]. This database also contains retention indices based on n-alkanes used as ref-
erence. Further, GC×GC-EI-TOFMS data of the supernatant samples were used to 
support compound identification. Based on the mass of the [M+H]+ ions of tentatively 
annotated metabolites, m/z values corresponding to the respective EI molecular ions 
and potential [M-CH3]+ fragment ions were calculated, searched in the GC×GC-EI-
TOFMS data and then subjected to a NIST 05 library search. The [M-CH3]+ fragment ion 
was used, because silylated metabolites often form this fragment with EI ionization, 
while the molecular ion is low abundant or not detectable. To make use of the retention 
indices stored in the GC-APCI-HRMS online database, n-alkanes (C8-C20 and C21-
C40) were run within the same batch as the supernatant samples on the GC×GC-EI-
TOFMS, retention indices were calculated and then compared to those stored in the 
GC-APCI-HRMS online database. Based on the fatty acids, [2H7]trans-cinnamate and 
22 metabolites (marked in Table 8.3), a prediction model for GC-APCI-HRTOFMS re-
tention times based on GC×GC-EI-TOFMS data and vice versa was established. The 
22 selected metabolites were unambiguously identified by means of their accurate 
mass, retention index and NIST 05 match >800. The aim was to comprehensively ex-
ploit GC-APCI-HRTOFMS and GC×GC-EI-TOFMS data for compound identification, 
which is beneficial for metabolite annotation as previously reported by other groups 
[78,79]. Linear correlation of GC-APCI-HRTOFMS and GC×GC-EI-TOFMS retention 
times of the seven standards (fatty acids and [2H7]trans-cinnamate) and 22 metabolites 
was obtained (R²=0.999) and GC-APCI-HRTOFMS retention indices based on n-
alkanes could be deduced from the corresponding fatty acids-based indices.  
Twenty-two compounds that are not included in the online database could be assigned 
by mass spectral matching (NIST 05 match >700 in all cases) and/or by matching of 
accurate masses and retention indices with an in-house GC-APCI-HRTOFMS metabo-
lite database. In total, 63 dissect compounds were annotated corresponding to 49 indi-
vidual metabolites and phosphate (see Table 8.3).  
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Table 8.3 Figures of merit for identified features in cell culture supernatants of MiaPaCa-2 cells. Features were extracted with an internal S/N threshold of ≥20. A 
total of 63 features could be assigned to 49 individual metabolites and phosphate representing approximately 46% and 24%, respectively, of all signals detected in 
GC-APCI I and II-HRTOFMS measurements. Twelve signals annotated with asterisks were identified solely by GC-APCI II-HRTOFMS in at least two out of three 
biological replicates. RI values based on fatty acids <900 were obtained through extrapolation. MeOx, group introduced by methoximation; std, analysis of an au-
thentic reference standard; TMS, trimethylsilyl group; db, GC-APCI-HRMS metabolite database by Pacchiarotta et al. [74]. Reprinted from [13].  
No.a  Dissect compound Elemental formula [M+H]+
Ret.time 
(min) 
Ref. 
RIb,c 
RId 
(%) 
m/z expt 
(Da) 
me 
(mDa)
Identification 
basis 
1 Pyruvate+1MeOx+1TMS+H C7H16NO3Si+ 10.73 458b -0.9 190.0920 -2.6 NIST; std 
2a Lactate+2TMS+H C9H23O3Si2+ 10.82 475b 1.2 235.1179 0.2 db; NIST; std 
3 Valine+1TMS+H C8H20NO2Si+ 11.39 514b -0.4 190.1304 -4.6 std 
4a Alanine+2TMS+H C9H24NO2Si2+ 11.58 536b 1.0 234.1354 -1.3 db; NIST; std 
5 Leucine+1TMS+H C9H22NO2Si+ 12.49 1160c -0.5 204.1416 -0.1 db; std 
6 3-Hydroxybutyrate+2TMS+H C10H25O3Si2+ 12.57 617b 0.7 249.1313 2.4 NIST; std 
7 Proline+1TMS+H C8H18NO2Si+ 12.85 1180c -0.6 188.1124 -2.2 db; stdg 
8 Isoleucine+1TMS+H C9H22NO2Si+ 12.88 1182c -0.5 204.1389 2.6 db; std 
9 3-Methyl-2-oxovalerate+1MeOx+1TMS+H C10H22NO3Si+ 12.92 644b 0.5 232.1360 0.3 NIST; std 
10 4-Methyl-2-oxovalerate+1MeOx+1TMS+H C10H22NO3Si+ 13.47 690b 0.6 232.1354 0.9 NIST; std 
11 Valine+2TMS+H C11H28NO2Si2+ 13.53 694b 0.4 262.1685 -3.2 NIST; std 
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Table 8.3 continued. 
No.a  Dissect compound Elemental formula [M+H]+
Ret.time 
(min) 
Ref. 
RIb,c 
RId 
(%) 
m/z expt 
(Da) 
me 
(mDa)
Identification 
basis 
12a Urea+2TMS+H C7H21N2OSi2+ 13.78 1246c 0.3 205.1143 4.4 db; NIST 
13a Benzoate+1TMS+H C10H15O2Si+ 14.05 1254c -1.0 195.0851 -1.5 db; NIST 
14 Serine+2TMS+H C9H24NO3Si2+ 14.19 744b -0.2 250.1292 -0.2 NIST; std 
15a Leucine+2TMS+H C12H30NO2Si2+ 14.43 768b 0.5 276.1782 2.7 db; NIST; std 
16 Glycerol+3TMS+H C12H33O3Si3+ 14.47 773b 0.7 309.1737 -0.5 NIST; std 
17a Phosphate+3TMS+H C9H28PO4Si3+ 14.50 1284c -0.1 315.1006 2.1 db; NIST 
18a Isoleucine+2TMS+H C12H30NO2Si2+ 14.79 797b 0.5 276.1786 2.4 db; NIST; stdg 
19 Threonine+2TMS+H C10H26NO3Si2+ 14.82 795b -0.2 264.1471 -2.5 NIST; stdf 
20 Proline+2TMS+H* C11H26NO2Si2+ 14.89 1308c -0.1 260.1492 0.4 db; NIST; stdg 
21a Glycine+3TMS+H C11H30NO2Si3+ 15.04 815b 0.1 292.1571 0.8 db; NIST; std 
22 Glycerate+3TMS+H C12H31O4Si3+ 15.39 847b 0.5 323.1495 2.9 NIST; std 
23 Fumarate+2TMS+H* C10H21O4Si2+ 15.53 858b 0.4 261.0955 1.8 db; NIST; stdg 
24 Serine+3TMS+H C12H32NO3Si3+ 15.86 910b 0.2 322.1653 3.2 NIST; std 
25 Threonine+3TMS+H C13H34NO3Si3+ 16.30 940b 0.2 336.1826 1.5 NIST; std 
26a Thymine+2TMS+H* C11H23N2O2Si2+ 16.50 1412c 0.0 271.1268 2.5 db; NIST; stdg 
27 Methionine+1TMS+H C8H20NO2SSi+ 16.60 1416c -0.2 222.0955 2.4 db 
28 Aspartate+2TMS+H C10H24NO4Si2+ 16.77 1430c -0.1 278.1209 2.9 db; std 
29 Nicotinamide+1TMS+H C9H15N2OSi+ 17.63 1029b -0.3 195.0905 4.3 NIST; std 
30 Malate+3TMS+H C13H31O5Si3+ 17.79 1044b 0.2 351.1433 4.0 NIST; std 
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Table 8.3 continued. 
No.a  Dissect compound Elemental formula [M+H]+
Ret.time 
(min) 
Ref. 
RIb,c 
RId 
(%) 
m/z expt 
(Da) 
me 
(mDa)
Identification 
basis 
31 Adipate+2TMS+H C12H27O4Si2+ 17.95 1054b 0.1 291.1415 2.7 stdf 
32 Glutamate+2TMS+H* C11H26NO4Si2+ 18.12 1536c 1.0 292.1371 2.4 dbg 
33 Erythritol+4TMS+H C16H43O4Si4+ 18.15 1070b 0.3 411.2219 1.4 NIST; std 
34a Methionine+2TMS+H C11H28NO2SSi2+ 18.26 1532c 0.0 294.1352 2.2 db; NIST 
35 Phenylalanine+1TMS+H C12H20NO2Si+ 18.66 1556c -0.3 238.1270 -1.2 db; std 
36 -ketoglutarate+1MeOx+2TMS+H C12H26NO5Si2+ 19.01 1132b 0.3 320.1316 2.8 NIST; stdg 
37 Phenylpyruvate+1MeOx+1TMS+H* C13H20NO3Si+ 19.22 1145b 0.0 266.1178 2.9 NIST; stdg 
38a Phenylalanine+2TMS+H C15H28NO2Si2+ 19.81 1644c 0.0 310.1660 -0.7 db; NIST; std 
39 Laurate+1TMS+H C15H33O2Si+ 19.97 1201b -0.1 273.2230 1.4 NIST; std 
40a Ribose+1MeOx+4TMS+H C18H46NO5Si4+ 20.60 1700c -0.2 468.2409 3.9 db; NIST 
41a Xylitol+5TMS+H C20H53O5Si5+ 21.18 1734c -0.8 513.2738 -0.4 db; NIST 
42 Ornithine+3TMS+H C14H37N2O2Si3+ 21.46 1767c -0.2 349.2116 4.2 db; std 
43 Glycerol-1-phosphate+4TMS+H C15H42PO6Si4+ 21.64 1333b 0.2 461.1748 4.3 std 
44a Ornithine+4TMS+H C17H45N2O2Si4+ 22.32 1387b 0.0 421.2545 0.8 db; NIST; std 
45 Myristate+1TMS+H* C17H37O2Si+ 22.49 1838c -0.8 301.2545 1.2 db; NISTg 
46a Hippurate+1TMS+H C12H18NO3Si+ 22.51 1414b -0.9 252.1014 3.6 db; NIST; stdg 
47 Lysine+3TMS+H C15H39N2O2Si3+ 22.70 1418b 0.0 363.2304 1.0 db; std 
48a Tyrosine+2TMS+H C15H28NO3Si2+ 23.11 1907c 0.2 326.1592 1.1 db; NIST; std 
49 Fructose+1MeOx+5TMS+H C22H56NO6Si5+ 23.27 1457b -0.5 570.2966 -1.8 NIST; std 
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Table 8.3 continued. 
No.a  Dissect compound Elemental formula [M+H]+
Ret.time 
(min) 
Ref. 
RIb,c 
RId 
(%) 
m/z expt 
(Da) 
me 
(mDa)
Identification 
basis 
50 Lysine+4TMS+H C18H47N2O2Si4+ 23.60 1490b -0.1 435.2673 3.6 db; NIST; stdg 
51a Tyrosine+3TMS+H C18H36NO3Si3+ 23.82 1509b -0.1 398.1949 4.8 db; NIST; stdg 
52 Sorbitol+6TMS+H C24H63O6Si6+ 23.99 1974c -0.3 615.3266 -3.1 db; std 
53a Pantothenate+3TMS+H C18H42NO5Si3+ 24.44 2016c -0.2 436.2326 3.9 db; NIST; std 
54 Palmitoleate+1TMS+H* C19H39O2Si+ 24.61 2030c -0.3 327.2702 1.2 dbg 
55a Palmitate+1TMS+H C19H41O2Si+ 24.82 2049c -0.3 329.2845 2.6 db; NIST 
56 Hippurate+2TMS+H* C15H26NO3Si2+ 25.24 1628b -0.8 324.1402 4.4 stdg 
57a Myo-inositol+6TMS+H C24H61O6Si6+ 25.74 1681b -0.2 613.3059 2.0 db; NIST; std 
58 Linoleate+1TMS+H* C21H41O2Si+ 26.66 2218c -0.5 353.2838 3.2 dbg 
59 Oleate+1TMS+H* C21H43O2Si+ 26.71 2222c -0.5 355.2990 3.7 dbg 
60 Cis-Vaccenate+1TMS+H* C21H43O2Si+ 26.77 2229c -0.5 355.2989 3.8 dbg 
61a Tryptophan+2TMS+H* C17H29N2O2Si2+ 26.85 1808b 0.7 349.1753 1.0 db; NIST; stdg 
62a Stearate+1TMS+H C21H45O2Si+ 26.96 2246c -0.6 357.3154 2.9 db; NIST 
63 Tryptophan+3TMS+H C20H37N2O2Si3+ 26.99 2250c -0.5 421.2118 4.0 db; stdg 
a Compound used for GC-APCI II-HRTOFMS and GC×GC-EI-TOFMS retention time correlation; b RI calculation based on fatty acids; c RI 
calculation based on alkanes; d Difference between RI in a standard and sample based on either fatty acids or alkanes relative to the deter-
mined RI in the sample; e Difference between predicted and measured mass; f Compound only extracted from GC-APCI I-HRTOFMS data; g 
Compound only extracted from GC-APCI II-HRTOFMS data. 
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Metabolite annotation was confirmed by the correct elemental formula using the Smart-
Formula tool and, if available, by analysis of a reference standard. Using the minimum 
reporting standards proposed by Sumner et al. for metabolomics data [26], 48 level 1 
and 15 level 2 identifications were obtained. Experimental masses deviated less than 5 
mDa from their calculated m/z values. Relative differences in retention indices did not 
exceed the threshold of 1.0% proposed by Strehmel et al. [128], except for lactate due 
to its early elution as previously reported [79]. Nevertheless, lactate identification was 
confirmed by a standard. The applied identification strategy is specified in Table 8.3 for 
all annotated compounds including information on retention time and accurate mass. 
Assigned compounds represented 46% and 24% of the total number of compounds 
extracted from APCI I and APCI II data, respectively. Twelve dissect compounds anno-
tated with asterisks in Table 8.3 were only extracted from the APCI II data of at least 
two supernatant replicates due to the improved signal-to-noise ratio obtained with the 
redesigned source. This could be confirmed by lowering the S/N threshold to 2, which 
then enabled the extraction of these twelve signals also from the APCI I data. Three 
additional low abundant compounds, namely -ketoglutarate-MeOx-2TMS, hippurate-
1TMS, and tryptophan-3TMS were only extracted from the GC-APCI II-HRTOFMS data 
of a single supernatant replicate but not found in the APCI I data set. Further, threonine-
2TMS and adipate-2TMS were exclusively extracted from APCI I data and proline-
1TMS, isoleucine-2TMS, lysine-4TMS and tyrosine-3TMS from APCI II data, although 
their respective peaks were fairly abundant. Since co-eluting compounds were present, 
this was attributed to failure of deconvolution by the dissect algorithm in these cases.  
For determination of repeatability, the “Find Molecular Feature” algorithm was used to 
extract features from the chromatograms of the three biological replicates, which were 
then aligned in a single data matrix using the Profile Analysis Tool to compare RSD 
values of the area integrals obtained with the two APCI sources. Extraction and bucket-
ing of features was performed separately for APCI I and APCI II data. Area integrals of 
a total of 412 (APCI I) and 1462 (APCI II) features were obtained and normalized to 
[2H7]trans-cinnamate. Next, RSDs were calculated for all features in both data sets. 
Cumulative distributions of RSD values for data acquired with both sources are shown 
in Figure 8.5. RSD values were distinctly (p <0.05, Wilcoxon signed rank test) lower for 
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APCI II measurements, as indicated by the steeper gradient over the first part of the 
corresponding curve. The median RSDs decreased from 33% to 24% using APCI II.  
 
 
Figure 8.5 Cumulative distributions of area RSDs of extracted GC-APCI I and II-HRTOFMS features from 
cell culture supernatant of MiaPaCa-2 cells. A total of 412 (APCI I) and 1462 (APCI II) features were 
extracted over 9-37 min using the “Find Compounds – Molecular Features” algorithm and normalized to 
[2H7]trans-cinnamate. RSD values were distinctly (p <0.05, Wilcoxon signed rank test) lower in case of 
APCI II measurements. Reprinted from [13]. 
Overall, improved peak abundances and shapes, as well as better ionization repeatabil-
ity were attained by APCI II. This is exemplified in Figure 8.6, in which the extracted ion 
chromatograms of fumarate-2TMS and nicotinamide-1TMS from three injection repli-
cates of a supernatant sample using either the APCI I or the APCI II source are over-
laid.  
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Figure 8.6 Influence of APCI source type on peak abundance and repeatability illustrated by the example 
of two metabolites identified in the supernatant of MiaPaCa-2 cells. Three injection replicates were ana-
lyzed and m/z values of [M+H]+ of fumarate-2TMS and nicotinamide-1TMS were extracted. APCI II in 
comparison to APCI I resulted in more abundant peaks and yielded better repeatability of the ionization. 
Reprinted from [13]. 
 
8.4 Conclusions 
The redesigned APCI II ion source provides lower quantification limits, broader linear 
ranges, and improved repeatability due to less ragged peak profiles in comparison to its 
predecessor. This is particularly obvious for late-eluting compounds due to an optimized 
heat distribution in the ionization chamber, which minimizes adsorption of high-boiling 
analytes to cold spots. Applied to a complex biological matrix, the APCI II source in-
creased the number of identified metabolites by one third, making GC-APCI II-
HRTOFMS a true alternative to GC×GC-EI-TOFMS, especially given easier data analy-
sis and the feasibility of coupling GC via the APCI II source to ultra-high-performance 
FTICR MS.  
 
 
 124
 
 
 
 
9 Development of an enantioselective quantitative 
profiling method for the oncometabolite D-2-
hydroxyglutarate 
9.1 Introduction 
Analysis of 2-hydroxyglutarate (2-HG) enantiomers has gained in importance in recent 
years. Apart from metabolic diseases such as D- or L-2-hydroxyglutaric aciduria 
[149,150], the accumulation of D-2-HG in several types of cancers harboring neo-
morphic mutations in the isocitrate dehydrogenase 1 and 2 genes has become a hot 
topic in cancer biology [151]. IDH1 and IDH2 are enzymes that catalyze the decarboxy-
lation of isocitrate to form -ketoglutarate using NADP+ and producing NAPDH. IDH1 is 
a cytosolic and peroxisomal enzyme while IDH2 is found in the mitochondria. In different 
types of human cancers, somatic point mutations have been found that result in a loss 
of normal catalytic activity and concomitantly a gain of function, which is the formation of 
D-2-HG from -ketoglutarate. Mutations in IDH1 or IDH2 are found frequently in grade 2 
– 3 gliomas and secondary glioblastomas and in 5-20% of acute myeloid leukemia 
(AML) patients, as well as other tumor types [152]. Figure 9.1 gives an overview over 
normal functions of the IDH1 and IDH2 enzymes in the cytoplasm and mitochondrion, 
respectively, together with other related cellular metabolic processes (top picture) and 
depicts reactions catalyzed by wild type and mutant IDH1 and IDH2 enzymes (lower 
picture) in the interconversion of isocitrate, 2-oxoglutarate and (R)-2-HG, respectively.  
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Figure 9.1 Normal enzymatic functions of IDH 1 and IDH2 together with related cellular metabolic pro-
cesses in the cytoplasm and mitochondrion (top picture) as well as reactions catalyzed by wild type and 
mutant IDH1 and IDH2 enzymes (lower picture) in the interconversion of isocitrate, 2-oxoglutarate and 
(R)-2-HG, respectively. Reprinted from [153]. 
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Several analytical methods have been used to study the role of D-2-HG in the formation 
and malignant progression of cancers, such as an enzymatic assay [154], NMR spec-
troscopy [155] as well as LC [156] or GC [155,157,158] coupled to MS. GC-MS has 
been most widely applied owing to its high robustness and ability to achieve low quanti-
fication limits. However, existing weaknesses among current procedures include unin-
tended [158,159] or poor [157] chromatographic separation of D and L enantiomers of 
2-HG, thus limiting the analysis to total 2-HG levels. Furthermore, indirect methods 
separating diastereomeric 2-HG derivatives on a non-chiral column have been reported 
[149], but inadvertent racemization and side reactions caused by contaminants in the 
derivatizing reagent may lead to erroneous quantitative results. On the other hand, 
direct enantioselective analysis of D/L-2-HG has been successfully applied [160]; how-
ever, applied derivatization strategy was neither simple nor fast and, according to the 
authors, had to be performed very carefully, which would render its automation difficult. 
Irrespectively of whether D/L-2-HG enantiomers were chromatographically resolved, 
quantitative data based on MS measurements is provided to a very limited extent [159], 
completely lacking [155], or a corresponding SIL-IS of 2-HG was not included for quanti-
fication [155,158], which may severely compromise reproducibility and accuracy. On top 
of that, determination of peak areas or concentration levels using GC-MS has been 
performed with electron ionization (EI) [157-160], which results in extensive fragmenta-
tion of molecular ions in general. Consequently, a fragment of lower mass has to be 
selected as quantification trace for the target analyte, which might be less specific and 
common to co-eluting compounds across various matrices hampering accurate quantifi-
cation or restricting general applicability of the method.  
Derivatization of 2-HG with methylchloroformate/methanol (MCF/MeOH) is simple and 
fast and lends itself to further automation as established for propyl chloroformate-
derivatized amino acids [38]. Further, in a previous study of our group, MCF/MeOH 
derivatization and separation on a chiral CD-based Rt-DEXsa capillary column yielded 
excellent resolution of amino acid enantiomers [39]. Soft ionization techniques, such as 
CI and APCI, meanwhile have a proven track record in metabolomics as an alternative 
to conventional GC-EI-MS due to higher selectivity and abundance of [M+H]+ ions over 
fragment ions [9,17,86,136].  
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In this chapter, the development of an enantioselective approach for the quantitative 
determination of D/L-2-HG using GC-APCI II coupled to a TOF-MS is presented based 
on the separation of MCF-derivatized D- and L-2-HG enantiomers on a chiral Rt-
DEXsa column. D/L-[2,3,3-2H3]2-HG was included as internal standard for accurate 
and robust quantification. The general applicability of the method was shown in different 
matrices including human serum, urine, cell extracts and cell culture supernatants.  
Sample preparation was done together with Claudia Samol and Nadine Nürnberger. 
Wolfram Gronwald and Magdalena Waldhier carried out NMR analysis and initial GC-
EI-qMS measurements, respectively. Katja Dettmer set up the quantitative HPLC-ESI-
MS/MS method for the determination of 2-HG in urine specimens.  
The results of this chapter will be part of a manuscript in preparation. 
 
9.2 Methods 
9.2.1 Sample preparation 
An aqueous stock solution of racemic D/L-2-HG at a concentration of 1 mM was pre-
pared and geometrically diluted over 17 points (0.02-1000 µM) for calibration purposes. 
Deuterium-labeled racemic D/L-2-HG was used as internal standard and an aqueous 
working solution with a concentration of 100 µM was prepared. For preparation of 
standard samples, 150 µL of stock solution or a dilution of racemic D/L-2-HG, according 
to the desired final standard concentration, were transferred with 10 µL of internal 
standard to a 2-mL glass vial for derivatization. Addition of standard and IS to superna-
tant or serum specimens was carried out prior to the precipitation step unless otherwise 
stated under Results and Discussion. To check for racemization, separate aqueous 
stock solutions of individual D and L enantiomers of 2-HG were prepared and 30 µL of a 
1 mM dilution of them were derivatized without IS.  
The entire set of biological samples analyzed in this project including serum, urine, and 
cell culture samples was provided by collaborators at the University Hospital of Re-
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gensburg. More details are provided under Results and Discussion. The samples were 
stored at -80°C until preparation. For extraction of cell pellets, 10 µL of IS (100 µM) 
were added to the pellet followed by 600 µL cold 80% MeOH (80/20 MeOH/H2O, v/v). 
The sample was vortexed and centrifuged at 4°C and 9500 × g for 5 min. The superna-
tant was collected and the pellet was washed with 200 µL cold 80% MeOH, centrifuged 
at 4°C and 9500 × g for 5 min and finally washed with 200 µL H2O and centrifuged at 
4°C and 11200 × g for 5 min. The supernatants were combined and evaporated to dry-
ness using a vacuum evaporator. For preparation of serum and cell culture superna-
tants, 150 µL of sample were spiked with 10 µL of internal standard and 600 µL of cold 
MeOH was added for protein precipitation. Then, the procedure described above for cell 
pellets was followed with the exception that the second wash of the protein pellet was 
also performed with 80% MeOH. Finally, derivatization of serum specimens with 
MCF/MeOH was performed directly in the aqueous phase using 150 µL of serum and 
10 µL of IS without prior protein precipitation. The latter protocol was also applied to 
urine samples. Manual derivatization with MCF/MeOH was carried out as described 
under 5.2.3.  
9.2.2 Analytical approaches 
GC-APCI-TOFMS 
As denoted in Results and Discussion, calibration was repeated several times in the 
course of method development using varying instrumental or operational settings. In 
fact, an APCI I source with water infusion was used, an injection volume of 2 µL was 
used, or no water was infused instead of the conventional settings described in sub-
chapter 5.3. 
D/L-2-HG calibration curves based on either one of the two derivatives for each enanti-
omer were obtained as described in more detail under 5.4.2. Method #1 in Table 9.1 
was employed in the spike-in experiment, whereas method #4 (Table 9.1) was used for 
quantification of urine and serum samples in section 9.3.4.  
 
 
 129
 
 
 
HPLC-ESI-MS/MS 
High-performance liquid chromatography – electrospray ionization – tandem mass 
spectrometry (HPLC-ESI-MS/MS) in negative ionization mode was employed as refer-
ence method for the determination of total levels of (D+L)-2-HG. The optimized method 
was capable of distinguishing 2-HG from 5-oxotetrahydro-2-furancarboxylate and also 
allowed quantification of the latter. A mixture containing 2-HG and 5-oxotetrahydro-2-
furancarboxylate at a concentration of 2 mM in water was serially diluted covering 16 
points over 0.06-2000 µM. For calibration, 90 µL of standard were transferred into a 
glass vial with a glass insert along with 10 µL of internal standard. The latter was ob-
tained from 500 µL of the original aqueous stock solution of deuterium-labeled D/L-2-
HG that was incubated with 200 µL of formic acid at 100°C for 30 min, evaporated to 
complete dryness, re-suspended in 500 µL of water, and diluted to a final concentration 
of 100 µM. To determine 2-HG levels in urine and serum, 10 µL of urine were added to 
10 µL of internal standard and 80 µL of water, and 50 µL of serum were precipitated 
with 250 µL of 100% MeOH and washed twice with 100 µL of 80% MeOH as described 
above. Dried extracts were reconstituted in 50 µL of water. 
Using an Agilent 1200 SL HPLC system (Böblingen, Germany), separation of analytes 
was achieved on a Supelco Discovery HS F5 (150 × 2.1 mm i.d., 3 µm) PFPP column. 
Elution with mobile phases A (0.1% formic acid in water, v/v) and B (acetonitrile) was 
performed as follows: 0-6.5 min, held at 100% A at a flow rate of 0.2 mL/min; 6.5-8 min, 
0-100% B at 0.35 mL/min; 8-10 min, held at 100% B at 0.35 mL/min; 10-10.1 min, 0-
100% A at 0.35 mL/min; 10.1-17 min, held at 100% A at 0.35 mL/min; 17-18 min, held 
at 100% A at 0.2 mL/min. The injection volume was 5 µL, and the column temperature 
was 30°C. MS/MS analysis was performed in MRM mode on a 4000 QTRAP from AB 
Sciex using one selective transition each for the unlabeled and labeled analytes as 
follows: m/z 147.1 (M-H)- to m/z 84.8 (product ion) for 2-HG, m/z 150.1 (M-H)- to m/z 
87.8 (product ion) for D3-labeled 2-HG, m/z 128.8 (M-H)- to m/z 100.8 (product ion) for 
5-Oxotetrahydro-2-furancarboxylate, and m/z 131.8 (M-H)- to m/z 88.0 (product ion) for 
D3-labeled 5-Oxotetrahydro-2-furancarboxylate. To obtain the calibration curves from 
the calibrator samples, nominal concentration ratio (analyte/internal standard) was plot-
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ted against peak area ratio (analyte/internal standard), whereby the corresponding 
labeled analogue was used for normalization for each target analyte as internal stand-
ard. Acquisition and analysis of data was carried out in Analyst version 1.5.1 from AB 
Sciex. 
Creatinine values were determined as previously described [161].  
 
NMR spectroscopy 
Serum specimens as well as aqueous and MCF derivatized standards of 2-HG and 5-
oxotetrahydro-2-furancarboxylate (1 mM each) were analyzed. Five hundred µL of se-
rum were filtered using Nanosep centrifugal devices (Pall Corporation, Port Washington, 
NY) with a 3K molecular weight cutoff. Four hundred µL of filtrate, aqueous standard, or 
derivatized standard that had been carefully evaporated and reconstituted in water, 
were transferred into an NMR tube, followed by the addition of 200 µL of potassium 
phosphate buffer, pH 7.4, and 50 µL of 29.02 mM TSP in D2O as internal standard. 
Following established protocols [162], 1D 1H and 2D 1H-13C TOCSY spectra were ac-
quired on a 600MHz Bruker Avance III (Bruker BioSpin GmbH, Rheinstetten, Germany) 
employing a triple resonance (1H, 13C 31P, 2H lock) cryogenic probe equipped with z-
gradients and an automatic cooled sample changer. Amix viewer V3.9.13 (Bruker Bio-
Spin) was used for manual inspection of spectra. Signals were assigned based on the 
predicted 1H chemical shifts by ChemDraw and assuming similar 1H intensities for me-
thyl groups of each of the three derivatives, whereas the identity of the methylchlo-
roformate signal was confirmed by comparison to a blank sample.  
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9.3 Results and discussion 
9.3.1 Selection of a specific quantifier ion trace from APCI-TOFMS 
versus EI-qMS mass spectra 
2-HG is a polar molecule that requires derivatization prior to GC analysis. Based on the 
experiences gained with the enantioselective GC analysis of amino acids in our labora-
tory, preliminary experiments were performed using derivatization with methyl chlo-
roformate/methanol (MCF/MeOH) and separation on an Rt-DEXsa column [39].  
GC-MS analysis yielded four different peaks for a derivatized 2-HG racemate, of which 
the late-eluting pair was more abundant and, hence, initially used for quantification. It 
corresponded to the D and L enantiomers of the methyl ester of 5-oxotetrahydro-2-
furancarboxylate formed as the condensation product from racemic D/L-2-HG. The 
example of a GC-APCI-TOFMS base peak chromatogram of a derivatized racemic 
standard of D/L-2-HG (100 µM each for the two enantiomers) is given in Figure 9.5, 
with structural formulas provided for the two pairs of derivatives (denoted as D/L-2-HG-
1MC-2E and D/L-2-HG-1E according to Figure 9.5). In the case of the more abundant 
methyl esters of D/L-5-oxotetrahydro-2-furancarboxylate, extensive fragmentation was 
observed in EI mass spectra, which were dominated by a fragment mass of m/z 85, 
while the relative intensity of the molecular ion with an m/z of 144 Da was <2% of the 
base peak in the absence of other ion species. However, m/z 85 as quantifier trace 
proved nonspecific for accurate D-2-HG quantification in the initial analysis of cell cul-
ture supernatants of DLD-1 colon cancer cells, as a highly abundant matrix compound 
present in cell culture media supplemented with bovine serum albumin yielded the same 
mass. Furthermore, such a low mass is probably common to several additional metabo-
lites.   
APCI as a soft ionization technique on the other hand preserved the [M+H]+ ion of the 
methyl esters of D/L-5-oxotetrahydro-2-furancarboxylate (m/z [M+H]+: 145.050 Da) by 
suppression of in-source fragmentation, while TOFMS analysis enabled the extraction 
of quantifier ions with a narrow width of ±10 mDa. With such an enhanced specificity, it 
 
 132
 
 
 
became clearly obvious that a matrix compound with a mass of m/z 220.086 was co-
eluting with D-2-HG in the initially analyzed cell culture supernatant sample, as shown in 
Figure 9.2B, which had not been obvious from the EI mass spectrum of the same peak 
(Figure 9.2A). Hence, further method development was solely carried out on the GC-
APCI-TOFMS instrument. Similar to these observations, such a benefit of soft ionization 
in terms of specificity has also been shown for the quantitative profiling of amino and 
nonamino organic acids by GC-MS employing CI coupled to MS/MS analysis [86] as 
well as in the case of pyrethroid insecticides by means of APCI-MS/MS [82].  
Despite the possibility to distinguish between D-2-HG-1E and the co-eluting matrix 
compound based on unique masses, the temperature ramp was modified to chromato-
graphically separate these two compounds to minimize possible matrix effects. As dis-
cussed in chapter 7, high amounts of co-eluting analytes or matrix compounds may 
suppress the signal of an analyte in APCI. Given that the signal of D-2-HG-1E that was 
spiked at a concentration of 50 µM into the supernatant sample was approximately as 
abundant as that of the co-eluting compound (Figure 9.2), comparably high amounts of 
the latter could be assumed to be present, possibly deteriorating lower quantification 
limits of the method in these samples due to suppression of the signal of D-2-HG-1E. 
Among the three different heating rates tested (4, 5, and 6°C/min), no co-elution oc-
curred solely in the case of 5°C/min for both 2-HG-1E enantiomers in the analysis of a 
randomly selected urine, serum, cell extract and supernatant samples. Hence, further 
experiments were carried out using 5°C/min as heating rate. As depicted in Figure 9.3, 
huge concentration differences of D- and L-2-HG could be initially detected in cell ex-
tracts and supernatants of dendritic cells from an IDH2 R140Q mutation transfected and 
untransfected cell line, as well as serum of an AML patient with an IDH2 R140Q muta-
tion versus healthy control. The L enantiomer was not detected. The IS of D/L-2-HG 
was poorly recovered (~30%) due to extraction losses for these biological samples. 
Hence, the corresponding peaks of D/L-[2,3,3-2H3]2-HG are small or not visible in Fig-
ure 9.3 due to the highly abundant endogenous metabolites and the resulting scaling of 
the chromatogram. It should be noted that the peaks for D/L-[2,3,3-2H3]2-HG still ex-
ceeded a S/N ratio of 10. 
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Figure 9.2 Ionization of D-2-HG-1E and a co-eluting matrix component by APCI versus EI. For illustra-
tion, a cell culture supernatant sample containing huge amounts of the co-eluting compound, from DLD-1 
colon cancer cells grown in DMEM medium supplemented with 10% fetal calf serum, was spiked with 
racemic D/L-2-HG (50 µM of each enantiomer), fortified with MeOH for protein precipitation, MCF-
derivatized and analyzed by GC-APCI-TOFMS and GC-EI-qMS. GC-EI-qMS method parameters were as 
previously described in [39] (method E) and adopted for GC-APCI-TOFMS. (B) Extracted ion chromato-
grams based on unique masses from the APCI-TOFMS mass spectrum revealed that D-2-HG-1E was co-
eluting with an unknown compound, whereas (A) the EI mass spectrum for the same chromatographic 
peak only yielded m/z 85 as base peak in the virtual absence of other characteristic ions. E, methyl ester 
group.  
Similar peak profiles in extracted ion chromatograms of D/L-2-HG-1E obtained from a 
standard and the latter biological samples demonstrate the formation of a selective 
mass trace for this compound by APCI (Figure 9.3). Furthermore, GC-APCI-TOFMS 
with MCF derivatization and separation on the chiral CD-based column provided high 
chromatographic resolution of the two enantiomers of 2-HG-1E, which were separated 
by more than 2.5 min. 
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Figure 9.3 Extracted ion chromatograms of D/L-2-HG-1E from a standard and biological samples. (A) 
Standard sample containing both unlabeled (total (D+L) concentration of 125 µM) and D3-labeled (minor 
peak, total (D+L) concentration of 6.7 µM) racemic D/L-2-HG. (B) Methanolic cell extracts of IDH2 R140Q 
mutation transfected and untransfected dendritic cells and (C) the corresponding cell culture supernatant 
samples. (D) Serum samples of an AML patient with an IDH2 R140Q mutation and a healthy control. 
Peak profiles of D-2-HG-1E (first peak) in the different biological matrices were very similar to the stand-
ard demonstrating the formation of a selective mass trace for this compound by APCI. This enabled the 
detection of huge concentration differences of D- and L-2-HG in cell culture and serum samples, respec-
tively. Experimental details and method parameters are described under 9.2.  
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9.3.2 Ionization behavior of D/L-2-HG in GC-APCI-TOFMS infusing 
water as modifier 
APCI requires traces of water vapor in the source for protonation of analytes [45]. As 
described in chapter 6, a tremendous effect of continuous water infusion on APCI of 
methyl chloroformate derivatives was observed, in particular for organic acids. Upon 
water infusion at 0.5 mL/h a more than 4-fold increase in abundance of the [M+H]+ ion 
of D/L-2-HG-1E was found, in comparison to no water infusion (APCI/-H2O), which 
proved optimum over the range of investigated infusion rates (0.1-0.6 mL/h in 0.1 mL/h 
increments, compare Figure 9.4). Water infusion exerted no effect on the ion species 
formed for that derivative as the [M+H]+ ion represented the base peak of the APCI 
spectrum and no fragments with a relative intensity >1% were observed. Interestingly, 
for the other pair of peaks in the chromatogram of a derivatized racemic standard of D/L 
2-HG corresponding to the D/L O-methoxycarbonyldimethyl ester of 2-HG (D/L-2-HG-
1MC-2E), a [M+H-CO2-CH3OH]+ fragment ion (m/z 159.065) dominated the APCI/-H2O 
mass spectrum of both enantiomers, while the corresponding [M+H]+ ion (m/z 235.081) 
was almost absent (relative intensity <1%). In contrast, the [M+H]+ ion represented the 
most abundant ion in the APCI/+H2O spectra. Nevertheless, its abundance was only 
one fourth of that of D/L-2-HG-1E, which was initially used for quantification of D/L-2-
HG. Figure 9.5 depicts the overlaid base peak chromatograms of a derivatized racemic 
D/L-2-HG standard acquired w/o water infusion, respectively, demonstrating that APCI 
ionization efficiency was distinctly promoted by water infusion (upper chromatogram in 
grey).  
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Figure 9.4 Impact of water infusion at different rates on APCI efficiency of D/L-2-HG-1E. Arithmetic 
means ±SD of [M+H]+ peak areas of D/L-2-HG-1E are given that were obtained by GC-APCI-TOFMS 
analysis of a 7.81 µM racemic D/L-2HG standard (N=3 derivatization replicates). Water was infused in 0.1 
mL/h increments over the range of 0.1-0.6 mL/h in consecutive runs and compared to no water infusion 
demonstrating that an infusion rate of 0.5 mL/h proved optimum yielding a more than 4-fold increase in 
peak areas. E, methyl ester group. 
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Figure 9.5 Impact of water infusion on APCI efficiency of an MCF-derivatized racemic D/L-2-HG stand-
ard. Water infusion distinctly increased peak abundances as demonstrated by the overlaid base peak 
chromatograms of the same standard acquired by GC-APCI-TOFMS without (chromatogram in black) 
and with (0.5 mL/h) water infusion (chromatogram in grey). The total (D+L)-2-HG concentration in the 
standard was 200 µM. MC, methoxycarbonyl group; E, methyl ester group.  
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9.3.3 Method validation 
Since D/L-2-HG-1E eluted as symmetric peaks with no interferences in the case of the 
biological samples, calibration was carried out over a concentration range of 0.02-1000 
µM. Table 9.1 presents figures of merit for the calibration curves.  
Table 9.1 Figures of merit for the quantitative profiling of D/L-2-HG by GC-APCI-TOFMS. Calibration was 
carried out over 0.02-1000 µM. Racemic D/L-[2,3,3-2H3]2-HG was added as internal standard prior to 
MCF derivatization. Several calibration curves were acquired in the course of method development that 
were based on either of the two derivatives and acquired with (0.5 mL/h) or without water infusion, with an 
APCI I or II source, and with different injection volumes. Water infusion and APCI II source yielded the 
lowest LLOQs for both enantiomers of 2-HG-1E, thus enabling quantification of 2-HG levels that are well 
below expected concentrations in physiological specimens, while higher LLOQs were obtained for D/L-2-
HG-1MC-2E in comparison to D/L-2-HG-1E. E, methyl ester group; MC, methoxycarbonyl group; IS, 
internal standard; LR, linear range; RSD, relative standard deviation.  
# Compound
1 D-2-HG-1E 0.5 APCI II 1 28.45 145.05±0.01 D3-D-2-HG-1E 0.9997 0.06-188 3.5 3.8
1 L-2-HG-1E 0.5 APCI II 1 31.20 145.05±0.01 D3-L-2-HG-1E 0.9988 0.06-188 3.5 2.2
2 D-2-HG-1E 0.0 APCI II 1 28.45 145.05±0.01 D3-D-2-HG-1E 0.9995 0.12-500 3.6 4.8
2 L-2-HG-1E 0.0 APCI II 1 31.20 145.05±0.01 D3-L-2-HG-1E 0.9972 0.49-500 3.0 6.8
3 D-2-HG-1E 0.5 APCI I 1 28.33 145.05±0.01 D3-D-2-HG-1E 0.9998 3.91-1000 2.4 10.9
3 L-2-HG-1E 0.5 APCI I 1 31.03 145.05±0.01 D3-L-2-HG-1E 0.9985 1.95-1000 2.7 2.5
4 D-2-HG-1MC-2E 0.5 APCI II 2 26.05 235.08±0.01 D3-D-2-HG-1MC-2E 0.9995 0.49-250 2.7 4.8
4 L-2-HG-1MC-2E 0.5 APCI II 2 26.36 235.08±0.01 D3-L-2-HG-1MC-2E 0.9986 0.24-250 3.0 9.5
† N=5, conc.=7.81 µM.
Water inf. 
(mL/h)
Inj. Vol. 
(µL) R²Source RT (min)
m/z Quantifier 
ion (Da) IS LR (µM)
Order of 
magnitude
RSD deriv. 
repl.† (%)
 
Three different calibrations were evaluated based on D/L-2-HG-1E (#1-#3 in Table 9.1). 
Calibration #1, which was performed while infusing 0.5 mL/h water infusion into the 
APCI II source, yielded the lowest LLOQ for the two enantiomers (0.06 µM), a broad 
linear concentration range over three and a half orders of magnitude, and good repeat-
ability with RSD of response of a calibration triplicate below 4%. The method benefitted 
from improvements in the APCI II source design over APCI I as well as the continuous 
infusion of water as modifier into the APCI II source, which is clearly obvious from the 
comparably poor performance of the methods that correspond to calibrations #2 and #3 
(Table 9.1). Such a low LLOQ for the quantitative determination of both enantiomers of 
2-HG in method #1 was well below expected concentration levels in human serum. In 
fact, Janin et al. [157] reported serum (D+L)-2-HG levels between 1-2 µM for controls 
and at least 10 times higher concentrations for patients with AML and an IDH mutation, 
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and suggested a diagnostic cutoff of 2 µM as a predictor of the presence of IDH muta-
tions and outcome in these patients.  
To further elaborate on the accuracy of method #1, a spike-in experiment in control 
serum was performed, using three different concentration levels of racemic D/L-2-HG (5 
µM, 50 µM, and 200 µM, N=3 derivatization replicates per spike-level). Concentrations 
in the derivatized samples were determined by means of the calibration curves, endog-
enous levels of D- and L-2-HG obtained from unspiked serum samples were subtracted, 
and recoveries then calculated. Figure 9.6 depicts arithmetic means ±SD of recovery in 
those experiments based on D/L-2HG-1E, which ranged well between 89-100% for the 
two enantiomers. 
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Figure 9.6 Arithmetic means ±SD of recovery of D/L-2HG in matrix spike-in experiments. Racemic D/L-2-
HG was spiked at three different levels (5 µM, 50 µM, and 200 µM, N=3 derivatization replicates per spike 
level) into human control serum, MCF derivatization was performed after precipitation of proteins with 
100% MeOH, and concentration levels were determined by means of the calibration curves based on 
D/L-2HG-1E (#1 in Table 9.1). Endogenous D/L-2-HG levels were obtained from three unspiked serum 
samples and subtracted from spiked ones for calculation of recovery. As a result, good recoveries be-
tween 89-100% were found for the two enantiomers. E, methyl ester group. 
Moreover, to check for racemization, individual standards of D and L enantiomers were 
analyzed (at a concentration of 200 µM, N=3 derivatization replicates each). Mean D- 
and L-2-HG-1E area ratios, i.e., the ratio of areas of D- or L-enantiomer divided by the 
sum of (D+L) enantiomers, were 0.6 and 1.8% in derivatized pure standards of L- and 
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D-2-HG, respectively. Hence, relevant falsely high concentrations of D- or L-2-HG due 
to racemization were only expected in the presence of very high concentrations of ap-
proximately 100 µM or higher of the other enantiomer.   
Although good accuracy of method #1 in matrix spike-in experiments could be demon-
strated, significant losses of 2-HG and its IS occurred during sample preparation as 
evidenced by the poor IS recovery of ~30% for serum specimens compared to stand-
ards, which entails higher LLOQ values in serum samples than in the standards. In 
addition to that, signal-to-noise of the analyte or IS may be compromised to a point 
where precision or accuracy becomes negatively affected in patient samples, which 
deteriorates a discriminant analysis between groups of them. To reveal the cause of 
analyte loss, samples containing solely IS or serum and IS were prepared in five differ-
ent ways and compared to each other in terms of IS recovery. Mean peak area ±SD of 
IS for the five different sets of samples (N=3 derivatization replicates) are presented in 
Figure 9.7, which were prepared as described below the bars. As a result, analyte loss 
could be clearly attributed to the precipitation step in the protocol, because ion suppres-
sion did not occur (fourth bar from left) and loss of IS due to evaporation was not ob-
served (second bar from left). As opposed to that, direct MCF derivatization of spiked 
serum without precipitation (fifth bar from left) yielded an almost full recovery of D3-D/L-
2-HG-1E. Hence, the latter protocol was applied for further analysis of serum, urine, and 
cell culture supernatants.  
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Figure 9.7 Arithmetic means ±SD of [M+H]+ peak areas of D3-D/L-2-HG-1E from MCF-derivatized IS and 
serum samples spiked with IS. Different sample preparation strategies were tested and compared with 
regard to increasing IS recovery in serum. Sample preparation was performed in order from left to right 
according to the labeling below the bars (N=3 derivatization replicates). Direct MCF derivatization and no 
precipitation of spiked serum yielded an almost full recovery of D3-D/L-2-HG-1E. SD, Deuterium-labeled 
standard was added (total (D+L) concentration of 6.7 µM); MCF, MCF derivatization; Dry, evaporation of 
solvent; Ser, 150 µL of control serum was added; PRC, precipitation with 100 % MeOH and two washing 
steps; E, methyl ester group.  
9.3.4 Lactonization of D/L-2-HG in derivatized standards and biologi-
cal samples 
As pointed out earlier, two peaks for each enantiomer of 2-HG were obtained in the 
analysis of an MCF-derivatized racemic D/L-2-HG standard (Figure 9.5). A constant 
area ratio of 4:1 was found for each enantiomer (peak #2/peak #1) in samples analyzed 
in the course of method validation. As the same was true for the IS, (peak #2/peak #2-
IS)-to-(peak #1/peak #1-IS) ratio of approximately 1 was obtained, e.g., 0.92±0.09 for 
the D enantiomer in 31 standards and spiked serum samples analyzed in the course of 
method validation. As further revealed by NMR, lactonization of 2-HG, which has been 
reported by others as well [149,160], occurred due to MCF derivatization. Figure 12.3 
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depicts overlaid 1H NMR spectra of 1mM MCF-derivatized standards of 2-HG and 5-
oxotetrahydro-2-furancarboxylate (B) showing that the latter yielded one signal of its 
corresponding methyl ester while 2-HG formed three different derivatives including the 
lactone species. Among these three derivatives, the two-fold derivatized 2-HG species 
did probably not elute from the GC column because of its free hydroxyl group. As op-
posed to that, aqueous standards of the same compounds were pure with no signal 
overlap of their methylene protons was observed in the corresponding 1H NMR spectra 
(Figure 12.3C).  
In contrast to the constant (peak #2/peak #2-IS)-to-(peak #1/peak #1-IS) ratio of about 1 
obtained so far, the analysis of serum of an AML patient with an IDH2 R140Q mutation 
(the same sample as in Figure 9.3D) resulted in a higher ratio of 1.2, while another 
sample of this type yielded an even higher ratio of 2.9. Therefore, it was hypothesized 
that lactone is present in these biological samples prior to derivatization, which could be 
proven by HPLC-ESI-MS/MS and NMR afterwards. Figure 12.4 shows a TIC chroma-
togram of a standard mixture of 2-HG and lactone (31.25 µM each) acquired by HPLC-
ESI-MS/MS on a Discovery HS F5 PFPP column. Both compounds were well separated 
and also present in the serum specimens. Accordingly, all signals in 2D 1H-13C TOCSY 
spectra of aqueous 2-HG and lactone standards overlapped with those from the serum 
samples (see Figure 12.3D). In addition to that, lactone was also found in urine speci-
mens that had not been subjected to derivatization. Consequently, quantification of 2-
HG by GC-APCI-TOFMS based on the lactone peak did no longer appear feasible and 
peak #1 corresponding to the three-fold derivatized open-chain 2-HG species was used 
instead.  
Peaks #1 of D and L enantiomers of 2-HG were well separated by 0.3 min and calibra-
tion was feasible. Figures of merit are given in Table 9.1 (method #4). Calibration and 
further quantification of 2-HG in biological samples was performed using 2 µL as injec-
tion volume since a 1.8-fold increase in peak area was obtained compared to previous 1 
µL, whereas peak area did not increase with a longer splitless time of 1.5 min. However, 
LLOQ values of 0.49 and 0.24 µL for D- and L-2-HG in standards were close to ex-
pected concentrations in human serum.  
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Figure 9.8 Bland-Altman plot to assess the agreement between GC-APCI-TOFMS and HPLC-ESI-
MS/MS in the quantification of total (D+L) urinary levels of 2-HG. A total of 23 urine samples from AML 
patients and 6 controls were analyzed by both methods. They were well in accordance with each other as 
indicated by an absolute and relative mean difference of -0.12 µM 2-HG/mM creatinine (represented by 
the centerline) and 6%, respectively. The outer lines correspond to mean ±1.96*SD of the differences. 
Nevertheless, cross-validation of the present GC-APCI-TOFMS approach with HPLC-
MS/MS using urine specimens from 23 wild-type IDH AML patients and 6 healthy con-
trols was possible, because normal urinary levels of 2-HG are higher than in serum. The 
two approaches yielded comparable (D+L)-2-HG levels as illustrated by the Bland-
Altman plot in Figure 9.8; in fact, absolute and relative mean difference of -0.12 µM/mM 
creatinine and 6%, respectively, were obtained over all samples. Only three out of the 
29 samples exhibited more than 30% deviation, but this was attributed to the particular 
sample or analysis rather than a general disagreement between the two methods. For 
23 samples less than 20% deviation was observed. Interestingly, an average enantio-
meric excess of 80% of the L enantiomer was found in these urine samples, which 
could solely be revealed by the GC-MS approach, but this was not significantly different 
between wild-type IDH AML patients and controls, as was the case for (D+L)-2-HG 
concentration levels normalized to creatinine. As opposed to that, large concentration 
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differences could be detected in qualitative and quantitative terms in cell extracts of 
IDH2 R140Q mutation transfected and untransfected dendritic cell lines and corre-
sponding cell culture supernatants, as well as serum specimens of a healthy control 
versus an AML patient carrying an IDH2 R140Q mutation (compare Figure 9.3). In the 
latter serum sample, (D+L)-2-HG concentration levels of 57 and 52 µM were determined 
by HPLC-MS/MS and GC-APCI-TOFMS, respectively, which were well in accordance 
with each other. However, the latter approach additionally revealed an enantiomeric 
excess of 98% of the D enantiomer. Such concentration and enantiomeric excess val-
ues for D/L-2HG are well comparable to other reports for the same type of sample 
[157,163].  
 
9.4 Conclusions 
A quantitative approach by GC-APCI-TOFMS was established for the enantioselective 
profiling of the oncometabolite D-2-HG and applied to various matrices including human 
serum, urine, cell extracts and cell culture supernatants. Both D and L enantiomers of 2-
HG were readily separable as their MCF derivatives on the employed chiral Rt-DEXsa 
column. Further, the method benefitted from highly specific quantifier ions due to soft 
ionization and high-resolution TOFMS. Moreover, the infusion of water as modifier im-
proved LLOQ and repeatability for both enantiomers, with the improved APCI II source 
yielding about 50-fold lower LLOQs than the original APCI I source. Omission of the 
protein precipitation step in the preparation of serum specimens increased recovery of 
the IS from 30% to almost 100%. 
The natural presence of the 5-membered lactone of 2-HG in biological samples repre-
sented an interesting finding, which might be of significance in the elucidation of the 
molecular mechanism, by which 2-HG potentially promotes tumor progression. Accord-
ing to this, quantification of 2-HG had to be based on its open-chain three-fold derivative 
resulting in LLOQ values of 0.49 and 0.24 µM for the D and L enantiomer, respectively, 
which are close to the expected serum concentrations. Hence, further optimization in 
terms of lower limits of quantification of the method may be required. The general ap-
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plicability of the method in distinguishing 2-HG concentration differences in serum of 
diseased and healthy individuals and the accurate quantification of urinary 2-HG levels 
could be shown, with GC-APCI-TOFMS concentration levels well in agreement with 
those determined by HPLC-MS/MS analysis. In addition to the latter approach, the 
developed GC-APCI-TOFMS method enabled the determination of the enantiomeric 
excess in the biological samples, which can be expected to be very helpful not only in 
the further elucidation of biological effects of 2-HG in tumors but also the utility of D-2-
HG as a diagnostic and/or prognostic tumor marker.  
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10 Conclusions and perspectives 
This thesis exemplifies the great potential of GC-APCI-TOFMS in metabolic fingerprint-
ing and profiling providing both the means for identification of unknown metabolites by 
accurate mass measurements and the sensitive determination of metabolites [9,10]. 
Significant gains in detection sensitivity could be realized for MCF derivatives by the 
continuous infusion of water into the APCI source. Further gains in reliability and accu-
racy were achieved by means of the recognition and minimization of matrix effects and 
a redesigned APCI source developed by Bruker Daltonics.  
The benefit of continuous water infusion during APCI of MCF-derivatized metabolites 
became particularly obvious in the comparative metabolic fingerprinting of control and 
17-DMAG treated cancer cell extracts. The doubling of identified, significantly regulated 
metabolites to a total of 23 was due to a significant increase in abundance of [M+H]+ 
ions as well as a concomitant decrease in technical variability. That the peak areas of 
significantly differentiating amino acids reflected true differences in concentration be-
tween the groups was corroborated through cross-validation by targeted HPLC-MS/MS 
analysis, yielding concordant results for 14 out of 15 amino acids that could be analyzed 
by both GC-APCI-TOFMS and HPLC-MS/MS. Further improvements in detection sensi-
tivity and repeatability for both MCF and MeOx-TMS could be realized employing a 
redesigned APCI source commercialized recently by Bruker Daltonics. Due to a tighter 
source construction, which reduces chemical background, and the minimization of gas 
turbulences, the absolute number of identified compounds increased by 33% compared 
to the original APCI source and was accompanied by a distinct decrease in RSD of area 
integrals of features extracted from the biological replicates.  
There remain areas for further improvement, such as the high level of manual interven-
tion still required in peak integration and metabolite identification, which might be facili-
tated by the introduction of comprehensive GC-APCI-MS libraries. Moreover, the lack of 
reference compounds impedes unambiguous assignment of unknowns. Recent years 
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have seen a flurry of novel computational approaches for identifying metabolites, but 
systematic evaluations of their performance are still lacking, making a definitive judg-
ment on their routine usefulness difficult. Overall, validated standard operating proce-
dures for the annotation of novel metabolites and open-access metabolite libraries have 
to be extended. The introduction of International Chemical Identifier (InChI) strings for 
consistent naming of identified metabolites as well as supporting global data exchange 
formats, e.g. the netCDF format, for sharing mass spectra and associated information 
constitute promising steps in this regard. Still, higher community efforts are necessary.  
GC-APCI-TOFMS proved to be a useful quantitative tool in metabolic profiling. The 
redesigned APCI II source, in comparison to APCI I, increased the linear range to al-
most three orders of magnitude mostly due to lower limits of quantification in the sub-
micromolar range. Hence, GC-APCI(II)-TOFMS appeared promising for the quantifica-
tion of potential biomarkers as exemplified here for the enantioselective profiling of the 
oncometabolite D-2-hydroxyglutarate, which accumulates in tumors harboring neo-
morphic mutations in IDH1 and IDH2 genes, respectively. The developed method relied 
on baseline separation of D and L enantiomers of 2-HG as their MCF derivatives on a 
chiral Rt-DEXsa column, highly specific quantifier ions due to soft ionization and high-
resolution TOFMS, and the infusion of water as modifier improved lower quantification 
limits and repeatability. During initial method development D-2HG was separated from a 
highly abundant matrix compound by modifying the temperature ramp to prevent matrix 
effects. In the further course of method development, quantification of D/L-2-HG based 
on the 5-membered lactone peak of D/L-2-HG proved unsuitable, because the lactone 
was naturally present in several of the investigated biological specimens. Quantitative 
analysis was thus based on the less abundant open-chain three-fold derivative of 2-HG 
that yielded LLOQ values of 0.49 and 0.24 µM for the D and L enantiomer, respectively, 
which are close to the expected serum concentrations. Hence, further optimization of 
the method may be needed, which might be achieved by increasing the yield of the 
three-fold derivative through modification of the derivatization protocol as well as max-
imizing ion transmission in the low mass range by specifically tuning the mass spec-
trometer. The method was successfully applied to various biological matrices including 
human serum and urine. The urinary 2-HG levels of 23 wild-type IDH AML patients and 
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6 healthy controls were well in accordance with those determined by HPLC-MS/MS. 
The natural presence of the 5-membered lactone of 2-HG in several tumor samples was 
of special interest as this finding might be helpful in elucidating the molecular mecha-
nism, by which D-2-HG potentially promotes tumor progression. Whether the D-lactone 
is biologically even more active than D-2-HG, is the focus of future investigations. 
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12 Appendix 
Table 12.1 Overview on recent GC(×GC)-APCI(+)-MS studies of environmental samples, foodstuffs, pharmaceutical impurities, pesticides, steroids and volatile 
organic compounds (Focus: 1=Ionization behavior, 2=Screening/ identification, 3=Quantification, 4=Cross-platform analysis, 5=Application).  
Authors/ Technique/ Field Samples Focus Highlights 
Ballesteroz-Gómez et al. 
(2013) [164] 
Direct probe/ GC/ GC×GC 
coupled to APCI-
HRTOFMS, LC-
ESI/APCI/APPI-
HRTOFMS  
Environmental 
Flame retardant 
standards/ elec-
tronic waste and 
car interior sam-
ples 
3, 5 Direct probe, GC, and GC×GC coupled to APCI-HRTOFMS were implement-
ed for targeted quantification of flame retardants in environmental samples 
and compared to common LC-HRTOFMS approaches. 
Targeted screening and quantification by GC-APCI-HRTOFMS exhibiting 
excellent detection capabilities revealed several previously unreported flame 
retardants in electronic waste and car interior samples.  
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Table 12.1 continued. 
Authors/ Technique/ Field Samples Focus Highlights 
Barrow et al. (2014) [165] 
GC-APCI-FTICRMS  
Environmental 
Water samples 
related to oil sands 
2, 5 GC-APCI-FTICRMS resolved nominal masses for a wide range of compounds 
in the analysis of oil sands process water. 
The resolution of isomers was seen as a huge added value given the rising 
demand for elaboration on component structure in environmental toxicity 
studies. 
Bristow et al. (2010) [7] 
GC-APCI-TOFMS, GC-
qMS with EI and CI 
sources 
Pharmaceutical 
Standards of or-
ganic compounds/ 
synthesized cy-
anoamide sample 
2, 4 High mass accuracy of GC-APCI-TOFMS (∆m: 1-2 mDa) allowed the identifi-
cation of impurities in organic reaction mixtures based on their elemental 
formulas.  
During optimization, compounds presenting a broad range of polarity could be 
detected, but RSDs were reported as fairly high.  
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Table 12.1 continued. 
Authors/ Technique/ Field Samples Focus Highlights 
Canellas et al. (2012) 
[166] 
GC-APCI-QTOFMS, GC-
EI-qMS  
Organic contaminants/ 
foodstuffs 
Acrylic adhesives/ 
standards of or-
ganic compounds/ 
Tenax® for migra-
tion studies 
2, 4 GC-APCI-QTOFMS appeared as complementary tool to GC-EI-qMS in the 
analysis of non-intentionally added substances in acrylic adhesives used in 
food packaging materials. 
The low degree of overlap between the two techniques was not further eluci-
dated; nevertheless, GC-APCI-QTOFMS revealed three new compounds of 
relevance. However, they did not diffuse into the packaged food and, hence, 
were considered as safe constituents of the packaging material.  
Canellas et al. (2014) 
[167] 
GC-APCI-QTOFMS, GC-
EI-qMS  
Organic contaminants/ 
foodstuffs 
Labels with adhe-
sive/ standards of 
organic com-
pounds/ Tenax® 
and natural pork 
intestine for migra-
tion studies 
2, 4 Unknown, toxic non-intentionally added substances from autoadhesive labels 
used for direct food contact were identified by GC-APCI-QTOFMS.  
Compared to GC-EI-qMS, calculation of elemental formulas, extensive data-
base search and acquisition of MS/MS mass spectra more than doubled the 
number of confirmed compounds, for which migration to the food simulants 
was shown in migration studies.  
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Table 12.1 continued. 
Authors/ Technique/ Field Samples Focus Highlights 
Cherta et al. (2013) [168] 
GC-APCI-QqQMS  
Pesticides/ foodstuffs 
Pesticide stand-
ards/ food samples
3 A quantitative GC-APCI-MS/MS method was developed and fully validated for 
142 pesticides followed by its application to six different food matrices.  
Highly abundant [M+H]+ ions as precursor ions favoring high selectivity and 
detection sensitivity were available in APCI as opposed to the extensive 
fragmentation in EI for these compounds.  
David et al. (2011) [169] 
GC-APCI-TOFMS  
Environmental 
Reference 
phthalate samples/ 
sediment extract  
1 Simultaneous quantification of two high-molecular-weight phthalates without 
comprising detection sensitivity was achieved by GC-APCI-TOFMS in sedi-
ments. 
Whereas EI yielded abundant, but unspecific fragment ions and only minor 
[M-CH3]+ ions that were specific for the two co-eluting compounds, the [M+H]+ 
ion represented the base peak of the APCI spectrum in both cases.  
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Table 12.1 continued. 
Authors/ Technique/ Field Samples Focus Highlights 
Domeño et al. (2012) [170] 
GC-APCI-QTOFMS  
Environmental 
PAH and NPAH 
standards/ moss 
samples 
3 Quantification of 15 PAHs and 8 nitrated PAHs by GC-APCI-QTOFMS was 
achieved at very low concentration levels in mosses.  
Acquired data can be used for pattern recognition of pollutants pointing to the 
different locations of sampling points and likely emissions.  
García-Villalba et al. 
(2011) [8] 
GC-APCI-TOFMS  
Foodstuffs 
Phenolic standard 
compounds/ Span-
ish extra-virgin 
olive oil samples 
2, 3 The use of GC-APCI-TOFMS for screening, structural assignment and quanti-
tative determination of phenolic compounds in virgin olive oil is demonstrated. 
Optimization of chromatographic and MS conditions and a full validation of the 
method (selectivity, linear range, LOD, precision, accuracy, matrix effect) was 
carried out.  
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Table 12.1 continued. 
Authors/ Technique/ Field Samples Focus Highlights 
Garratt et al. (2005) [171] 
APCI-MS/ linked GC-
APCI/EI-MS  
Foodstuffs/ VOCs 
Transgenic lettuce 
plants and azy-
gous controls 
5 Six VOCs were studied by means of combined GC-APCI/EI-MS in the head-
space from transgenic lettuce plants expressing an IPT gene that exhibited a 
senescence-suppressing effect by autoregulated cytokinin biosynthesis.  
Significant increases in acetaldehyde, ethanol and dimethyl sulphide in trans-
genic lettuce could be related to other indices of cellular senescence, demon-
strating the general applicability of the approach.  
Gómez-Pérez et al. (2014) 
[172] 
GC-APCI-QTOFMS 
Pesticides 
Pesticide stand-
ards/ meat sam-
ples  
1, 3 A total of 71 pesticides were evaluated by GC-APCI-QTOFMS in terms of 
their ionization behavior and quantitative performance for the application to 
meat samples.  
Quantitative analysis was carried out for fifty-one analytes that had shown 
acceptable performance in the validation study including the determination of 
linear quantification range, LOD, recovery, intra- and inter-day precision, and 
matrix effect.  
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Table 12.1 continued. 
Authors/ Technique/ Field Samples Focus Highlights 
Matysik et al. (2014) [131] 
GC-APCI-TOFMS  
Steroids 
Standards for 
sterols and related 
analytes/ human 
EDTA-plasma 
5 The general applicability of GC-APCI-TOFMS for simultaneous screening and 
determination of concentration levels of sterols in human plasma was shown.  
Well-controlled humidity was established in the modified APCI source with 
regard to reproducible ionization. 
Nácher-Mestre et al. 
(2014) [173] 
GC-APCI-QTOFMS  
Pesticides/ aquacultural 
Pesticide and 
polycyclic aromatic 
hydrocarbon 
standards/ feed 
ingredients in 
aquafeeds/ aq-
uafeeds/ fish sam-
ples 
2 A reliable screening method based on GC-APCI-QTOFMS was developed 
and validated for 133 pesticides and 24 PAHs in aquacultural and fish sam-
ples. 
Screening detection limit of a compound, i.e. the threshold concentration at 
which detection becomes trustworthy, was set at the lowest spike-in concen-
tration level that yielded a positive identification hit in at least 19 out of 20 
replicate matrix samples. 
Several matches for the validated compounds were reported in fish samples. 
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Table 12.1 continued. 
Authors/ Technique/ Field Samples Focus Highlights 
Östman et al. (2006) [135] 
GC-microchip APCI-
QqQMS  
VOCs 
Standards of vola-
tile organic com-
pounds/ human 
urine 
5 The general suitability of GC-microchip APCI-MS for qualitative and quantita-
tive analysis of volatile and semi-volatile compounds was demonstrated.  
Mass spectra produced by microchip APCI in this study yielded the same type 
of information as conventional APCI.  
Portolés et al. (2010) [59] 
GC-APCI-QTOFMS, GC-
EI-TOFMS  
Pesticides/ foodstuffs 
Pesticide stand-
ards/ food samples
1, 2 GC-APCI-QTOFMS was evaluated for wide-scope pesticide screening pur-
poses in three varieties of food samples. 
Water as modifier led to the predictable presence of [M+H]+ ions for 90 out of 
100 model pesticides favoring rapid screening, whereas the EI molecular ion 
is typically absent. 
MS/MS experiments increased confidence in the identity of several detected 
compounds in real food samples.  
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Table 12.1 continued. 
Authors/ Technique/ Field Samples Focus Highlights 
Portolés et al. (2012) [82] 
GC-APCI-QqQMS, GC-EI-
QqQMS  
Pesticides/ foodstuffs 
Pyrethroid stand-
ards/ fruit and 
vegetables sam-
ples  
1, 4 The beneficial impact of APCI with water as modifier over EI was demonstrat-
ed for GC-QqQMS analysis of pyrethroids, which are highly fragmented in EI.  
More specific MRM transitions based on [M+H]+ ions as precursor ions and 
lower detection limits in food samples were obtained.  
Strong matrix effects were observed for several pyrethroid/ food matrix com-
binations.  
Portolés et al. (2014) [174] 
GC-APCI-QTOFMS/ GC-
EI-TOFMS  
Environmental 
Standards of or-
ganic contami-
nants/ groundwa-
ter samples 
2, 4 A wide-scope screening method for initially 170 organic contaminants was 
established based on GC-APCI-QTOFMS and compared to GC-EI-TOFMS.  
Detection of these compounds based on molecular-ion searching was more 
effective than matching deconvoluted EI mass spectra to reference libraries.   
Number of compounds included in GC-APCI-QTOFMS screening approach 
could be extended by 85 because of the predictable presence of [M+H]+ ions 
and the simultaneous acquisition of high and low collision energy spectra.  
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Table 12.1 continued. 
Authors/ Technique/ Field Samples Focus Highlights 
Raro et al. (2014) [175] 
GC-APCI-QTOFMS  
Steroids 
Steroid standards 1 Ionization behaviour of 60 underivatized and TMS-derivatized anabolic an-
drogenic steroids and steroid metabolites was studied.  
Water as modifier proved beneficial for the formation of dominating [M+H]+ 
ions that may serve as selective and sensitive precursor ions in tandem MS. 
Relationship between steroid structure and observed ions was established 
that might be helpful in the elucidation of unknown metabolites of steroids.  
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Table 12.2 Gas chromatographic and mass spectrometric characteristics of the MCF and MeOx-TMS derivatives of the 20 standard compounds and fatty acids 
selected for method evaluation. Retention times, quantifier ions, prominent ions (marked in bold) present in APCI(+) mass spectra acquired at water infusion rates of 
0.0 mL/h and 0.4 mL/h, respectively, and calculated logPoctanol/water values, as a measure of lipophilicity, for both MCF and MeOx-TMS derivatives, including the 
number of trimethylsilyl groups of the latter derivatives, are presented. Reprinted from [14].  
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Adipate 12.49 175.0965 0.95 2TMS 14.55 291.1442 291.1506 (100), 201.0973 (44.2) 2.74
Ala 11.08 162.0761 102.0597 (100), 162.0766 (41.3), 130.0531 (10.2) 162.0770 (100), 102.0557 (27.1), 130.0507 (25.2) -0.16 2TMS 8.50 234.1340 234.1373 (100), 144.0848 (7.0) 234.1377 (100), 144.0858 (5.6) 2.25
4-Aminobutyrate 14.65 176.0917 176.0915 (100), 144.0656 (74.9), 130.0501 (37.8) 0.12 3TMS 13.83 320.1892 320.1970 (100), - 320.1961 (100), - 3.52
Asp 16.33 220.0816 160.0613 (100), 128.0359 (23.2), 220.0818 (14.3) 220.0820 (100), 160.0612 (38.9), 188.0558 (17.2) -0.36 3TMS 14.18 350.1634 350.1712 (100), 278.1287 (5.0) 350.1698 (100), - 3.07
Benzoate 10.33 137.0597 137.0618 (100), - 137.0606 (100), - 2.12 1TMS 11.74 195.0836 195.0860 (100), 105.0350 (9.9) 2.60
Fumarate 9.03 145.0495 145.0508 (100), 113.0272 (7.6) 145.0505 (100), 163.0606 (72.7), 113.0237 (10.2) 0.43 2TMS 11.98 261.0980 261.1021 (100), 171.0489 (9.9) 261.1020 (100), 189.0605 (8.5) 1.76
Glu 17.92 234.0972 234.0970 (100), 202.0707 (34.6), 174.0758 (13.8) -0.19 3TMS 15.43 364.1790 364.1867 (100), 274.1327 (8.5) 364.1849 (100), 292.1439 (10.8) 3.20
Hippurate 19.92 194.0812 194.0814 (100), 105.0401 (52.5) 194.0822 (100), 105.0352 (9.6) 0.80 1TMS 20.67 252.1050 252.1086 (100), 162.0570 (13.9) 252.1090 (100), 162.0553 (8.3) 1.88
Ile 13.89 204.1230 144.1036 (100), 204.1229 (13.2) 204.1238 (100), 144.1025 (63.7) 1.21 2TMS 10.77 276.1810 276.1868 (100), 158.1378 (5.4) 276.1857 (100), 204.1436 (5.3) 3.62
Leu 13.73 204.1230 144.1038 (100), 204.1238 (16.2) 204.1235 (100), 144.1024 (53.2) 1.21 2TMS 10.49 276.1810 276.1864 (100), 186.1330 (5.3) 276.1857 (100), 204.1436 (6.5) 3.62
Malonate 8.18 133.0495 133.0507 (100), 101.0284 (72.9), 119.0359 (43.9) 133.0504 (100), 119.0351 (54.2) -0.12 2TMS 10.65 249.0973 1.73
Met 18.10 222.0795 0.46 2TMS 14.64 294.1374 294.1433 (100), - 294.1427 (100), 222.1008 (7.0) 2.98
Methyl-malonate 8.50 147.0652 115.0443 (100), 133.0523 (93.6), 147.0672 (54.2) 147.0662 (100), 133.0503 (73.8) 0.24 2TMS 10.56 263.1129 2.09263.1175 (100), 251.1493 (90.1), 
117.0743 (37.7), 161.1008 (14.8)
251.1540 (100), 263.1176 (67.6), 
117.0745 (10.8)
195.0865 (100), 179.0506 (88.1), 
105.0357 (35.8)
202.0712 (100), 174.0772 (65.0), 142.0527 (54.0), 
234.0983 (26.2), 114.0590 (20.9)
249.1024 (100), 178.1104 (47.2), 
303.1225 (28.8), 159.0482 (18.3)
249.1002 (100), 303.1204 (67.3), 
178.1099 (25.7)
162.0589 (100), 174.0762 (64.6), 222.0797 (20.6), 
114.0594 (14.1)
222.0803 (100), 162.0594 (44.5), 190.0552 (20.3), 
174.0770 (11.8)
MCF derivatives MeOx-TMS derivatives 
115.0796 (100), 111.0484 (92.5), 143.0719 (68.1), 
129.0577 (10.2), 175.0965 (3.3)
175.0971 (100), 161.0814 (86.7), 143.0708 (55.9), 
129.0554 (21.7), 115.0766 (18.6), 111.0448 (11.6)
201.0970 (100), 291.1492 (80.5), 
111.0450 (25.6)
144.0659 (100), 130.0526 (95.9), 112.0425 (51.0), 
176.0958 (25.8)
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Table 12.2 continued. 
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Nicotinate 11.35 138.0550 138.0567 (100), - 138.0558 (100), - 0.79 1TMS 12.65 196.0788 196.0826 (100), - 196.0827 (100), - 1.66
Nval 13.23 190.1074 130.0887 (100), 190.1074 (9.4) 190.1082 (100), 130.0874 (64.1), 158.0817 (10.5) 0.86 2TMS 10.15 262.1653 262.1697 (100), 172.1164 (6.6) 262.1703 (100), 190.1287 (5.7) 3.27
Phe 19.55 238.1074 238.1085 (100), 178.0873 (49.7), 190.0509 (27.4) 1.19 2TMS 16.04 310.1653 310.1715 (100), - 310.1698 (100), 238.1285 (5.7) 3.76
Phenylacetate 11.74 151.0754 151.0764 (100), 91.0612 (14.2) 151.0760 (100), 91.0548 (6.4) 1.91 1TMS 12.62 209.0992 209.0992 (100), 193.0701 (18.1) 209.1024 (100), - 2.54
Pro 15.45 188.0917 128.0742 (100), 188.0930 (14.7) 188.0924 (100), 128.0718 (49.0) 0.27 2TMS 11.29 260.1497 260.1540 (100), 170.1012 (6.1) 260.1543 (100), 188.1127 (11.4) 2.17
Suberate 15.13 203.1278 203.1287 (100), 189.1132 (90.7) 1.88 2TMS 16.92 319.1755 3.64
Val 12.64 190.1074 130.0889 (100), 190.1082 (8.4) 190.1083 (100), 130.0873 (70.6), 158.0816 (12.8) 0.70 2TMS 9.76 262.1653 262.1698 (100), 144.1219 (5.8) 262.1693 (100), 190.1275 (6.7) 3.11
Nonanoatec 10.90 173.1536 173.1541 (100), - 173.1548 (100), 191.1648 (17.8) 3.84 1TMS 12.01 231.1775 231.1779 (100), 215.1371 (10.2) 231.1779 (100), 141.0390 (5.4) 4.72
Undecanoatec 13.48 201.1849 201.1854 (100), - 201.1857 (100), 219.1959 (15.2) 4.86 1TMS 14.46 259.2088 259.2084 (100), 243.1745 (6.9) 259.2090 (100), - 5.74
Tridecanoatec 15.96 229.2162 229.2166 (100), - 229.2171 (100), 247.2269 (15.0) 5.88 1TMS 16.76 287.2401 287.2405 (100), - 287.2403 (100), - 6.76
Pentadecanoatec 18.34 257.2475 257.2478 (100), - 257.2481 (100), 275.2580 (13.7) 6.90 1TMS 18.98 315.2714 315.2721 (100), - 315.2719 (100), - 7.78
Heptadecanoatec 20.56 285.2788 285.2802 (100), - 285.2800 (100), 303.2909 (7.6) 7.92 1TMS 21.10 343.3027 343.3040 (100), - 343.3026 (100), 271.2628 (5.5) 8.80
Nonadecanoatec 22.81 313.3101 313.3114 (100), - 313.3105 (100), 331.3173 (5.5) 8.94 1TMS 23.15 371.3340 371.3347 (100), - 371.3350 (100), 299.2929 (7.4) 9.82
a m/z  of [M+H]+ marked in bold. Masses of fragment and adduct ions exceed a S/N of 20 and a relative intensity of 10%, except the most intensive fragment ion in a spectrum exceeds only 5%. b Calculated by ACD/Labs V12.01. c Concs. = 67 M and 100 M for MCF 
and MO-TMS derivatives, respectively. 
MCF derivatives MeOx-TMS derivatives 
178.0872 (100), 190.0506 (42.3), 238.1078 (14.7), 
146.0616 (13.1)
171.1024 (100), 189.1128 (53.9), 143.1085 (46.2), 
139.0772 (28.5), 111.0849 (27.1), 203.1283 (8.1)
319.1819 (100), 229.1287 (65.9), 
139.0763 (12.9)
319.1818 (100), 247.1398 (35.1), 
229.1244 (11.5)
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Table 12.3 Impact of different rates of continuous water infusion on APCI of MCF and MeOx-TMS derivatized standard compounds. Mean FCs in peak area of 
[M+H]+ ions in relation to no water infusion and RSDs of peak areas for N=5 derivatization replicates are given for both MCF (200 µM each) and MeOx-TMS (100 
µM each) derivatives (A=amide group, E=methyl ester group). ANOVA and post hoc tests were performed based on the [M+H]+ peak areas.a,b Reprinted from [14]. 
 MCF derivative 0.1 mL/h  0.2 mL/h  0.3 mL/h  0.4 mL/h 0.5 mL/h 
 FC RSD (%) FC RSD (%) FC RSD (%) FC RSD (%) FC RSD (%)
Adipate-2Ec 23.0j 19.3 71.8g 30.0 133.7g 17.0 163.9g 4.2 137.8g 24.7 
Ala-1A-1Ec 9.8j 25.6 30.4g 6.3 29.8g 40.0 36.7g 16.7 27.3g 9.8 
4-Aminobutyrate-1A-1Ec 5.0j 3.1 16.3i 30.1 30.8g 12.0 33.7g 30.9 32.4g 22.0 
Asp-1A-2Ec 4.7j 42.0 13.9g 32.8 17.9g 30.1 15.6g 22.6 12.0g 23.1 
Benzoate-1Ec 2.0h 34.6 2.6g 13.6 2.7g 13.1 1.8h 14.7 2.1g 17.1 
Fumarate-2Ec 1.7i 12.0 2.0g 30.4 1.8g 28.7 1.2j 15.0 1.3j 21.7 
Glu-1A-2Ec 5.3j 32.8 14.9g 27.9 14.7g 27.5 16.8g 24.9 14.4g 24.5 
Hippurate-1Ec 4.5h 17.2 9.5g 13.5 8.0g 16.3 7.1g 32.4 5.2g 13.4 
Ile-1A-1Ec 6.0i 18.6 15.1g 18.0 17.4g 24.7 15.9g 32.3 16.6g 12.7 
Leu-1A-1Ec 7.3i 22.7 15.2g 7.9 15.1g 42.7 14.6g 33.2 13.1g 33.9 
Malonate-2Ec 57.1i 33.5 93.6g 7.7 137.2g 25.7 163.9g 3.5 126.9g 12.7 
Met-1A-1Ec 6.8j 48.4 15.3g 22.7 20.9g 34.0 16.3g 32.0 13.7g 26.2 
Me-malonate-2Ec 59.8h 22.7 98.8g 14.4 125.8g 27.8 142.0g 15.7 121.3g 24.0 
Nicotinate-1Ec 1.0j 13.1 2.1g 31.2 1.7i 23.6 1.7i 10.4 1.2j 48.2 
Nval-1A-1Ec 4.3j 42.4 14.6g 7.8 15.4g 17.9 17.0g 27.3 13.3g 19.1 
Phe-1A-1Ec 4.4i 30.4 10.5g 18.0 12.0g 18.7 8.6g 28.0 10.0g 6.3 
Phenylacetate-1Ec 5.8g 31.2 9.0g 18.7 10.1g 14.4 9.7g 10.8 6.9g 9.7 
Pro-1A-1Ec 3.1i 29.2 7.0g 9.6 7.6g 9.2 10.8g 7.6 7.2g 21.4 
Suberate-2Ec 10.5j 30.7 38.4g 34.4 47.7g 14.9 60.5g 24.7 35.0g 27.5 
Val-1A-1Ed 4.4j 18.2 13.3g 39.9 18.8g 9.7 21.6g 6.9 15.4g 27.1 
Geometric mean 6.2 23.2 14.3 17.9 16.6 20.4 16.6 16.3 13.8 19.2 
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Table 12.3 continued. 
 
MeOx-TMS derivative 0.1 mL/h  0.2 mL/h  0.3 mL/h  0.4 mL/h 0.5 mL/h 
 FC RSD (%) FC RSD (%) FC RSD (%) FC RSD (%) FC RSD (%)
Adipate-2TMSd 1.2j 35.1 1.7j 54.2 2.2i 31.8 2.4h 13.6 2.2i 24.2 
Ala-2TMSf 1.1 31.9 1.0 24.4 1.2 30.2 1.3 29.5 1.0 20.6 
4-Aminobutyrate-3TMSf 1.2 19.1 1.2 25.8 1.3 36.5 1.3 21.1 1.5 19.3 
Asp-3TMSf 0.9 31.6 1.1 44.0 1.0 20.7 1.6 41.5 1.3 33.1 
Benzoate-1TMSd 1.5j 50.5 2.6h 9.7 2.4h 26.0 2.3h 31.9 1.9i 30.0 
Fumarate-2TMSf 1.3 16.1 1.4 25.4 1.1 24.5 1.3 35.6 1.5 19.9 
Glu-3TMSf 1.6 37.6 0.8 21.2 1.3 24.8 1.5 45.1 1.1 39.1 
Hippurate-1TMSc 1.1j 35.5 1.7i 13.9 1.3j 37.9 0.9j 37.9 2.4g 13.9 
Ile-2TMSf 1.2 23.4 1.3 32.7 1.2 30.9 1.6 16.1 1.0 55.2 
Leu-2TMSf 1.1 37.3 1.4 39.6 0.9 32.6 1.3 31.4 1.0 51.3 
Malonate-2TMSf 1.8 43.2 2.1 15.7 2.0 27.2 1.7 20.5 2.2 29.1 
Met-2TMSf 1.0 38.9 0.8 35.6 0.7 47.8 0.9 45.6 1.1 21.2 
Me-malonate-2TMSf 1.1 41.0 1.4 30.2 1.4 36.4 1.4 26.0 1.3 17.6 
Nicotinate-1TMSe 1.5j 12.8 1.3j 27.6 1.6i 20.1 1.7h 12.8 1.6i 20.8 
Nval-2TMSf 0.9 30.3 0.8 25.4 0.7 41.1 1.3 41.4 0.7 32.3 
Phe-2TMSf 0.9 28.6 1.3 30.6 1.2 14.6 1.6 30.3 1.3 22.0 
Phenylacetate-1TMSd 1.3j 23.1 1.8i 17.0 2.1h 28.8 2.3g 16.9 1.7i 24.4 
Pro-2TMSe 1.1j 34.4 1.1j 17.5 0.8j 13.4 1.6i 29.6 0.8j 26.2 
Suberate-2TMSf 1.1 13.9 1.3 29.3 1.5 15.8 1.6 25.0 1.4 18.1 
Val-2TMSf 0.8 17.8 0.7 26.5 0.7 31.6 1.1 40.1 0.9 29.5 
Geometric mean               1.2    28.1      1.3    25.3      1.2    27.2      1.5   27.6      1.3    25.7 
a Ranges of p values in ANOVA indicated as follows: c p <0.001; d p <0.01; e p <0.05; f p >0.05.  
b Ranges of p values in post hoc test indicated as follows: g p <0.001; h p <0.01; i p <0.05; j p >0.05.    
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Table 12.4 Area under the curve values for the corresponding ROC curves of MCF and MeOx-TMS 
derivatives for all pairwise fold changes. ROC curves were generated from 20 compounds spiked at 
six different concentrations into aliquots of a serum extract, followed by derivatization (N=5 derivatiza-
tion replicates per spike level) and GC-APCI-TOFMS analysis without and at a water infusion rate of 
0.4 mL/h. Reprinted from [14]. 
FC AUC MCF derivatives AUC MeOx-TMS derivatives 
 0.0 mL/h 0.4 mL/h 0.0 mL/h 0.4 mL/h 
1.17 0.36 0.64 0.60 0.50 
1.20 0.65 0.46 0.64 0.64 
1.25 0.57 0.67 0.58 0.66 
1.33 0.42 0.82 0.44 0.51 
1.40 0.77 0.73 0.74 0.63 
1.50 0.66 0.77 0.73 0.76 
1.50 0.77 0.77 0.81 0.77 
1.67 0.79 0.86 0.81 0.85 
1.75 0.79 0.84 0.80 0.77 
2.00 0.81 0.95 0.85 0.87 
2.00 0.84 0.92 0.92 0.84 
2.33 0.85 0.87 0.87 0.88 
2.50 0.90 0.93 0.91 0.90 
3.00 0.93 0.96 0.94 0.89 
3.50 0.95 0.94 0.94 0.90 
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Table 12.5 Figures of merits of linear regression analysis of expected and observed fold changes in the MCF spike-in experiment as a function of water infusion. 
In the spike-in bucket table, blank feature area values were subtracted as “background” from the peak areas of investigated features, i.e., features that could be 
extracted from both, APCI/-H2O and APCI/+H2O spectra. All possible fold changes were plotted and respective slopes and intercepts of linear regression equa-
tions, regression coefficients and mean RSD values over all fold changes are listed. In the absence of [M+H]+ ions, a fragment ion was monitored instead, with 
the respective mass given after the underscore character. For alanine, 4-aminobutyrate, malonate, and methylmalonate, no ions could be extracted across all 
spike-in levels in the absence of water infusion. Reprinted from [14]. 
feature  0.0 mL/h  0.4 mL/h  
  slope intercept r mean RSD/% slope intercept r mean RSD/%
Adipate_m/z 115a 1.56 -0.41 0.832 32.7 1.33 -0.26 0.922 21.0 
Asp_m/z 160a 1.14 -0.11 0.945 19.5 1.20 -0.16 0.944 20.1 
Benzoate 1.29 -0.21 0.884 25.0 1.11 -0.07 0.935 19.5 
Fumarate 1.29 -0.20 0.884 31.3 1.11 -0.06 0.877 25.0 
Glu_m/z 202a 0.29 0.73 0.498 32.1 0.52 0.49 0.709 24.2 
Hippurate 1.08 0.01 0.816 38.6 0.80 0.21 0.883 21.6 
Ile 1.04 0.13 0.655 51.4 1.30 -0.22 0.856 29.4 
Leu 1.37 0.04 0.350 67.2 0.70 0.29 0.873 22.5 
Met_m/z 162a 1.18 -0.05 0.761 44.1 1.00 0.03 0.891 25.8 
Nicotinate 1.62 -0.43 0.792 40.7 1.37 -0.26 0.883 22.5 
Nval_m/z 130a 1.90 -0.70 0.876 32.8 1.06 -0.02 0.919 17.8 
Phe 0.67 0.39 0.683 35.1 0.68 0.33 0.800 24.0 
Phenylacetate 1.77 -0.53 0.629 47.3 0.98 0.05 0.916 16.1 
Pro 1.18 -0.01 0.727 44.0 0.81 0.22 0.826 28.4 
Suberate_m/z 189a 0.37 0.61 0.735 20.4 0.53 0.45 0.887 15.9 
Val_m/z 130a 1.00 0.06 0.787 33.5 0.89 0.15 0.841 29.9 
a Mass of investigated feature corresponding to a fragment. 
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Table 12.6 Determination of elemental compositions of known MCF derivatized spike-in compounds. Compounds from the spike-in mix (concn=200 µM) were 
spiked into a serum extract (N=5 derivatization replicates), followed by MCF derivatization and GC-APCI-TOFMS analysis without and with water infusion at 0.4 
mL/h. Mass accuracy was determined after internal recalibration of mass spectra. In addition, isotope abundance accuracy (referred to as percentage error of the 
first isotope as well as mSigma value obtained from DataAnalysis, Bruker Daltonics) and average rank of correct elemental formula with total average number of 
calculated formulas are presented (A=amide group, E=methyl ester group). Reprinted from [14]. 
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Adipate-2E C8H15O4+ 175.0965 -0.3±1.8 c 52.3±0.0 2 4 -0.6±0.1 -0.1±0.4 7.1±0.3 2 4
Ala-1A-1E C6H12NO4+ 162.0761 -0.7±0.5 0.4±1.3 9.0±2.0 2 4 -0.2±0.5 0.4±0.5 6.8±0.7 2 4
4-Aminobutyrate-1A-1E C7H14NO4+ 176.0917 c c c c c 0.0±0.4 0.3±1.4 9.5±2.9 2 4
Asp-1A-2E C8H14NO6+ 220.0816 -0.6±0.5 c 55.1±0.0 4 8 -0.8±0.4 c 55.1±0.0 4 8
Benzoate-1E C8H9O2+ 137.0597 -0.8±1.0 0.3±0.2 4.9±0.6 1 3 1.0±1.2 0.0±0.3 4.6±0.4 1 4
Fumarate-2E C6H9O4+ 145.0495 -0.6±0.8 0.5±0.4 6.9±0.8 2 4 1.4±3.0 -0.6±0.6 15.4±3.5 1 3
Glu-1A-2E C9H16NO6+ 234.0972 -1.1±0.9 -2.7±2.2 21.6±11.7 3 8 -0.4±0.4 0.0±0.7 9.3±2.5 2 7
Hippurate-1E C10H12NO3+ 194.0812 -0.9±0.5 -0.3±1.0 8.5±2.1 2 5 -0.8±0.5 0.3±0.5 7.6±0.7 2 4
Ile-1A-1E C9H18NO4+ 204.1230 -0.6±0.7 c 60.9±0.0 3 4 -0.9±0.3 0.4±0.4 8.1±0.8 2 4
Leu-1A-1E C9H18NO4+ 204.1230 -0.5±0.3 c 60.9±0.0 3 4 -0.9±0.4 0.4±0.2 7.9±0.2 2 4
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Table 12.6 continued. 
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Malonate-2E C5H9O4+ 133.0495 -0.4±0.8 c 33.2±0.0 2 4 1.2±1.4 0.1±0.2 5.7±0.3 2 3 
Met-1A-1E C8H16NO4S+ 222.0795 -0.2±0.8 -2.9±1.9 28.2±13.7 5 8 -0.8±0.2 0.5±0.3 4.0±1.4 2 8 
Me-malonate-2E C6H11O4+ 147.0652 -1.0±1.4 -3.0±2.0 28.1±12.9 2 4 0.2±0.8 0.4±0.4 6.6±0.9 2 3 
Nicotinate-1E C7H8NO2+ 138.0550 -0.5±1.0 -0.6±0.5 5.9±1.7 1 2 1.1±1.2 0.2±0.5 4.9±1.5 1 2 
Nval-1A-1E C8H16NO4+ 190.1074 -0.6±0.4 c 54.5±0.0 3 4 -0.4±0.3 0.5±0.2 7.7±0.5 2 4 
Phe-1A-1E C12H16NO4+ 238.1074 -0.7±0.5 c 79.6±0.0 7 8 -1.3±0.5 0.5±0.3 10.3±0.5 2 7 
Phenylacetate-1E C9H11O2+ 151.0754 -0.6±0.4 -0.6±1.0 7.7±2.2 1 3 0.3±0.8 0.2±0.4 5.5±0.9 1 4 
Pro-1A-1E C8H14NO4+ 188.0917 -0.8±0.3 c 54.3±0.0 3 4 -0.6±0.2 -0.2±0.8 8.0±1.8 2 4 
Suberate-2E C10H19O4+ 203.1278 -0.4±0.7 c 65.1±0.0 3 4 -1.1±0.6 0.0±0.5 8.4±0.5 2 4 
Val-1A-1E C8H16NO4+ 190.1074 -1.0±0.2 c 54.5±0.0 3 4 -0.8±0.5 0.6±0.3 7.9±0.5 2 4 
a Difference between predicted and measured variable; b Sorting according to mSigma value; c Not detected. 
Calculation parameter: positive adducts, M+H; m ≤±5mDa; charge, 1; even electron number; filter H/C element ratio ≤3; check 
ring plus double bonds from -0.5 to 40; 0 ≤ nN ≤ 5; 0 ≤ nP ≤ 1; 0 ≤ nS ≤ 2.  
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Table 12.7 Figures of merit for the study of matrix effects via spike-in experiment in chapter 7. Concentra-
tions of spike-in compounds in spike-in mixtures for E. coli, serum and urine are given, the internal stand-
ard used for quantification of each spike-in compound is listed, and mean recoveries ±SD for the internal 
standards in the three different matrices are presented. Since endogenous metabolite concentrations 
varied among the three matrices, separate spike-in mixtures were used. Volumes of 0, 10, 20, 30, 40, 50, 
and 60 µL for spike-in levels 1-6 were added to aliquots of pre-processed matrix, which corresponded to 
absolute amounts between 0.08-24.24 nmol of the spike-in metabolites. The final volume of MeOx-TMS 
derivatized matrix sample was 110 µL. 
 
Compound E. coli 
spike-in 
mix Conc. 
(µM) 
Serum 
spike-in 
mix Conc. 
(µM) 
Urine    
spike-in 
mix Conc. 
(µM) 
Corresponding internal 
standarda 
 
  
Spike-in compound     
2-Ketobutyrate 75.0 75.0 75.0 [U-13C]pyruvate 
3-Methyl-2-oxovalerate 75.0 75.0 69.9 [U-13C]pyruvate 
Methylmalonate 138.6 9.8 47.9 [U-13C]fumarate 
Nicotinate 98.1 75.0 75.0 [2H7]trans-cinnamate 
Phenylacetate 75.0 75.0 75.0 [2H7]trans-cinnamate 
Glycerate 64.9 10.6 35.3 [U-2H]succinate/        
[U-13C]fumarate     
Fumarate 67.9 75.0 29.3 [U-13C]fumarate 
-Ketoglutarate 7.8 75.0 113.8 [2,3,3-2H3]malate 
Phenyllactate 75.0 75.0 75.0 [U-13C]lactate/          
[2H7]trans-cinnamate     
Phenylpyruvate 8.1 75.0 75.0 [U-13C]pyruvate 
Hydroxyphenylacetate 75.0 75.0 79.3 [2H7]trans-cinnamate 
Homovanillate 75.0 75.0 20.9 [2,2,4,4-2H4]citrate/ 
[2H7]trans-cinnamate     
Phosphoglycerate 24.1 75.0 36.6 [2,2,4,4-2H4]citrate/ 
[2H7]trans-cinnamate     
Hydroxyphenylpyruvate 75.0 75.0 17.2 [2,2,4,4-2H4]citrate/ 
[2H7]trans-cinnamate     
Pyruvate 410.6 75.0 194.2 [U-13C]pyruvate 
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Table 12.7 continued. 
 Mean  
recovery in 
E. colib (%)
Mean  
recovery in 
serumb (%) 
Mean  
recovery in 
urineb (%) 
 
  
Internal standard    
[U-13C]pyruvate 107.9±11.2 113.4±22.4 83.6±33.5 
[U-13C]lactate 69.3±3.9 102±9.3 96.2±25.6 
[U-2H]succinate 59.2±4.6 93.8±10.7 83.7±12.6 
[U-13C]fumarate 94.5±11.9 97±9.6 76.1±12.1 
[2,3,3-2H3]malate 99.7±6.9 99.8±8.1 80.4±11 
[2H7]trans-cinnamate 109.8±7.2 103.8±18.2 90.6±19.1 
[2,2,4,4-2H4]citrate 99.6±7.4 64.3±7.4 57.9±9.3 
a Internal standards in bold were chosen instead of those with poor re-
covery. b Calculation based on area integrals of [M+H]+ in the spiked 
matrix samples (N=30) divided by those in standards (N=12). 
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Table 12.8 List of compounds contained in our in-house GC-APCI-HRTOFMS database of 100 MeOx-
TMS derivatized metabolite standards. Mostly sugars, fatty acids, amines, organic acids, alcohols, amino 
acids and amino acid metabolites are included. Isomer elution numbers are given for metabolites yielding 
multiple peaks after derivatization. MeOx, group introduced by methoximation; TMS, trimethylsilyl group. 
No.  Metabolite 44 Lactate, 2TMS 
1 N-Acetyl-aspartate, 2TMS 45 Lactose-1, MeOx, 8TMS 
2 N-Acetyl-D-glucosamine, MeOx, 4TMS 46 Lactose-2, MeOx, 8TMS 
3 N-Acetyl-neuraminate, MeOx, 6TMS 47 Laurate, TMS 
4 Acetylputrescine, 2TMS 48 Leucine, TMS 
5 cis-Aconitate, 3TMS 49 Leucine, 2TMS 
6 Adipate, 2TMS 50 Lysine, 3TMS 
7 Alanine, 2TMS 51 Lysine, 4TMS 
8 Aspartate, 2TMS 52 Malate, 3TMS 
9 Aspartate, 3TMS 53 Malonate, 2TMS 
10 Citrate, 4TMS 54 Mandelate, 2TMS 
11 Creatinine, 3TMS 55 Mannitol, 6TMS 
12 Dihydroorotate, 3TMS 56 Methylmalonate, 2TMS 
13 Dimethylsuccinate, 2TMS 57 3-Methyl-2-oxovalerate, MeOx, TMS 
14 Erythritol, 4TMS 58 4-Methyl-2-oxovalerate, MeOx, TMS 
15 Ethanolamine, 2TMS 59 Myo-inositol, 6TMS 
16 Fructose-1, MeOx, 5TMS 60 Nicotinamide, TMS 
17 Fructose-2, MeOx, 5TMS 61 Nicotinate, TMS 
18 Fumarate, 2TMS 62 Nonadecanoate, TMS 
19 GABA, 3TMS 63 Nonanoate, TMS 
20 Glucose-1, MeOx, 5TMS 64 Norvaline, TMS 
21 Glucose-2, MeOx, 5TMS 65 Norvaline, 2TMS 
22 Glucose-6-phosphate-1, MeOx, 6TMS 66 Ornithine, 3TMS 
23 Glucose-6-phosphate-2, MeOx, 6TMS 67 Ornithine, 4TMS 
24 Glycerate, 3TMS 68 Orotate, 3TMS 
25 Glycerol, 3TMS 69 Pantothenate, 3TMS 
26 Glycerol-1-phosphate, 4TMS 70 Pentadecanoate, TMS 
27 Glycine, 3TMS 71 Phenylacetate, TMS 
28 Heptadecanoate, TMS 72 Phenylalanine, TMS 
29 Hippurate, TMS 73 Phenylalanine, 2TMS 
30 Hippurate, 2TMS 74 Phenyllactate, 2TMS 
31 Homogentisate, 3TMS 75 Phenylpyruvate, MeOx, TMS 
32 Homovanillate, 2TMS 76 Phosphoenolpyruvate, 3TMS 
33 2-Hydroxybutyrate, 2TMS 77 3-Phosphoglycerate, 4TMS 
34 3-Hydroxybutyrate, 2TMS 78 O-Phosphorylethanolamine, 4TMS 
35 5-Hydroxy-indoleacetate, 2TMS 79 Proline, TMS 
36 5-Hydroxy-indoleacetate, 3TMS 80 Proline, 2TMS 
37 Hydroxyphenylacetate, 2TMS 81 Pyruvate, MeOx, TMS 
38 Hydroxyphenylpyruvate, MeOx, 2TMS 82 Quinolinate, 2TMS 
39 Hydroxyproline, 3TMS 83 Ribitol, 5TMS 
40 Isoleucine, TMS 84 Serine, 2TMS 
41 Isoleucine, 2TMS 85 Serine, 3TMS 
42 Itaconate, 2TMS 86 Sorbitol, 6TMS 
43 -Ketoglutarate, MeOx, 2TMS 87 Suberate, 2TMS 
 
 
 177
 
 
 
Table 12.8 continued. 
No.  Metabolite 
88 Succinate, 2TMS 
89 Threonine, 2TMS 
90 Threonine, 3TMS 
91 Thymine, 2TMS 
92 Tridecanoate, TMS 
93 Tryptophan, 2TMS 
94 Tryptophan, 3TMS 
95 Tyrosine, 2TMS 
96 Tyrosine, 3TMS 
97 Undecanoate, TMS 
98 Valine, TMS 
99 Valine, 2TMS 
100 Vanillate, 2TMS 
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Table 12.9 Mean signal-to-noise ratios of FAMEs computed from four subsequent replicate runs by 
means of GC-APCI I or APCI II-HRTOFMS. The “Find Compounds – Chromatogram” peak finder was 
applied on EICs of protonated molecules (concentration range: 5-13 µM). Student’s t-tests with correction 
for multiple testing according to Benjamini and Hochberg [89] were performed on signal-to-noise ratios. 
For comparison of the not normally distributed mean S/N, the Wilcoxon signed-rank test was used. Re-
printed from [13]. 
FAME Mean S/N 
[M+H]
+
 
APCI I
Mean S/N 
[M+H]
+
 
APCI II
 
  
C11:0 a 3100 10389
C13:0 a 6708 20694
C14:1 a 4718 17974
C15:1 a 1619 6040
C15:0 a 1268 7038
C16:1 17392 19306
C17:1 a 3503 10269
C17:0 a 2988 11120
C18:1c a 12543 22875
C18:1t a 6903 14504
C18:0 a 18250 37792
C20:1 a 5174 11573
C20:0
 a 16589 22813
C21:0 a 6636 15339
C22:1 a 2387 14289
C22:0 a 6813 29035
C23:0 a 3455 17251
C24:1 a 1468 11356
C24:0 a 3164 23060
Arithmetic mean b 6562 16985
a
 padj <0.05 (Student’s t-test, corrected for multiple testing). 
b
 p <0.05 (Wilcoxon) 
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Table 12.10 Figures of merit for ISs used in metabolite profiling by GC-HRTOFMS with either the APCI I 
or the APCI II source. Calibration curves of twenty MeOx-TMS derivatized metabolites were analyzed. 
(TMS derivatization status and isomer elution number are given for metabolites yielding multiple peaks 
after derivatization). Reprinted from [13]. 
Compound GC-APCI II-HRTOFMS 
ret.time 
(min)
m/z  
[M+H]
+
 
ion
GC-APCI I-
HRTOFMS
GC-APCI II-
HRTOFMS
  RSDa (%) RSDa (%) 
[U-
13
C]lactate 10.87 238.13 2.0 5.8 
[U-
13
C]3-hydroxybutyrate 12.55 253.15 7.3 3.2 
Nval-2TMS 13.90 262.17 8.0 4.5
[U-
2
H4]succinate 15.00 267.14 6.0 3.7 
[U-
13
C]fumarate 15.54 265.11 2.6 2.4 
[
2
H7]trans-cinnamate 18.56 228.14 4.7 1.4 
[U-
13
C]glucose-1 23.50 576.32 5.8 2.4 
[4,6,7-
2
H3]5-HI-[
2
H2]AA 26.75 341.18 7.6 9.9 
[U-
13
C]lactose-1 31.86 960.51 8.1 9.5 
Arithmetic mean   5.8 4.8 
a
 Concentration = 100 µM, N = 5 derivatization replicates. 
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Figure 12.1 GC-APCI-TOFMS mass spectra of the MeOx-TMS derivatives of suberate and valine. Spec-
tra A and B were acquired without, spectra C and D at 0.4 mL/h of continuous water infusion into the 
APCI source (Standard concn=100 µM, TMS=trimethylsilyl group). Reprinted from [14]. 
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Figure 12.2 GC-APCI-TOFMS mass spectra of the MCF-derivatives of suberate and valine acquired 
without and at five different rates of water infusion. (A-F) refer to suberate-2E and (G-L) to valine-1E-1A, 
respectively. Water-infusion rate was increased in 0.1 mL/h increments from 0.1 to 0.5 mL/h (standard 
concn=200 µM, E=methyl ester group, A=amide group). Reprinted from [14]. 
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Figure 12.2 continued. 
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Figure 12.3 NMR analysis of aqueous and MCF derivatized standards of 2-HG and 5-Oxotetrahydro-2-
furancarboxylate as well as serum of an AML patient with an IDH2 R140Q mutation. (A) Predicted 1H-
NMR chemical shifts in ppm (blue numbers) of the investigated derivatives of standard analytes by 
ChemDraw. (B, C) Overlaid 1D 1H spectra of (B) MCF derivatized and (C) aqueous standards of 2-HG 
(green in (B), yellow in (C)) and 5-oxotetrahydro-2-furancarboxylate (orange in (B), green in (C)) at a 
concentration of 1 mM each. (D) Overlaid 2D 1H-13C TOCSY spectra of serum of an AML patient with an 
IDH2 R140Q mutation (green) and aqueous standards of 2-HG (red) and 5-oxotetrahydro-2-
furancarboxylate (orange). Experimental details are given in the experimental section of chapter 9. NMR 
peak assignments in (B) were based on predicted 1H chemical shifts and similar 1H intensities for methyl 
groups of each of the three derivatives (numbering is shown in (A)). Lac, 5-Oxotetrahydro-2-
furancarboxylate; Metderiv, methyl ester.   
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Figure 12.3 continued. 
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Figure 12.4 HPLC-ESI-MS/MS analysis of a standard mixture of 2-HG and 5-oxotetrahydro-2-
furancarboxylate (31.25 µM each) on a Discovery HS F5 PFPP column. 150 × 2.1 mm, 3 μm, 120 Å, 
Discovery HS F5 (Supelco), P=134 bar. Elution with mobile phases A (0.1% formic acid in water, v/v) and 
B (acetonitrile) was performed using the following linear gradient: 0-6.5 min, hold at 100% A at a flow rate 
of 0.2 mL/min; 6.5-8 min, 0-100% B at 0.35 mL/min; 8-10 min, hold at 100% B at 0.35 mL/min; 10-10.1 
min, 0-100% A at 0.35 mL/min; 10.1-17 min, hold at 100% A at 0.35 mL/min; 17-18 min, hold at 100% A 
at 0.2 mL/min. Detection was carried out using electrospray ionization in negative mode and multiple 
reaction monitoring on a 4000 QTRAP from AB Sciex. Further details are given in the experimental sec-
tion of chapter 9. 
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15 Summary 
With the commercial introduction of atmospheric pressure chemical ionization for gas 
chromatography in 2008, GC-APCI coupled to high-resolution time-of-flight mass spec-
trometry (GC-APCI-HRTOFMS) became an interesting addition to the metabolomics 
toolbox. APCI is a soft ionization technique and its application to hyphenate GC to high 
resolution MS opens up promising new means for the identification of unknown signals 
in complex matrices. The actual utility of GC-APCI-HRTOFMS in metabolic fingerprint-
ing and profiling applications to biological matrices is the topic of this doctoral thesis.  
During comparison of GC-APCI-HRTOFMS with GC×GC-EI-TOFMS, GC-EI-TOFMS, 
GC-CI-qMS, and GC-EI-qMS in my master thesis, it was noticed that reproducibility of 
APCI was affected greatly by differences in humidity in the laboratory. Therefore, the 
impact of humidity in the APCI source on ionization efficiency and repeatability was 
systematically studied in the initial project of this doctoral thesis. Water was continuous-
ly infused to ensure a constant humidity during APCI in the analysis of methylchlorofor-
mate (MCF)- and methoxime-trimethylsilyl (MeOx-TMS) derivatized metabolites. These 
two different derivatization strategies are most commonly pursued in GC-MS based 
metabolome analyses. Several infusion rates were tested and a rate of 0.4 mL/h yielded 
an average 16.6-fold increase in intensity of the protonated molecules ([M+H]+) of 20 
MCF-derivatized metabolites through suppression of in-source fragmentation. Water 
infusion, however, did not improve efficiency and repeatability of APCI of methoxime-
trimethylsilyl (MeOx-TMS) derivatives of metabolite standards. Then, the impact of 
water infusion on metabolic fingerprinting of biological specimens was investigated. 
Water infusion led to a marked increase in the number of metabolites identified in MCF-
derivatized cancer cell extracts via their [M+H]+ ions and improved repeatability of peak 
areas, almost doubling the number (N=23) of identified, significantly regulated metabo-
lites (false discovery rate <0.05) between controls and cancer cells treated with the 
heat-shock protein 90 (Hsp90) inhibitor 17-DMAG.  
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Next, matrix effects caused by co-eluting compounds were investigated that might influ-
ence ionization. Strikingly, recovery of three out of seven internal standards used in a 
spike-in experiment was below 75% in one or several of the three biological matrices 
tested, namely Escherichia coli extract, serum, and urine. This was due to suppression 
by their respective endogenous metabolite that was present at a high concentration. Ion 
suppression caused by a co-eluting compound was further shown for three pairs of co-
eluting standards employing standard mixtures with increasing concentrations of the co-
eluting compounds. Overall these experiments demonstrated that matrix effects have to 
be taken into consideration in GC-APCI-MS.  
In the course of my doctoral thesis, Bruker Daltonics (Bremen, Germany) introduced a 
redesigned APCI source. To test the capabilities of this source, MeOx-TMS derivatized 
supernatants of untreated cancer cells were analyzed by GC-APCI-HRTOFMS using 
both the original APCI I and the redesigned APCI II source. The latter source almost 
doubled the number of spectral features with signal-to-noise ratios greater than 20 that 
could be extracted from metabolite fingerprints and increased the absolute number of 
identified metabolites by 33% from 36 to 48. In addition, the median area RSDs of ex-
tracted features decreased from 33% to 24%. These improvements further resulted in a 
more than fourfold median decrease in lower limits of quantification to 0.002 - 3.91 µM 
as evidenced for 20 MeOx-TMS derivatized metabolite standards and a concomitant 
increase in the linear range by 0.5 to almost three orders of magnitude.  
Finally, GC-APCI(II)-HRTOFMS was applied to the enantioselective quantitative profil-
ing of the oncometabolite D-2-hydroxyglutarate (D-2-HG). MCF derivatization and GC 
analysis on a chiral -cyclodextrin (Rt-DEXsa) column were used to separate the D 
from the L enantiomer of 2-HG. Separation was optimized to avoid co-elution of D-2-HG 
with a highly abundant matrix compound present in cell culture media supplemented 
with bovine serum albumin. The use of APCI-HRTOFMS yielded highly specific quanti-
fier ions and the infusion of water enhanced lower limits of quantification and repeatabil-
ity by factors of ten and two, respectively. Analysis of a racemic 2-HG standard after 
MCF derivatization yielded a total of four peaks instead of the expected two signals for 
the D- and L-enantiomer. It was then shown that in addition to an open-chain three-fold 
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derivative of 2-HG the methyl ester of the D/L-2-HG lactone is formed during derivatiza-
tion. Since lactone of D/L-2-HG was found to be naturally present in biological speci-
mens, the developed method was eventually based on the open-chain three-fold deriva-
tive of 2-HG yielding LLOQ values of 0.49 µM (D-2-HG) and 0.24 µM (L-2-HG). The 
GC-APCI(II)-HRTOFMS approach was successfully applied to the determination of D/L-
2-HG concentration levels in urine specimens of 23 acute myeloid leukemia (AML) 
patients and 6 healthy controls, which were validated by HPLC-MS/MS. The yet to be 
discovered source of 2-HG lactone in sera of AML patients carrying neomorphic iso-
citrate dehydrogenase mutations promises to shed new light on the pathogenesis and 
progression of AML. 
In summary this doctoral thesis demonstrates that GC-APCI-HRTOFMS is a useful 
addition to the established GC-MS approaches in metabolomics. Studies on factors 
potentially influencing the ionization, namely water infusion, matrix effects and source 
type, distinctly widened the applicability of GC-APCI-HRTOFMS for qualitative and 
quantitative analysis of MeOx-TMS and MCF derivatized metabolites. The ability of 
APCI along with water infusion to efficiently ionize a broad range of MCF metabolites 
was proven and in the following applied to comparative metabolic fingerprinting in ex-
tracts of treated cancer cells. Finally, the outstanding quantitative capabilities of GC-
APCI(II)-HRTOFMS were used in a first enantioselective profiling application for quanti-
tative determination of the oncometabolite D-2-HG. Altogether, this doctoral thesis con-
tributed significantly to the excellent progress GC-APCI-MS has made towards becom-
ing a routine tool in metabolomics. 
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16 Zusammenfassung 
Mit der kommerziellen Einführung der chemischen Ionisation bei Atmosphärendruck für 
die Gaschromatographie im Jahr 2008 wurde GC-APCI in Kombination mit hochauflö-
sender Massenspektrometrie (GC-APCI-HRTOFMS) als zusätzliches Verfahren für das 
Methodenspektrum in der Metabolomik interessant. Bei der APCI handelt es sich um 
eine weiche Ionisationstechnik. In Kombination mit GC und hochauflösender MS eröff-
net APCI neue erfolgversprechende Möglichkeiten zur Identifizierung von unbekannten 
Signalen in komplexen Matrices. Diese Doktorarbeit behandelt die Frage, inwiefern GC-
APCI-HRTOFMS in „Metabolic Fingerprinting“ und „Metabolic Profiling“-
Untersuchungen in biologischen Matrices nützlich ist.    
Im Laufe des Vergleichs von GC-APCI-HRTOFMS mit GC×GC-EI-TOFMS, GC-EI-
TOFMS, GC-CI-qMS und GC-EI-qMS wurde festgestellt, dass sich Schwankungen in 
der Luftfeuchtigkeit im Labor sehr stark auf die Reproduzierbarkeit der APCI auswirkten. 
Deshalb wurde im anfänglichen Projekt dieser Doktorarbeit systematisch untersucht, ob 
die Feuchtigkeit in der APCI-Quelle die Ausbeute und Wiederholbarkeit der Ionisierung 
beeinflusst. Die Zugabe von Wasser erfolgte kontinuierlich während der Analyse von 
mittels Chlorameisensäuremethylester (MCF)/MeOH und sequenzieller Methoximie-
rung/Silylierung derivatisierten Metaboliten, um einen konstanten Feuchtigkeitsgehalt 
bei der APCI zu gewährleisten. Diese beiden unterschiedlichen Derivatisierungsstrate-
gien werden in Metabolomics-Untersuchungen mittels GC-MS am häufigsten gebraucht. 
Verschiedene Infusionsraten von Wasser wurden getestet. Durch Zugabe von 0.4 mL 
Wasser pro Stunde konnten die Intensitäten der protonierten Moleküle ([M+H]+) der 
verwendeten 20 MCF derivatisierten Metabolitenstandards durchschnittlich um das 
16.6-fache erhöht werden. Dies wurde aufgrund der resultierenden geringeren Frag-
mentierung in der APCI Quelle erreicht. Die Zugabe von Wasser führte hingegen im Fall 
von mittels sequenzieller Methoximierung/Silylierung (MeOx-TMS) derivatisierten Meta-
bolitenstandards zu keiner Verbesserung bezüglich Ausbeute und Wiederholbarkeit der 
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APCI. Anschließend wurde überprüft, inwiefern sich die Zugabe von Wasser bei der 
Untersuchung von biologischen Proben mittels „Metabolic Fingerprinting“ auswirkt. Die 
Zugabe von Wasser erhöhte dabei die Anzahl der über das jeweilige protonierte Mole-
kül identifizierten Metabolite in MCF-derivatisierten Extrakten von Krebszellen deutlich 
und verbesserte die Wiederholpräzision der Peakflächen, was die Zahl der identifizier-
ten und signifikant regulierten Metabolite (False Discovery Rate <0.05) zwischen Kon-
trollen und den mit dem Hitzeschockprotein 90 (Hsp90) Inhibitor 17-DMAG behandelten 
Krebszellen auf insgesamt 23 fast verdoppelt hat. 
Des Weiteren wurden mögliche Ionisierungseffekte aufgrund von ko-eluierenden Mat-
rixbestandteilen untersucht. Insbesondere lag die Wiederfindungsrate von drei der sie-
ben verwendeten internen Standards im Spike-in Experiment unterhalb von 75% in 
einer oder mehreren der drei untersuchten biologischen Matrices (Escherichia coli Ex-
trakt, Serum und Urin). Dies war auf Ionensuppression durch den jeweiligen endogenen 
Metaboliten zurückzuführen, der hochkonzentriert vorlag. Durch eine ko-eluierende 
Standardverbindung hervorgerufene Ionisierungseffekte konnten ferner experimentell 
für drei solcher Paare aufgezeigt werden. Dabei wurden die mit den Analyten ko-
eluierenden Standardverbindungen in steigenden Konzentrationen eingesetzt. Insge-
samt hat sich in allen Experimenten zu Matrixeffekten herausgestellt, dass diese in der 
GC-APCI-MS berücksichtigt werden müssen. 
Im Verlauf meiner Doktorarbeit wurde eine neu entworfene APCI-Quelle von Bruker 
Daltonics (Bremen, Deutschland) vorgestellt. Um die Leistungsfähigkeit dieser Quelle 
zu überprüfen. wurden MeOx-TMS derivatisierte Zellkulturüberstände unbehandelter 
Krebszellen mittels GC-APCI-HR-TOFMS analysiert. Dies erfolgte sowohl unter Ver-
wendung der ursprünglichen APCI I Quelle als auch der neu entworfenen APCI II Quel-
le. Letztere Quelle konnte die Zahl der aus den metabolischen Fingerabdrücken ge-
wonnenen Signale mit Signal-zu-Rausch-Verhältnis >20 fast verdoppeln. Darüber 
hinaus gelang es, die absolute Anzahl identifizierter Metabolite in diesen Proben um 
33% von 36 auf 48 zu steigern und die mediane relative Standardabweichung der Peak-
flächen obiger gewonnener Signale von 33% auf 24% zu verringern. Außerdem war es 
unter Verwendung der verbesserten APCI II Quelle möglich, die mediane untere Quanti-
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fizierungsgrenze für 20 MeOx-TMS derivatisierte Metabolitenstandards um mehr als 
das Vierfache auf 0.002-3.91 µM zu erniedrigen und gleichzeitig den linearen Bereich 
um eine halbe Größenordnung auf insgesamt drei Konzentrationsgrößenordnungen zu 
erhöhen.  
Schließlich wurde GC-APCI(II)-HRTOFMS zur enantioselektiven, quantitativen Bestim-
mung des Onko-Metaboliten D-2-Hydroxyglutarat (D-2-HG) verwendet. MCF Derivati-
sierung mit nachfolgender gaschromatographischer Analyse mittels einer chiralen -
Cyclodextrin (Rt-DEXsa) Kapillarsäule wurden eingesetzt, um das D- vom L-
Enantiomer des 2-HGs abzutrennen. Die Trennung wurde optimiert, um die Koelution 
von D-2-HG und einer hochabundanten Matrixkomponente in Zellkulturmedien mit zu-
gegebenem Rinderserumalbumin zu vermeiden. APCI und TOFMS ergaben Ionen von 
hoher Spezifität für die Quantifizierung. Die Zugabe von Wasser verbesserte die unte-
ren Quantifizierungsgrenzen und die Reproduzierbarkeit der Methode um das Zehn- 
bzw. Zweifache. Bei der Analyse eines racemischen 2-HG Standards nach MCF Deriva-
tisierung konnten anders als vermutet insgesamt vier statt zwei Signale für das D- und 
L-Enantiomer detektiert werden. Daraufhin wurde gezeigt, dass zusätzlich zum offen-
kettigen Dreifachderivat der Methylester des Lactons von 2-HG während der Derivati-
sierung gebildet wird. Dadurch, dass das fünfgliedrige Lacton von D/L-2-HG natürlich in 
biologischen Proben vorkommt, wurde in der entwickelten Methode schließlich das 
offenkettige Dreifachderivat von 2-HG zur Quantifizierung herangezogen. Daraus resul-
tierten untere Quantifizierungsgrenzen von 0.49 µM (D-2-HG) und 0.24 µM (L-2-HG). 
GC-APCI(II)-HRTOFMS konnte erfolgreich zur Bestimmung von D/L-2-HG Spiegeln in 
Urinproben von 23 Patienten mit akuter myeloischer Leukämie (AML) und 6 gesunden 
Probanden angewandt und die erzielten Ergebnisse mittels HPLC-MS/MS validiert 
werden. Die Aufklärung des Ursprungs des 2-HG-Lactons in Serumproben von AML 
Patienten mit mutierter Isocitrat-Dehydrogenase verspricht neue Einblicke in Entstehen 
und Fortschreiten von AML zu geben. 
Zusammengefasst konnte in dieser Doktorarbeit aufgezeigt werden, dass GC-APCI-
HRTOFMS ein nützliches zusätzliches Verfahren zu den etablierten GC-MS Methoden 
in der Metabolomik ist. Studien zu Faktoren, welche die Ionisierung möglicherweise 
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beeinflussen – nämlich die Zugabe von Wasser, Matrixeffekte und Quellentyp – konnten 
die Anwendbarkeit von GC-APCI-HRTOFMS für die qualitative und quantitative Analyse 
von MeOx-TMS und MCF derivatisierten Metaboliten erheblich steigern. Dabei konnte 
nachgewiesen werden, dass mittels APCI und Wasserzugabe eine große Bandbreite an 
MCF derivatisierten Metaboliten ionisiert werden kann. Dies wurde nachfolgend bei der 
vergleichenden Analyse metabolischer Fingerabdrücke von Extrakten behandelter 
Krebszellen angewandt. Schlussendlich wurde die ausgezeichnete quantitative Leis-
tungsfähigkeit von GC-APCI(II)-HRTOFMS in einer ersten enantioselektiven „Metabolic 
Profiling“-Anwendung für die Quantifizierung des Onko-Metaboliten D-2-HG genutzt. 
Summa summarum hat diese Doktorarbeit einen wichtigen Beitrag zur zukünftigen, 
routinemäßigen Anwendung der GC-APCI-MS in der Metabolomik geleistet.  
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